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Airway disease is the primary cause of mortality for the over 70,000 patients with Cystic
Fibrosis (CF) worldwide. It is characterized by lung infection, inflammation, and impaired
mucociliary clearance (MCC) arising from depletion of the airway surface liquid (ASL) at the
organ-scale. Dysfunction in the CF transmembrane conductance regulator protein causes
dysregulation in ion and liquid transport alone and via other transport-related proteins.
Analysis of cell-system interactions is experimentally complex, however, and motivates the
use of mechanistic mathematical models that can also be used to design and optimize treat-
ments for the disease.
Tc99m or In111-labeled DTPA (DTPA) are small-molecule radiological probes that allow
for observation of paracellular liquid convection and solute transport at cellular and organ
scales, respectively. Previous work has shown that DTPA is hyperabsorbed in CF in a manner
that strongly correlates with ASL hyperabsorption. The models of this dissertation describe,
in part, the mechanisms that underlie this correlation. At the lung-scale, a physiologically
motivated pharmacokinetic model was developed to describe the action of hypertonic saline
(HS) as an inhaled therapy in CF. This model predicts that MCC is reduced in patients with
CF because they have a reduced fraction of functional ciliated airway – a model parameter
– that is increased via HS-induced airway rehydration. This prediction was verified in vitro
in human bronchial epithelial (HBE) cultures.
iv
A separate, cell-scale model accurately characterizes transcellular liquid transport in
HBE cultures using transport parameters that agree well with previously reported values,
producing ion flux estimates from the model fit to ASL and DTPA absorption that were
similar to known physiological values. It also implicates diminished constitutive Cl- secretion
in ASL dehydration but suggests that reduced paracellular integrity is the predominant factor
leading to hyperabsorption in CF. The cell- and lung-scale models were then used to analyze
treatment failure and suggest modifications of a clinical trial, which is the first indication of
the utility of airway transport models in designing treatments for patients with CF.
Keywords: Cystic Fibrosis, Mathematical Modeling, Epithelial Transport, Mucociliary Clear-
ance, Airway Surface Liquid Absorption.
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1.0 INTRODUCTION
1.1 MULTISCALAR TRANSPORT IN HUMAN AIRWAYS
Cystic Fibrosis (CF) lung disease manifests on multiple in the airway transport system. CF
is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)
gene. Disease-causing mutations lead to defects in ion and liquid transport, as well as
other cell-structure defects [5, 12, 13, 14]. In health at the molecular scale, proteins such
as the epithelial sodium channel (ENaC) serve as a highly specific, single-atom gateway
[13, 15], and CFTR provides an anion transport route as well as regulatory control over
other transport pathways. At the cell scale, the net effect of the system of ion channels and
pumps present at the epithelial surface allows for homeostatic regulation of cell volume and
composition [9, 12, 16, 17]. And at the tissue scale, the coordinated efforts of cilia drive a
gel-like mucus flow out of the airways taking with it inhaled particles and pathogens [18,19,
20, 21, 22]. In patients with CF, diminished or absent Cl- transport [4, 23] and dysregulated
ion transport in transport proteins other than CFTR [3,24,25] lead to airway surface liquid
(ASL) dehydration [24]. ASL dehydration collapses the periciliary liquid layer (PCL) beneath
hyperviscous mucus, abolishing mucociliary clearance (MCC) [18]. This defect in mucociliary
clearance causes patients to be more susceptible to airway infections, and the subsequent
inflammation and scarring caused by chronic and recurring infections leads to bronchiectasis
and respiratory failure, which is the primary cause of patient mortality in CF.
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1.1.1 Fundamental Elements of Airway Epithelial Ion and Liquid Transport
Electrochemical potential, µˆ, is the primary driving force for epithelial transport at small
scales. Gibbs Free Energy, ∆G, also provides a thermodynamic driving force during transport
against an electrochemical gradient [26]. In the case of the passive flux of a single ion across
a membrane, only the membrane potential (Em), described by the Nernst equation (1), and
the chemical potential, µ (2), need to be considered. ∆µˆ (3), is the sum of the chemical and
electrical potential energies:
Em =
RT
zF
ln
[Ionin]
[Ionout]
(1)
∆µ = RTln
[Ionin]
[Ionout]
(2)
∆µˆ = ∆µ+ zFEm (3)
Here R is the gas constant (J/mol-K), T is the temperature (K), z is the valence of the
ion, and F is the Faraday constant. The cell or its external environment, however, are not
single-ion solutions. In this circumstance, the electrical potential can be balanced across
a membrane (henceforth as Vm = 0), while a partial molar driving force remains. As an
example, initially equimolar solutions of K+ and Na+ could be separated by an ion permeant
membrane. There would be no initial electrical driving force as the valence of both ions is
the same, but their respective partial molar (i.e. µi) gradients would cause both species to
diffuse across the membrane until electrochemical equilibrium is reached. Thus it is necessary
to account for the electrical contributions of all (or the most prevalent) ions in a polyionic
system. In the case of biological systems, only the electrical effects due to Na+, K+ and
Cl− are usually considered via the three-ion case of the Goldman-Hodgkins-Katz equation
(GHK) (4):
Vm =
RT
F
ln
PNa[Na
+
out] + PK [K
+
out] + PCl[Cl
−
in]
PNa[Na
+
in] + PK [K
+
in] + PCl[Cl
−
out]
(4)
2
Where Pi is the permeability of the ion, i. From (4) the total electrochemical potential for
transport of an ion can be determined, again as the sum of the partial molar energy and the
electrical energy [26](5):
∆µˆi = ∆µi + zFVm (5)
The two terms on the right-hand-side of (5) can be thought of as diffusive and conductive
driving force terms, respectively. If voltage-driven flux is assumed to be dominant, it may be
beneficial to treat the system as an electrical circuit subject to Ohm’s law, Je = σE, where
Je is the current density (or charge flux), with conductivity σ. Goldman [27] derived the
flux relationship (6), assuming that the electromagnetic field is constant, that is nonlinear
in terms of conductance:
Je = Vm
Λ+ − Λ−eRTF Vm
1− eRTF Vm
(6)
Where Λ+ and Λ− are upper and lower bounds on feasible conductivities, given by Λ+ =
Pi
(zF )2
RT
[Ionin] and Λ− = Pi
(zF )2
RT
[Ionout], respectively. Via L’hospital’s rule it is evident that
(6) predicts that limVm→0 Je 6= 0, which must hold true if diffusive gradients are present. In
that case we have:
lim
Vm→0
Je = PizF ([Ionin]− [Ionout]) (7)
Thus, the charge flux is related to the diffusive flux, Jd via the equation Jd =
Je
zF
. Indeed,
Goldman notes that due to nonlinearities in biological systems, diffusive laws, such as Fick’s
law (8), may be as useful as Ohm’s law relations [27] wherein:
Jd = Pi([Ionin]− [Ionout]) (8)
Regardless of the flux equation used, transport dynamics of solutes in biological systems can
be studied compartmentally because of the compartmental organization of biology (e.g. cell,
tissue, organ, etc.). Thus, using molar dynamics of the ni solutes in a cell as an example,
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modelers can derive systems of ordinary differential equations to describe solute influx and
eﬄux through k = 1, . . . , K transport pathways over time as shown in (9):
dni
dt
= AC
K∑
k
(Ji,k) (9)
Where AC is the area of the surface (e.g. apical membrane) through which flux occurs. From
this form, all models of epithelial solute and transport at the cellular scale relevant to this
work are derived. However, it is prudent to first discuss the structure and pathways involved
in the epithelial transport system.
1.1.2 Airway Epithelial Structure and Function
1.1.2.1 General Epithelial Structure and Function Epithelial tissues are, regardless
of context, interfacial tissues. The skin and the cornea are manifest examples of the interfacial
function of epithelia, as they protect body systems from external threats. Internally, epithelia
primarily occupy the interface between organ systems and facilitate transport between these
organ systems. Intestinal epithelia serves to transport nutrients from the digestive tract to
the bloodstream while also serving as a barrier to external threats; the proximal tubules in
the kidney transports sodium from the bloodstream, drawing water with it; lung epithelia
secrete liquid and surfactants to keep airways hydrated and alveoli open for gas exchange.
In general, epithelia have the following structural elements in common: an apical interfa-
cial membrane, a junctional space that facilitates intercellular communication and paracel-
lular liquid and solute transport, and a basement membrane where the epithelium attaches
to connective tissues in the body. This is illustrated for a generalized epithelial monolayer
in Figure 1.1.
Transport in epithelial tissues occurs through either the transcellular route - via molecular
channels and pumps - or the paracellular route - via the tight junction. The tight junction
is more permeant in “leaky” tissue types (e.g. cornea, airway, intestine) than “tight” tissues
(e.g. kidney, bladder) where almost no paracellular liquid or solute transport occurs [28].
Although lacking information for human (or any species) bronchial epithelial cells, Table
9.3 of Charles House’s book [29] demonstrates well the order-of-magnitude differences in
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Figure 1.1: Diagram of the general structure of epithelial monolayers. Epithelial cells ad-
here to a basement membrane of connective tissue (or coated substrate in tissue cultures).
Transcellular transport occurs in all epithelia via channels and pumps in the apical and
basolateral membranes. Paracellular transport occurs through the tight junction in “leaky”
epithelia, and only to a very small extent in “tight” epithelia.
hydraulic permeability (Lp), electical resistance and potential difference, and ion transport
rate that distinguish “leaky” from “tight” epithelia.
Characterization of a tissue type as either “leaky” or “tight” has traditionally been based
on electrophysiological measurements of junctional resistance. Indeed, electrophysiology has
been fundamental in the development nearly all current knowledge regarding ion transport
in biology. Hans Ussing’s development of the chamber that now bears his name opened
the doors to investigating transport at the cell and tissue scale [30]. In that work, Na+
absorption was identified as the source of the electrical conductivity of frog skin. Na+ was
considered as a possible source of the current due to previous work from Ussing that showed
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net Na+ absorption across frog skin [31] where Na+ influx and eﬄux were measured using
identical concentrations of Na22 and Na24 isotopes via the relation given in (10) [31]:
log10
Jin
Jout
=
Vm
58
(10)
Thus, the electrical potential can be determined across the membrane in such a way as to
assess net ion transport. As an aside, [31] also introduces the utility of radiological methods
to study epithelial transport, which are discussed in detail in the subsequent chapter of this
dissertation.
The Ussing chamber has improved with the advance of electronics since its invention,
but it’s form and concept remain the same. As depicted in Figure 1.2 an Ussing Chamber
consists of two large (≈3 mL) electrolyte-containing fluid compartments separated by an
epithelial monolayer.
Operation of the Ussing Chamber entails placing electrodes near the monolayer (improv-
ing the quality of the constant-field assumption) and measuring the current of the epithelia
under either short- or, less-frequently, open-circuit conditions. Short-circuit current (ISC)
calculations conditions require that the voltage across the monolayer be “clamped” (i.e. held
constant at 0), which is convenient for computing net ion flux according to the Goldman
equation (6). Li and colleagues provided a brief but detailed overview of the modern Ussing
Chamber [32].
The Ussing Chamber can also be applied to study individual membrane potentials. Fig-
ure 1.2 shows the simplest equivalent circuit diagram of the epithelial ion transport sys-
tem [33]. From this representation it is easily observed that the three general transport
pathways (apical and basolateral membranes and the paracellular junction) are individual
resistors that provide a measurable electrical effect and can be studied individually or to-
gether depending on experimental design. The values for apical and basolateral membrane
potentials (Va and Vb) can be calculated using (11) and (12), respectively:
VA =
EA(RB +RP ) + EBRA
RA +RB +Rp
(11)
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Figure 1.2: Diagram of an Ussing Chamber and the equivalent simplified circuit diagram.
A cellular monolayer separates two compartments of electrolyte solution on the apical and
basolateral sides. Electrodes on either side of the monolayer measure electrical current,
resistance, and potential.
VB =
EB(RA +RP ) + EARB
Ra +RB +RP
(12)
Here Ea and Eb are the electromotive potentials across the apical and basolateral membranes,
respectively. The paracellular resistance, RP , is due to the occluding effect of junction
proteins like actin, claudins, connexins, and zonula occludens proteins [34]. The density
and structure of these proteins is what largely determines the “tightness” of an epithelial
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tissue type, where tighter epithelia have increased electrical resistance. The apical (RA) and
basolateral (RB) resistances are related to the density of channels and transporters in the
apical and basolateral membranes. Higher densities and turnover rates correlate with lower
resistances. In general, the apical membrane is transport limiting and RA > RB due to the
rapid homeostatic action of basolateral transporters like the Na+/K+-ATPase (NaKP), and
the Na-K-Cl-Cl (NKCC) cotransporter [35].
1.1.2.2 Airway Liquid and Solute Transport in Health and CF The diagram in
Figure 1.3 illustrates the well-described channels and transporters in the airway epithelium.
Of most importance to this dissertation is CFTR, and how its absence or dysfunction
contribute to CF lung disease. CFTR has 5 protein regions [6]: two transmembrane regions
that together form the anion channel, and three cytosolic regions: two nucleotide binding
domains (NBD1 and 2) and a regulatory (R) domain that work in concert for channel gating.
Its structure is depicted in Figure 1.4.
For gating to occur, CFTR requires phosphorylation by protein kinase A (PKA) in
its R domain, which serves as “gatekeeper.” The phosphorylation in R domain causes a
conformational change that allows NBD1 and NBD2 to interact and hydrolyze ATP, thus
opening the gate [6]. Mutations in the NBD1 coding region are the most common sources
of CFTR dysfunction leading to disease, but location is not considered a primary factor in
disease classification. Currently, there are six classes of disease-causing CFTR mutations [36]:
1. No full length CFTR produced due to a nonsense mutation near the C-terminus
2. Little or no CFTR trafficked to the membrane. The most common mutation, ∆F508, is
of this class.
3. The gating of the ion channel of CFTR is affected. Ivacaftor [37] is approved to treat
many mutations of this class.
4. The conductance of CFTR is reduced.
5. The synthesis amount of CFTR is insufficient.
6. CFTR is less stable in the membrane.
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Figure 1.3: Known pathways for liquid and ion transport in airway epithelia. CFTR is
thought to regulate ENaC and SLC26A9 through intracellular signaling and other domain
interactions [2, 3]. Other passive Cl− and K+ channels exist in the apical and basolateral
membranes (though basolateral K+ channels are more speculative). Active, dedicated Cl−
transport also occurs in the basolateral membrane, where Na+ and K+ are also actively
transported with and without Cl−. HBE are “leaky,” thus they also have a high degree of
paracellular water and small solute transport [4, 5].
Type 1 mutations are usually very brief truncations of CFTR due to a mutated stop
codon in the gene. They make up roughly 10% of the patient population [38]. The type
2 deletion of the phenylalanine at position 508 (part of NBD1) in CFTR (∆F508 as a
genotype) is the most common CF-causing mutation, present in ≈85% of patients with
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Figure 1.4: CFTR in its closed state (left) does not allow Cl- or other anions to pass through
the apical membrane. Once the R domain is phosphorylated, the NBDs will interact to
hydrolyze 2 ATP causing a gating event that allows Cl- to move down its electrochemical
gradient. Adapted from [6]
CF [39] and ≈45% are homozygous for the ∆F508 allele [40]. Roughly another 5% of
patients bear a type 3 disease causing mutation (e.g. G551D or G551S) in the NBD1
encoding region of their genome [41]. These type 2 and 3 mutations prevent proper gating
of CFTR, and thus show no electrochemical sensitivity to stimulation by forskolin, which
stimulates PKA [37]. This has been useful in the identification of pharmaceuticals to treat
defective CFTR directly, as evidenced by the fact that the only currently approved CFTR
modulators are the ”potentiator” ivacaftor [37, 41] in type 3 mutations and the ”corrector”
lumacaftor [40,42] for ∆F508 homozygote patients in combination with ivacaftor. These two
drugs cover roughly 50% of the patient population, which is a promising advance in the field
of treating CF. Investigation into these types of targeted therapies will continue [43] and
no doubt should. However individual patient response to treatment is varied, particularly
in the case of the lumacaftor-ivacaftor combination therapy [40, 44]. With more than 2,000
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different disease causing mutations [45] and interpatient variability even within genotypes
there is still a need for better generalized therapies that can treat 100% of patients effectively
and also affordably. Therapies like hypertonic saline and ibuprofen can accomplish similar
improvements in lung function as the combination therapy [40], but cost 2 to 4 orders of
magnitude less per year [46]. The promise of systems medicine in this case of generalized
therapies is that mathematical models can provide optimized and personalized dose and
treatment scheduling for every individual patient, which is a primary motivating factor for
this thesis. To do so requires a systems understanding that studies disease effects at a much
broader systems scope than CFTR alone.
1.1.2.3 The Airway Transport System At the cell scale, the primary effects of ab-
sence or dysfunction in CFTR occur in the apical membrane and result in airway surface
liquid (ASL) dehydration. ASL dehydration, in turn, causes mucociliary clearance failure
due to the increased viscosity of the mucus. Inhaled pathogens and particles become en-
trapped in the static mucus and leading to infection, inflammation and fibrosis. This process
is detailed in Figure 1.5
CFTR is both a chloride channel and a transport regulator; it regulates ENaC through
PKA [2,47] and members of the solute carrier 26 (SLC26) family through its R domain [48],
in some cases forming a Cl−-HC0−3 exchange complex [3]. Obviously, these pathways are
directly affected by the absence or dysfunction of CFTR that is the cause of CF. Intuitively,
the severity of CF as a disease is an indicator of the relative importance of these apical
pathways for transport in health. The role of ENaC in Na+ transport has already been
discussed, but its importance is further highlighted in CF where absence of CFTR leads to
increased Na+ (thus, also liquid) absorption [2,49]. SLC26A9 has constitutive Cl− transport
activity that is significantly decreased in CF cells [3]. Ca2+-activated Cl− channels (CaCC)
in the lungs, particularly transmembrane protein 16A (TMEM16A), are thought to be the
only remaining Cl− secretion route in CF [24, 50]. Apical K+ conductance through the
large conductance Ca2+-activated K+ (BK) channel has also been postulated to assist in the
maintenance of ASL volume [51]. Any net flux of ions through the apical membrane will also
cause osmotic water transport through aquaporins (AQP) in the same direction; AQPs also
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Figure 1.5: Normal ASL/PCL (depicted in light blue) homeostasis and MCC are maintained
by proper function of CFTR and ENaC at the apical membrane of the airway epithelium
(left). In CF (right) the ASL becomes dehydrated due to the absence of CFTR and subse-
quent dysregulation of Na+ absorption via ENaC. Mucus becomes viscous and unclearable,
leading to chronic infections and subsequent inflammation and scarring.
facilitate water transport in the basolateral membrane. Schreiber and colleagues suggested
that CFTR also regulates AQP-3 in the airways, in addition to its regulation of other ion
channels [52].
Basolateral transport primarily maintains cellular homeostasis in terms of volume and
electrochemical properties, including pH. The primary transporters involved are NKCC,
which transports a Na+ and K+ with two Cl− electroneutrally [53], and NaKP, which main-
tains the high intracellular K+ concentration through ATP-driven pumping in an electrogenic
exchange of 2 K+ for an eﬄux of 3 Na+ [54,55]. There are other anion channels that transport
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Cl−, including volume sensitive outward rectifying channels (BORC) and inward rectifying
channels (BIRC) [55]. The presence of a basolateral K+ channel has been reported [56]. The
contribution of non-transporter routes for K+ is likely small and negligible for Na+.
As discussed previously, HBE are leaky. There is little question whether ions move
paracellularly through the junctional space, and most solutes with hydrodynamic radius
<3.8 nm will also traverse the junction [57]. However, there is a large divide in the field
about whether water primarily traverses the junctions or even does so at all. Hill and
Shachar-Hill [57, 58] and Fischbarg [59, 60] advocate a predominantly paracellular route for
liquid transport. Ruess [61], along with MacLaren and colleagues [62], have stated that
paracellular water transport is unnecessary to explain the transport behavior observed in
leaky epithelia. Spring and his students have published strong evidence against paracellular
transport in Madin-Darby canine kidney (MDCK) cells [63], but Spring was less inclined to
make a claim in favor of either side of the debate [64].
Recent work has sought to address at least part of question in human bronchial epithe-
lia. Using a two-probe functional imaging method wherein inhaled non-absorbable large
molecule Tc99m-labeled sulfur colloid (TcSC) and absorbable small-molecule In111-labeled
DTPA (DTPA), it has been determined that DTPA is hyperabsorbed in the airways of pa-
tients with CF [8,21]. It has also been observed that there is an in vitro correlation between
the absorption of DTPA and liquid absorption in HBE cell culture [65]. DTPA can only tra-
verse the paracellular space of the epithelium. Paracellular liquid transport likely influences
DTPA transport via convection. Identifying the convective effects requires an understanding
of the other primary driving mechanism for paracellular transport of DTPA: diffusion. This
is facilitated by the use of a mathematical model as stated in [59].
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1.2 MODELING ACROSS BIOLOGICAL SCALES
1.2.1 Modeling Epithelial Solute and Liquid Transport at the cellular scale
1.2.1.1 Systems Biology Overview Systems biology is an expansive field. In one sense
it is the application of systems analysis and engineering tools to study of biology. In another,
more philosophical, sense it is an alternative to the traditionally reductionist approach in
biology. Whereas biological research often studies the components of life as individual el-
ements, systems biology focuses on the synergistic interactions of those elements and the
systems processes they drive. The interactions of operations within a system can be for-
mally modeled; those interactions in biological systems are no exception. The interactions
of molecules and cell and organ processes in biology are what give rise to life and health or
disease. In his seminal review [66] Hiroaki Kitano cited four primary areas that could be
elucidated through the use of a systems approach: systems structures, dynamics, control,
and design methods. Systems structure concerns the network of elements that comprise a
system while dynamics concern the time-dependent behavior of those elements and the sub-
sequent evolution of the network. Understanding the structure and dynamics allows for the
application of control over states in the system through external inputs (e.g. therapeutics)
and design of favorable interactions or interventions to affect system output in a desired
manner. Jonathan Bard [67] describes the aims of systems biology from the perspective of a
biologist as two-fold: the narrow aim focuses on protein network interactions (but not the re-
ductionist understanding of protein functionality); the broader aim seeks to relate molecular
interactions in the cell to phenotypic outputs.
Indeed, the equations from Section 1.1.1 fit into the first two categories proposed by
Kitano. The GHK equation 6 is built upon the structure of an electrochemical system, and it
describes the dynamic, passive movement of ions across a membrane. The often complicated
tasks that are accomplished by enzymes and other proteins can also be viewed as chemical
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reaction sequences that are well-described by mass-action kinetics. As an example of mass
action kinetics, the Langmuir-Hinshelwood mechanism of catalysis on a surface is:
A+ S
k1↔
k2
AS
k3→ B + S (1.1)
Takes a reactant A that associates and dissociates in an elementary way with catalysis site
S given kinetic rate constants k1 and k2, respectively, to form reaction intermediate AS.
This intermediate is converted into product B with constant k3 and the catalysis site is
unchanged. If S is imagined to be the binding pocket of an enzyme or transport protein it
could be assumed that the mathematical form that governs enzymatic conversion or transport
of A over time should be the same as the Langmuir-Hinshelwood expression:
dA
dt
= − k3A
k2
k1
+ A
(1.2)
And this is indeed the case with the modification that because the enzymatic reaction occurs
in the aqueous phase, the right hand side should be multiplied by initial enzyme concentra-
tion, S0. Then by observation, when A >>
k2
k1
the rate ν = dA
dt
≈ k3S0 is at its maximum,
hence νmax = k3S0. By defining KM =
k2
k1
and calling it the Michaelis constant, the ubiqui-
tous Michaelis-Menten equation of systems biology is obtained:
dA
dt
= − νmaxA
KM + A
(1.3)
Equation forms for active transport through NaKP [54,68] and NKCC [53,69] stem from the
mass-action kinetic descriptions of the reaction network structure of each transporter. As
examples, the rate equation of Lindenmayer and colleagues [54]:
νpump = νpump,max
(
NaC
NaC +Kint,Na(1 +KC/Kint,K)
)3(
KB
NaB +Kext,K(1 +NaB/Kext,Na)
)2
(1.4)
Reflects the stoichiometry of NaKP in its exponents as well as an inhibitory terms in the
denominator for pumping against concentration gradients in the cell interior (int) or exterior
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(ext), but the Michaelis-Menten components of their mass action derivation are recognizable.
More obvious still are these elements in the NKCC equations of Miyamoto and colleagues [53]:
νNKCC = νNKCC,max
(
NaB
NaB +KCONa
)(
KB
KB +KCOK
)(
ClB
ClB +KCOCl,1
)(
ClB
ClB +KCOCl,2
)
−νNKCC,max
(
NaC
NaC +KCONa
)(
KC
KC +KCOK
)(
ClC
ClC +KCOCl,1
)(
ClC
ClC +KCOCl,2
)
(1.5)
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Where the basolateral (B, inward) and cellular (C, outward) rate terms are the product
of a Michaelis-Menten term for each transported ion. While somewhat reductionist, these
rigorous studies on molecular function have found utility in a number of undeniably systems-
focused models [16,17,70] of epithelial physiology.
An example of systems biology in the broader sense at work in epithelial transport
would be that of Bertrand and colleagues [7]. They employed a model of exocytosis based
on membrane electrical characteristics. Using standard parameter estimation techniques
with 5 parameters they were able to characterize exocytosis events in goblet-like cells based
on an increase in monolayer capacitance and resistance. This simpler model, self-described
as ”lumped”, makes good on one of the promises of systems biology: emergent biological
behavior can be characterized by simple, physically grounded models [71].
An extension of model prediction and analysis is the use of models for process control and
design, which are more relevant from an engineering and clinical applications perspective.
The primary goal of process control is to maintain desired process operation conditions
(setpoint tracking) in light of external perturbations (disturbances). In medicine, good
patient health is the desired operating condition and disease can be viewed as a disturbance to
that process. Traditionally, medicine has operated solely under physician control (under the
strong assumption of patient compliance), as illustrated in Figure 1.6. This comprises both
the obvious feedback regime wherein a doctor makes treatment decisions based on patient
charts, as well as feedforward control (i.e. prophylactics). However, biological nonlinearities
produce synergisms that often obfuscate underlying causes of disease and lead to unexpected
side-effects. The fundamental assumption of this dissertation is that physician decisions are
most often good, but usually based on linear disease-treatment expectations that could be
improved if personalized, model-based predictions of patient response to treatment are given
to support clinical actions. This clinical decision support system (DSS) or treatment design
scheme is given Figure 1.6.
In this paradigm, final treatment decisions are solely in the hands of the physician,
but they are informed by rigorous, quantitative predictions of a course of therapy that
is optimal within measurement error and timing. This paradigm has been explored in a
number of fields: in cancer chemotherapy [72, 73, 74, 75] and neutropenia [76]; in glucose
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Figure 1.6: Top: Standard-of-care Physician-Patient treatment feedback loop. Bottom: A
clinical DSS for treatment design using model-informed physician decisions for patient care.
control in diabetes [77, 78, 79, 80] and critical care [81, 82]; in sepsis [83, 84] and many other
diseases [85, 86].
1.2.2 Systems Biology in Airway Transport at the Cellular Scale
Most of the mathematical models used in the the study of epithelial liquid and ion transport
have been utilized for their structural and dynamical insight. Beginning with Hartmann and
Verkman [87], differential algebraic equation (DAE) models have been used to predict ion
fluxes in airway epithelia. Their work was able to roughly match experimental data from
the Ussing Chamber in dog trachea, but they did not account for dynamic cell volumes due
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to water flux, nor did they evaluate paracellular transport. Novotny and Jakobssen [88, 89]
made a signigicant step forward in airway modeling by accounting for liquid and ion trans-
port in the paracellular space while also modeling cell volume regulation in the thin-film
environment of native airway. They also considered how CF might effect transport [89].
The structure of their model is physiologically detailed and produces accurate estimates of
homeostatic liquid volumes and transport processes over the minutes-length time scale of
Ussing Chamber experiments. However, their numerical integration method - Euler inte-
gration with algebraic electrical constraints solved via Newton’s method at every step - is
unstable over time periods of simulated hours. Falkenberg and Jakobssen [55] translated the
Novotny model from Fortran c©into Matlab and added pH regulation. Despite the change
of programming language - and the more advanced DAE solution capabilities of the Matlab
program - the Euler-Newton differential algebraic equation solution approach from [88] was
preserved. Thus, modifications to the integration approach used for their model would need
to be made to provide long-term model stability. Fischbarg and Diecke [90] developed a
similar model of fluid and electrolyte transport that accounted for paracellular water and
flux in the corneal epithelium that calculates similar flux values to those of [87]. Also in the
eye, Zhu and Chauhan [91] developed a model of tear dynamics that accounted for the elec-
trosmotic effects involved in liquid and ion transport. Terashima and colleagues developed
a model that described volume regulation of cardiac cells that accounted for many similar
transport mechanisms to those in the airway epithelium [92].
In 2013, two ODE models of airway liquid and transport in nasal epithelia were presented
by different groups that were very similar structurally and parametrically. The first model,
by Garcia and colleagues [16], differs in terms of pathways represented in the second model,
by O’Donoghue and colleagues [17], only by the addition of apical K+ transport. Both
models used Monte Carlo methods to estimate model parameters and used Ussing Chamber
data from the same experiments performed by Willumsen and Boucher [56, 93]. In terms of
scope, Garcia and colleagues demonstrated that nasal epithelial transport parameters could
be readily identified using a mathematical model [16]. O’Donoghue and colleagues extended
that finding by also asserting their model prediction that CF cells demonstrate increased Na+
permeability, which has been reported experimentally in human bronchial epithelia [2, 49].
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The primary utility of both studies is stated as the rapid prediction of HNE culture transport
behavior in Ussing Chamber experiments.
The Ussing Chamber is not, however, representative of the in vivo environment of the
airway epithelial tissues. HNE and HBE have a semi-infinite basolateral fluid reservoir in
the bloodstream, but they exist at a ”thin-film” air-liquid interface (ALI). Airway cells
homeostatically regulate the ASL volume and composition [12, 94] while also maintaining
their own internal volume and composition [9]. It is known that ENaC and CFTR are
regulated by the ASL volume [13,49]. The characteristic “ramp-up” behavior of ISC observed
in Ussing Chamber experiments using airway epithelia is due to the effect of ASL flooding
on ENaC permeability [13], and is a clear visualization of the switch between thin-film and
flooded transport paradigms. Other transport transport effects such as fluid secretion due
to phasic shear stress acting on purinergic signaling pathways is only observable in the thin-
film environment [24, 49, 95]. The thinness of the thin-film makes ion transport difficult to
measure - though it can be done with more specialized electrodes [12] - since the electrodes
used in Ussing Chamber experiments cannot be sufficiently submerged in the native ASL,
which also hinders comparison of ion transport in the two regimes. These discrepancies
motivate developing measurement methods and models that can describe liquid and solute
transport in the physiological thin-film setting.
The most readily accessible dynamic observable in the thin-film is ASL height (at the
center of the cell culture) [5, 9, 12, 70, 96]. Height does not correlate with measurements of
volume [65, 97], which are usable in the thin-film or otherwise. Thereofore, it may be more
useful to inform thin-film models using ASL volume data. Na+ and Cl− concentrations are
easy to obtain as they can be measured in the thin film using flame emission or small elec-
trodes [12, 94]. Intracellular volume can be measured as well via fluorescence microscopy,
which useful in informing homeostatic mechanisms present in homeostatic models. ATP and
Ca2+ concentrations have also been measured over time [24, 95, 98]. Each of the aforemen-
tioned thin-film measurements could be useful for modeling the liquid and solute transport
process involved in maintaining homeostasis in the cell and ASL. To date, however, thin-film
models have only used ASL and cellular height/volume [70, 96] and ATP [96] to inform or
test their predictions. The model of Warren and colleagues [70] is similar in structure to
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many of the electrophysiological models of liquid and solute transport processes in the liter-
ature(that of O’Donoghue and colleagues [17] is modeled after it) with full treatment of ion
fluxes using the GHK equation 6. It also considers the effect of a step change in intracellular
Ca2+ (due to osmotic or other stress) on Cl− secretion via CaCCs. The step change is a
somewhat arbitrary simplification of the Ca2+ response seen in physiological cell stress, but
serves to improve model fit. The model by Warren et al. does not account for paracellular
liquid transport or the known ASL regulation effects on ion transport, providing a clear
path forward for future models. The other thin-film model by Herschlag and colleagues [96]
is interesting in its parsimony. They take an ion-agnostic perspective, accounting for only
the general effect of cation and anion transport and purinergic signaling on ASL volume
regulation. Their successful incorporation of a phasic shear stress model of ASL regulation
is a novel notion in the modeling literature as well.
The stated research scope of these aforementioned models is directed toward the benchtop
study of airway liquid and solute transport and the identification of new therapies. Currently
none of these models have been used in a manner considering disease control and therapeutic
design possibilities. This presents an opportunity to use systems biology tools in a novel
way within a field where so much of the experimental data is generated from devices meant
for experimental control and design. As a motivating point, regardless of the epithelial
transport process studied, the Ussing Chamber is an important engineering tool because
it allows for the control of an entire physiological transport system using only voltage and
current measurements. Furthermore, it allows for input design that can elucidate model
parameters [7]. This was illustrated by Bertrand and colleagues wherein the control aspect
was addressed in the first figure of [7] (reproduced with permission in Figure 1.7), and design
was one of the featured results of that work.
One of the takeaways from Figure 1.7 should be that the concepts of control have been
generally introduced to the field of epithelial biology through the Ussing Chamber. If adopted
and applied more widely in the field, control and also design of epithelial response to external
inputs (i.e. therapies) could be used to effect better patient care in CF and other diseases of
epithelial origin. This notion is one of the essential motivations for this thesis. Ultimately,
though, any design that does not account for returning mucociliary clearance in patients
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Figure 1.7: Detailed layout of voltage clamp with feedback control loop evident as part
of transepithelial impedance measurement hardware (reproduced from [7] with permission).
Inputs and set-point (Voffset) illustrate the essential components for biological control in the
Ussing Chamber.
with CF will fail to account for what is a key setpoint maintaining patient lung function.
This must be accomplished by also modeling airway transport on the whole-lung scale.
1.2.3 Systems Biology in Airway Transport at the Organ Scale
Measurements of MCC have long been used to gauge treatment response in patients with
cystic fibrosis and are now an accepted biomarker to that end [99]. The recently developed
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method of measuring DTPA absorption in the lung has also shown utility for indicating
therapeutic benefit [1,8]. These studies usually produce data-dense time-series measurements
of particle clearance, which are well-suited for model-based analysis.
Incidentally the field of pharmacokinetic (PK) modeling focuses on the routes by and
the rates at which compounds of interest are cleared from the body. At the most basic
level, PK models can be empirical statistical estimates of residence time in the body given
as an area under a clearance curve (AUC) [8,100]. Added detail is provided with the use of
”compartments” that partition drug disposition in the body into model states that interact
with other compartments via specific clearance rates. These model compartments can be
purely mathematical constructs [101, 102] or represent the transport that occurs between
organs and tissue in the body [103] or more often a combination of the two [1, 80] with
varying degrees of detail.
Most of the literature on PK studies in CF focuses on antibiotics and antifungals [101,104,
105, 106, 107, 108, 109, 110,111, 112]. While some of these studies involve oral or intravenous
administration of the therapeutic of interest, none of the existing inhaled compounds for CF
lung infections - tobramycin [101, 105], colistin [108, 113], aztreonam [114], and levofloxacin
[115] - utilize mechanistic compartment-based PK models.
In fact, few compartment based models of lung clearance exist that account for the effect
of MCC on an inhaled drug [116]. One such model has been used to characterized insulin
delivery in isolated perfused rat trachea [117], and another described the PK characteristics
of inhaled corticosteroids [118]. In the aforementioned studies, pharmacodynamics (i.e. the
description of drug efficacy over time) are also relevant, but may be considered separately.
PK descriptions of radiopharmaceutical lung clearance are odd in that the probes used to
measure MCC and absorption have no pharmacodynamic effect [8, 21]. However, in the
case of treating patients with CF PK models of probe MCC can be used to directly gauge
the PD of mucociliary-targeted therapies. The addition of probe absorption to PK models
of MCC can then also assess the PD of absorption-targeted therapies through the strong
correlation between probe absorption and liquid absorption [65]. Moreover, describing the
causality of this correlation requires a detailed mechanistic focus on airway epithelial solute
transport. Such a multi-scalar understanding of airway transport would not only allow
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for PK-PD characterization of therapies. Rather, this description could be used to design
optimal treatment schedules for patients with CF.
1.2.4 Dissertation Overview
Lung disease is the primary cause of mortality for patients with Cystic Fibrosis. Failure in the
mucociliary apparatus due to airway dehydration prevents inhaled particles and pathogens
from being cleared out of the lung, leading to infection, inflammation, and bronchiectasis.
Rescue of mucociliary clearance, either via direct hydration or restoration of CFTR func-
tion and/or correction of the concomitant ion transport defects should improve respiratory
function in patients with CF. Therefore, a robust, physiologically motivated mathematical
description of mucociliary clearance in the lung could be useful as predictor of therapeutic
benefit. The addition of a model of solute absorption in the lung could provide additional
understanding about therapeutic effect and provide a link to the in vitro observations of
correlation between ASL liquid and solute absorption. This is the focus of chapter 2. The
resultant model described Chapter chapter 2 has simple kinetic parameter descriptions of
TcSC and DTPA clearance with an added physiological parameter, the fraction of functional
ciliated area/airway (FFCA), that is decreased in patients with CF and in CF cells in vitro.
FFCA is increased both in vivo and in vitro via hydration, particularly by way of inhaled
hypertonic saline, a therapy in CF. FFCA is therefore a trans-scalar parameter that relates
CF lung disease at the organ scale down to a cell-scale defect.
The lung-scale description of DTPA absorption in chapter 2 is useful in demonstrating
clinical benefit of therapies with physiological grounding. However, it does not explain the
mechanisms that lead to increased MCC through increased FFCA, nor does explain the
DTPA hyperabsorption present in the lungs of patients and its abrogation via osmotic ther-
apy. chapter 3 begins to address these shortcomings through development and analysis of a
detailed mathematical model of cell-scale liquid and solute transport. The resultant model
accurately captures liquid and DTPA transport behavior from data, and the coincident ion
fluxes are within reported values despite being an emergent property of the model state
and parameter values. The model structure is robust and physiologically reasonable vari-
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ations in the parameter values allow for the identifiability of individual patient transport
characteristics. Also presented is a detailed analysis of treatment failure in an investigative
hypertonic saline delivery device. Identification of most-likely failure modes informs the
design of theoretically more effective treatment formulations or dose schedules.
chapter 4 presents a newly developed parameter identification tool that assesses practical
identifiability via the profile likelihood in the Pyomo modeling environment. A series of
case studies focuses on the interrelation of model observability and identifiability through
a canonical chemical engineering reaction system and the Chapter 2 lung-clearance model.
chapter 5 will provide perspective and prospective insight regarding future improvements
in modeling airway epithelia and treatment design in Cystic Fibrosis, including a proposed
optimal treatment formulation.
The final chapter, (chapter 6) details a research project performed in parallel with the
main topic of this thesis. The academy is not only responsible for the collection of knowledge
but also its dissemination and the optimization thereof. Accordingly, this thesis also contains
research on the effect of external stakeholder input on engineering product design. This work
was performed using data recorded from the notebook responses of undergraduate chemical
engineering students. Primary focus was directed toward understanding how customer and
external stakeholder voice could affect final product performance and economics for the
benefit of product users. Within that investigation, considerations were made regarding
both quantitative and qualitative student outputs as well as for student experience level.
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2.0 PHYSIOLOGICALLY RELEVANT LUNG-SCALE MODELING OF
MUCOCILIARY AND ABSORPTIVE PULMONARY CLEARANCE
2.1 MUCOCILIARY CLEARANCE AND ABSORPTION IN THE LUNG
Cystic Fibrosis (CF) is an autosomal recessive disease that arises from a defect in the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CF affects multiple organ
systems, with the most detrimental effects occurring in the lungs [119]. CFTR encodes an
anion channel on epithelial surfaces, that is dysfunctional or absent from the CF epithelium.
The associated loss of Cl− and HCO−3 secretion along with a tendency to hyperabsorb Na
+
through the epithelial sodium channel (ENaC) results in osmotic gradients that favor rapid
absorption of the airway surface liquid (ASL) layer, leading to dehydrated airway mucus and
impaired mucociliary clearance (MCC) [120], [21]. The inability to clear pathogens via MCC
leads to chronic infection, inflammation, airway damage, and premature respiratory failure.
Inhaled agents that reverse osmotic gradients in the airways are used to treat the ASL
dehydration defect associated with CF. Hypertonic saline (HS) is one such osmotic agent that
has been shown to increase both MCC and lung function in patients with CF [22], [121]. More
recently CFTR modulators have been developed that substantially improve lung function in
individuals with specific CFTR mutations [41].
Outcome measures and biomarkers that quantify the basic pathophysiology of CF lung
disease are needed to allow for the rapid screening of new therapeutics for CF. Ideally,
these screening methods seek to quantify the basic pathophysiology of CF lung disease.
Mucociliary clearance scans, which quantify the clearance of a radiopharmaceuticals from
the lungs, are one such functional imaging method for studying outcomes in CF.
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This method was expanded herein to include measuring the clearance of a radiolabeled
small-molecule that can be absorbed as well as cleared via MCC. Similar techniques have
been used in the past to resolve the individual components of lung clearance [122], [123].
The in vivo method utilizes Technetium 99m sulfur colloid (TcSC) a non-absorbable particle
probe and Indium 111-DTPA (DTPA) an absorbable small molecule probe. The probes are
delivered together in a liquid aerosol. Figure 2.1 presents a schematic for pharmaceutical
clearance from the airway epithelium. Shown at left in Figure 2.1, the small molecule probe
(green) clears more rapidly than the particle probe (blue). It assume that MCC clears the
probes at similar rates and that the difference in their clearance rates is therefore associated
with the absorption of the small molecule (red).
Figure 2.1: Left panel: schematic of transport routes in the airway epithelium.
The black and white horizontal arrows represent mucociliary clearance of TcSC and DTPA,
respectively. DTPA (downward white arrow) absorbs across the airway epithelium via the
paracellular route. Water (downward blue arrow) also absorbs across the epithelium via
the transcellular and paracellular routes. Right panel: normalized TcSC (blue circles) and
DTPA (green circles) retention curves with the difference between the respective datasets at
each time point shown as absorption (red circles) in CF subject 8.
Previous in vitro studies have demonstrated a relationship between DTPA and airway
surface liquid absorption rates [65]. DTPA absorption is increased both in vivo in CF
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airways and in vitro in CF airway cell cultures [8, 65]. Decreases in DTPA absorption after
osmotic therapies have also been demonstrated in vitro and in vivo [8, 65]. Thus, multi-
probe methods offer a potential means of measuring of both MCC and ASL absorption
rates [8]. Successful CF therapies should restore ASL volume by correcting defective airway
epithelial ion transport [42, 124]. The restoration of airway hydration should be rapidly
detectable through these multi-probe imaging methods as decreased liquid absorption rates
are reflected through slower absorption of DTPA and improvements in MCC cause increased
TcSC clearance.
While many medications are given via inhalation, few mechanistic PK descriptions of
inhaled drug clearance out of the lung exist. The PK models that do exist are generally
one (systemic) or two (lung and blood) compartment models [101,105,108,113,114,115,125]
and generally do not consider MCC. The information gained from an at least partially
physiological description of the mucociliary and absorptive clearance of pharmaceuticals in
the lungs could provide insight toward improving drug efficacy. Furthermore, in the case
of functional imaging, PK models stand to provide a more detailed description of airway
diseases (e.g. CF) that cause changes in the MCC and absorptive properties of the airways.
This chapter begins by evaluating the utility of a previous, semi-physiological PK model
for inhaled insulin by applying its structure to the functional imaging data of particle and
small molecule clearance from the human respiratory tract. Presented after that is an ex-
tended compartment-based model that better allows an informed physiologically motivated
model structure and identifiable parameter values. The goal in developing this model is to
better resolve the specific physiological mechanisms that contribute to the composite func-
tional imaging result. While used to gauge response to HS inhalation, the PK aspect of
these models measures the clearance of the probes and not the clearance of HS. However,
these mechanism-specific measurements may provide more sensitive and detailed evaluations
of therapeutic efficacy than the currently used image-derived metrics. The challenge is to
construct a mathematical representation of the physiology that can resolve the underlying
mechanisms and their interactions.
There have been a number of mechanistic compartment-based PK models for inhaled
pharmaceuticals [116, 117, 118, 126, 127], but none have considered the PK behavior of the
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radiopharmaceuticals used for functional imaging from which the data originates, nor has
anyone assessed absorption kinetics with the methodology employed here. It is hypothe-
sized that by dividing the lung into a solely absorptive peripheral lung region and separate
central lung region that has both absorption and MCC capability, and by subdividing this
central lung region into fractions with and without functional ciliated airway, the dynamics
of simultaneous particle and small molecule probe clearance from the lung are reproduce-
able. Further hypothesized is that (i) functional ciliated airway clears at the same rate in
patients with CF and non-CF subjects; (ii) the fraction of functional ciliated airway (FFCA)
is decreased in CF (i.e. a binary distinction between clearing and non-clearing regions);
and (iii) FFCA can be increased through inhalation of HS. The models provide estimates
of FFCA, MCC, and lung absorption, the latter of which is believed to be related to liq-
uid hyper-absorption in CF small airways. These measured parameters may substantially
expand the utility of the functional imaging measurement by providing more mechanistic
insight into lung physiology and response to therapeutic agents (a list of all abbreviations
and their definition used in this work can be found in Table 2.1).
2.2 MATERIALS AND METHODS
2.2.1 Functional Imaging Methods
Data from previously reported clinical imaging studies were utilized [8]. These studies in-
cluded both adult (n=12) and pediatric (n=9) patients with CF and healthy controls (n=9).
Raw imagining data from this study can be found in the supplement in Table S1 pf [1].
An aerosol based functional imaging technique that measures the clearance of two different
radiopharmaceutical probes from the lungs over 80 minutes was used. Indium-111-labeled
diethylene triamine pentaacetic acid (DTPA) is a small molecule probe (≈500 Da) that is
cleared from the lung through both absorption and MCC while Technetium-99m-labeled
sulfur colloid (TcSC) is a particle probe (≈300nm) that is cleared only by MCC. DTPA ab-
sorption is calculated by subtracting the TcSC clearance rate (MCC) from the total In-DTPA
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Table 2.1: Abbreviations and constants in this chapter.
Abbreviation Description
AIC Akaike Information Criterion; a Metric of Model Appropriateness
ASL Airway Surface Liquid Layer
C Imaging Region of Interest About the Central Lung; Analogous to L in
Model
CF Cystic Fibrosis
CFTR Cystic Fibrosis Transmembrane Conductance Regulator
CI Confidence Interval
DMEM Dulbecco’s Modified Eagle Medium
DTPA Indium-111 Diethylene Triamine Pentaacetic Acid
ENaC Epithelial Sodium Channel
FFCA Fraction of Functional Ciliated Airway
HBE Human Bronchial Epithelial (cell)
HS Hypertonic Saline
IS Isotonic Saline
k Number of Free Parameters in Model
MCC Mucociliary Clearance
N Number of Data Points Analyzed for Model Fit
ODE Ordinary Differential Equation
PK Pharmacokinetic
Tc-SC Technetium-99m Sulfur Colloid
Wi Weighting Factor of the i
th Element of the Dataset for AIC
yi i
th Value of Dataset
yˆi i
th Value of Model Fit
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clearance rate. Both probes were mixed and delivered together via nebulizer in the same liq-
uid aerosol. All patient studies were approved by the University of Pittsburgh Institutional
Review Board (clinicaltrial.gov numbers NCT01223183 and NCT01486199).
The aerosolized probes were delivered simultaneously by nebulizer using a technique
that deposited aerosol primarily in the airways [8]. Their clearance (normalized decrease
in radioactive counts over time) was then independently assessed over 80 minutes using
dynamic planar scintigraphy. Images were corrected for background, decay, and spillover
in the emission spectra of the probes prior to analysis [8]. Whole, peripheral and central
lung zones were considered, where the central zone was defined as a rectangle with 1
2
the
height and width of the whole lung region of interest positioned along the medial lung border
and centered vertically. At t=10 minutes (11th imaging frame) subjects inhaled nebulized
saline treatments for 10 minutes. Adult patients with CF inhaled 7% hypertonic saline (HS,
n=11) on one testing day and isotonic saline (IS) on the other. Control and pediatric CF
subjects performed a single testing day with isotonic saline. Changes in DTPA absorption
in response to osmotic therapies have previously been demonstrated both in vitro [65] and
in vivo [8]. Analysis of the TcSC and DTPA retention curves as well as DTPA absorption
(ex: Figure 2.1) plotted with a logarithmic ordinate showed that the data did not follow a
monoexponential profile, which guided selection of the model structure and kinetics necessary
to accurately reproduce the data.
2.2.2 Initial Model Structure
Sakagami [116] proposed a robust modeling scaffold for inhaled pharmaceuticals that takes
into account the regional pharmacokinetic (i.e. MCC and ABS) differences between the
large conducting airways (L) and the distal lung (D), consisting of smaller airways and
alveoli. Analysis of the corresponding system of compartment-based ordinary differential
equations (ODEs) yielded a bi-exponential retention curve for TcSC as proposed by Byron
[117]. However, this model structure could not be reconciled with the whole of the data used
herein (see Discussion).
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2.2.3 Model Parameter Estimation
Regression of model parameters, regardless of model structure, was performed sequentially
as follows. Model parameters were estimated using nonlinear least-squares regression (via
lsqnonlin in MATLAB, c©2013, The MathWorks, Natick, MA) between model predictions
and experimental data. The experimental design allowed for sequential estimation of the
MCC and absorption rate parameters as follows:
1. The parameters that govern MCC (kLT and FFCA) were fit to the TcSC retention data.
2. The regressed MCC parameters were then fixed, and the absorption rate parameters
(kDB and kLB) were fit to the absorption curve.
3. Parameter uncertainty was calculated using the nlparci function in MATLAB ( c©2013,
The MathWorks, Natick, MA) to obtain confidence intervals on all model parameters.
2.2.4 Model Analysis
The assumptions above were tested individually, and in combination, for appropriateness
using the Akaike Information Criterion (AIC). Akaike [128] originally proposed that model
appropriateness could be assessed according to the equation:
AIC = (−2)ln(maximum likelihood) + 2k (2.1)
Where a Gaussian distribution represents the maximum likelihood of the data and k is the
number of free parameters in the model. Thus, the model with the least value of AIC is
deemed most appropriate in terms of model fit and parsimony. Yamaoka and colleagues [129]
further elaborated on this information criterion by proposing that for a process with Gaussian
error the AIC can found from the equation:
AIC = Nln(
N∑
i=1
((yˆi)− yi)2/N) + 2k (2.2)
Where yˆi is the model fit and yi is the data value at the i
th image of the N=80n set because
there are 80 images per patient and n patients per study group.
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2.2.5 In Vitro Assessment of Ciliary Activation
We developed an in vitro imaging assay to measure the fraction of the epithelium that has
functional MCC in order to test the hypotheses that FFCA is decreased in CF and that
hydration can recruit areas of otherwise non-functional cilia. Fully differentiated human
bronchial epithelial (HBE) cell cultures were viewed using a phase-contrast objective (Nikon
Eclipse TI). These cultures were derived from lungs removed at the time of lung trans-
plantation and prepared using previously described methods approved by the University of
Pittsburgh IRB [13]. A series of 10 images was taken of each culture that allowed for the de-
termination of the change in pixel intensity between successive images in the stack, as shown
and Video 1. Ciliary beat can be observed under these conditions and is characterized by
a change in light intensity measured by the camera. This change in light intensity can be
translated to a change in pixel intensity in the images obtained when placed in sequence to
form a movie of ciliary motion (see Figure 2.3).
The average change in pixel intensity of all cultures was determined in both CF lines
(n=6) and a non-CF line. Average changes in the intensity of each pixel from 12 untreated
cultures from the non-CF line were measured and the average change in intensity over all
pixels was used as a baseline measurement of functional ciliary movement. Pixels in each
stack with average change in intensity greater than the non-CF baseline were said to have
functional ciliary movement. To test the effect of osmotic agents, 5 µL of either isotonic
(300 mOsm) or hypertonic (600 mOsm) saline was added to the apical surface of cells prior
to imaging. To test for saturating effects of hydration, Dulbecco’s Modified Eagle Medium
(DMEM) was sequentially added from the basolateral bath to the apical surface of the
cultures as follows: 10 µL of DMEM was added to the apical surface of the cells from the
basolateral bath before the cells were imaged, and an additional 10 µL of basolateral DMEM
was added to the apical surface prior to a second, identical, imaging routine.
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Figure 2.2: Video of recorded ciliary activity with three regions of ”hurricane” activity
visible. First image is Figure 2.3 superimposed on the video. The superimposition can be
recovered by scrolling to the previous page (in the digital format of the dissertation).
2.3 PRELIMINARY ANALYSIS
This section presents and analyze an example of a flexible compartmental PK model of MCC
and absorption-based drug clearance from the lung developed by Sakagami and colleagues
[116]. This model structure takes into account the regional PK differences between the large
conducting airways (L) and the distal lung (D) consisting of smaller airways and alveoli
[9]. This model had four kinetic parameters to be solved for by regression: kDL and kLT
as MCC rate constants, and kAP and kAL as absorption rate constants. The model also
has a dosing parameter (C/P) that represents the ratio of radiopharmaceuticals delivered
to the large airways as compared to the distal lungs. Using this as a starting point, the
case of first order clearance kinetics via both absorption and MCC in both L and D was
34
Figure 2.3: A pseudo-color image of non-CF HBE cells under 10x enhancement is shown.
The viewing frame is identical to that in 1. Darker (more blue) regions show areas with
lower average change in pixel intensity during 1 whereas lighter (more yellow) regions show
areas with higher average change. In combination with1 it is shown that regions that display
little visible movement are more blue, and the regions with visible motion, particularly the
“hurricane” regions, are more yellow.
considered. Under the assumption that TcSC is not absorbed in any lung region, analysis
of the corresponding system of compartment-based ordinary differential equations (ODEs)
yielded a bi-exponential retention curve for TcSC as proposed by Byron [126]. Regression of
the model parameters was performed sequentially. First, the MCC rate parameters were fit
to the TcSC retention data. Those values were then fixed and the absorption rate parameters
were fit via the same functions to the absorption curve for DTPA. In the case where C/P
was allowed to vary model fit was excellent, as illustrated in Figure 2.4 for MCC and Figure
2.5
35
Figure 2.4: Model estimated MCC (red) based on functional imaging data (blue) in non-CF
subjects, CF subjects without and with HS inhalation, and pediatric patients with CF. C/P
was allowed to be fit in this case, allowing for estimation of the deposition pattern that best
describes the whole lung clearance curves.
However, interrogation of model parameters revealed that while kLT values were on the
same order of magnitude as reported in [116] C/P values were below unity. This does
not agree with measured C/P values that were in excess of 2 for all subjects as would be
anticipated based on the use of a breathing pattern designed to promote airways deposition
[8]. In an attempt to reconcile the model structure with the imaging metric, the model was
refit with a C/P lower bound of 1.5. As illustrated in Figure 2.6, the model fit of MCC
suffered from extreme heteroskedasticity. The text and data in Figure 2.7 provide evidence
that bounding the C/P model parameter facilitated agreement with the imaging metric
in terms of its estimation but at the expense of model fit, particularly in terms of MCC.
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Figure 2.5: Model estimated DTPA absorption (red) based on functional imaging data (blue)
in non-CF subjects, CF subjects without and with HS inhalation, and pediatric patients
with CF. Best fit parameters as well as normalized TcSC and DTPA clearance (TcCL and
InCL) and absorption (Abs) are given in each panel for their respective patient group. C/P
estimates do not agree with the values obtained directly from imaging data.
Furthermore, analysis of the model parameters via the asymptotic method from a numerically
approximated Jacobian yielded wide confidence intervals. These intervals were in excess of
± 10 times the nominal parameter value indicating poor model parameter identifiability.
C/P determines the deposition fractions in compartments with assigned physiological
clearance types: fast MCC in central lung, slow MCC in the periphery. C/P was too small
in the better fitting case, and MCC was too slow in the constrained case. This indicated
that a good fit required a lower contribution of large airway clearance behavior than could
be justified by the deposition data. This understanding is the basis of the concept that in
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Figure 2.6: Model estimated MCC (red) based on functional imaging data (blue) in non-
CF subjects, CF subjects without and with HS inhalation, and pediatric patients with CF.
C/P was allowed to be fit in this case, allowing for variation in deposition pattern that best
describes the whole lung clearance curves.
the large airways only a fraction of area with working ciliary clearance exists. The resultant
model structure and analysis of its behavior are the focus of the rest of this chapter.
2.4 RESULTS
2.4.1 Model Synthesis and Assumptions
Tthe original model of Sakagami [116] was extended structurally to account for the dynamics
and deposition observed in the clinical data set. Founded on a basic understanding of lung
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Figure 2.7: Model estimated DTPA absorption (red) based on functional imaging data (blue)
in non-CF subjects, CF subjects with out and with HS inhalation, and pediatric patients
with CF. Best fit parameters as well as normalized TcSC and DTPA clearance (TcCL and
InCL) and absorption (Abs) are given in each panel for their respective patient group. C/P
estimates do not agree with the values obtained directly from imaging data.
anatomy and physiology, the lung structure can be lumped into two key dynamical structures
as shown in Figure 2.8.
Additional assumptions made in synthesizing this model are as follows:
• A fraction of the large airways (L), which are represented in the central (C) lung region
of interest (ROI) [130], has functional MCC, with MCC in the remainder of L being
non-functional. This allows the subdivision of L into two sub-compartments: LF , which
has functional MCC, and LN , which has no functional MCC.
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Figure 2.8: Schematic model structure describing the clearance of small molecule
and particle probes from the lung. Initial depositions: T0=trachea, C0=central,
P0=peripheral. See Table 1 for full list of model abbreviations.
• The initial doses of the radiopharmaceuticals delivered to either the central (C0) or
peripheral (P0) lung regions are described as the number of counts within C or in the
area outside of C but within the whole lung ROI in the first image, respectively [8]
(Figure S1 provides a visual representation of the C and P ROIs).
• 10% of inhaled radiopharmaceuticals were assumed to deposit in the trachea (T0) [116].
However, neither counts in T nor the bloodstream (B) have a unique impact on the
clearance of the TcSC and DTPA.
• MCC in the distal lung D, which contains small and intermediate-sized airways in addi-
tion to alveoli [130], is a slow process; given the 80-min timescale of the data this rate
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cannot be resolved with confidence. As a result, the MCC term from D to L, kDL, is
neglected.
The result of these assumptions is a three-compartment model for MCC in the lung wherein
two compartments (D and LN) are absorptive and one compartment (LF ) has MCC in
addition to absorptive clearance, as shown in Figure 2.
2.4.2 Model Equations
Equations modeling the transport of both of the probes are outlined below. The model pa-
rameters kLT , kDB, kLB and FFCA, the fraction of L with functional MCC, were determined
by nonlinear least-squares regression as described in Methods. For TcSC clearance, kDB
and kLB are set equal to 0. The mathematical description of this model, written as ODEs
representing the change in counts in each model compartment, is as follows (see Table 2.2
for full list of model abbreviations and Appendix B for code to simulate the equations):
dD
dt
= −kDBD (2.3)
dLN
dt
= −kLBLN (2.4)
dLF
dt
= −kLBLF − kLTLF (2.5)
dT
dt
= kLTLF (2.6)
dB
dt
= kDBD + kLB(LN + LF ) (2.7)
2.4.3 Model Fit and Predictions
The ability of the model to reproduce therapeutic response after the inhalation of hypertonic
saline was studied using imaging data from patients with CF who inhaled isotonic saline (IS)
41
Table 2.2: Model parameters in the work presented herein
Parameter Description
B Bloodstream Model Compartment (units counts)
C0 Initial Counts in L (units counts)
D Distal Lung Model Compartment (units counts)
FFCA Free Parameter; Fraction of C0 in LF (units counts)
L Large Airway Model Super-Compartment (units counts)
LF Sub-compartment of L with Functional MCC (units counts)
LN Sub-compartment of L without Functional MCC (units counts)
kDB Free Parameter; Rate Constant of Absorption in D (units min
−1)
kDL Free Parameter (Unused in Final Model); Rate Constant of MCC from D
to L (units min−1)
kLB Free Parameter; Rate Constant of Absorption in L (units min
−1)
kLT Free Parameter; Rate Constant of MCC from L to T (units min
−1)
P0 Initial Counts in D (units counts)
T Trachea Model Compartment (units counts)
and hypertonic saline on alternating study days [8]. Retention of TcSC, which is a metric of
MCC, is shown with model fit for each patient group in Figure 3 [21]. Data from pediatric
patients with CF and healthy controls who inhaled isotonic saline is also shown. The model
captured the dynamics of MCC in all patient groups. The previously described increases
in MCC associated with HS inhalation are apparent in the image-derived data and the
model fits. However, as previously reported, no statistical differences in baseline MCC were
detected between the CF IS, pediatric CF, and control groups [8].
DTPA is assumed to deposit in the same regions and clear by MCC at the same rate
as TcSC; DTPA absorption is then captured by regressing the parameters kDB and kLB.
Additionally, the previous studies have shown that the absorption of DTPA is proportional
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Figure 2.9: TcSC retention (mean ± SEM) vs. model fit (black line) for four
patient subgroups. (A) Non-CF subjects (n=9) (B) patients with CF (n=12). (C) patients
with CF after inhalation of hypertonic saline (n=11). (D) Pediatric patients with CF. Data
from [8].
to the absorption of airway surface liquid in vitro [65]. As such, the effect of hypertonic saline
on liquid absorption, using DTPA as an analog, is shown in Figure 4, along with the model
fit for each group [8]. The model again captured the dynamics of absorption in all groups.
Increased baseline rates of DTPA absorption are apparent in both adult and pediatric CF
groups, as previously described [8].
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Figure 2.10: DTPA absorption (mean ± SEM) vs. model fit (line) for four patient
subgroups (A) Non-CF subjects (n=9) (B) patients with CF (n=12). (C) patients with CF
after inhalation of hypertonic saline (n=11). (D) Pediatric patients with CF. Data from [8].
The model predicts that both TcSC retention and liquid absorption will follow tra-
jectories within narrow envelopes based on the predicted upper and lower 95% confidence
intervals (CIs) of the model parameters. These CI envelopes are derived using all possible
combinations of the upper and lower 95% CIs and nominal values of the model parameters
to generate the extreme values of model predictions. Figure 5 shows that predicted model
trajectories lead to different final values of TcSC retention for all adult patient groups, with
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no overlap in trajectory envelopes of CF IS and non-CF groups for t>18 min and no overlap
between non-CF and HS trajectories for t>27 min. In other words, the three adult patient
subgroups have characteristically different total MCC behavior. Pediatric CF clearance tra-
jectories closely resemble those of adult patients with CF, but are not shown for ease of
interpretation. Patients with CF display less MCC than non-CF subjects, which appears to
contradict the finding in [8]. However, the present work evaluates the entire time course of
clearance, while the end of study value (t=80 min) was used as the evaluation time point
in [8]. By using the entire data sequence, particularly the dynamic response at short times,
it is possible to parametrically estimate and differentiate - with confidence - the MCC and
absorption dynamics between patients with CF and non-CF subjects. These analyses also
indicate that MCC function in patients with CF can be rescued by HS treatment, which
caused total MCC to exceed that of non-CF subjects.
Figure 6 shows that the model-predicted trajectories for liquid absorption have no overlap
for all t>0. Pediatric CF trajectories again resemble those of adult patients with CF, but
are not shown. Patients with CF have higher absorption than non-CF subjects, which can
be partially remediated by HS treatment. Combined, the results in Figures 5 and 6 indicate
that HS has two distinct mechanisms of action, both rescuing MCC and ameliorating liquid
hyperabsorption [22].
It has been proposed that the apparent increase of MCC following HS treatment occurs
by increasing the rate at which MCC occurs [22], [131]. The model suggests that the intrinsic
rate of MCC is the same in all patient groups, and the rescue of MCC can be attributed to the
recruitment of inactive portions of the airway. Figure 7A shows that the rate of MCC, kLT ,
is not significantly different between all patient groups (p>0.05). However, the parameter
FFCA (Figure 7B), which describes the fractional area of large airways with functional MCC,
is significantly lower in patients with CF versus non-CF subjects (p<0.05). Patients with CF
given HS, however, show a significantly increased FFCA (p<0.05). This would support the
concept of increased MCC, not through an intrinsic rate increase, but through an increase
in the overall epithelial area contributing to MCC.
The model also agrees with previous reports that absorption, represented by kDB and
kLB in the model, is increased in patients with CF vs. non-CF subjects (p<0.001 both
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Figure 2.11: Estimated TcSC retention trajectories for three patient subgroups.
Non-CF (red with dashed line), CF IS (green with dotted dashed line), CF HS (blue with
line). Shaded envelope characterizes 95% confidence interval (CI) of retention prediction by
the model. Pediatric CF subjects not shown due to overlap with adult CF.
parameters) [8, 132]. The model demonstrates that HS inhalation decreases absorption in
the peripheral lung (kDB), which includes both small and intermediate sized airways and
alveolar regions, more than IS inhalation (p<0.001). All model parameters are similar when
comparing baseline measurements in the pediatric and adult CF IS groups (p=NS). The
parameters, as well as those of similar studies, are shown in Table 2.3.
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Figure 2.12: Estimated DTPA absorption trajectories for three groups. Non-CF
(red with dashed line), CF IS (green with dotted dashed line), CF HS (blue with line).
Shaded envelope characterizes 95% confidence interval (CI) of retention prediction by the
model. Pediatric CF subjects not shown due to overlap with adult CF.
2.4.4 In Vitro Evaluation of Model Prediction
In order to verify that hydration increases the fraction of functional ciliated area, CF HBE
cultures were imaged (6 lines, n=12 filters) before and after addition of 10 µL of Dulbecco’s
Modified Eagle Media (DMEM) (Sigma-Aldrich, St. Louis, MO, USA), a liquid cell culture
media, to the apical surface and again after a second addition of 10 µL of DMEM. It was
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Figure 2.13: Least-squares solutions for model parameters are shown with 95%
confidence intervals for four groups: Non-CF (NCF), CF HS, CF IS, and Pediatric CF
(CFP). (A) MCC rate constant (kLT ) (min
−1). (B) Fraction (FFCA) of large airway with
functional MCC. (C) Peripheral lung absorptive rate constant (kDB) (min
−1). (D) Large
airway absorptive rate constant (kLB) (min
−1).
determined that hydration of HBE cells by addition of 10 µL significantly increases the
fraction of functional ciliated area (p<0.0005) above baseline. No further increase in FFCA
was observed following a second addition of 10 µL DMEM (p=NS), as shown in Figure 8A.
CF HBE cells were imaged following apical addition of either 5 µL IS (n=6) or HS (n=6).
A comparison of relative effect of IS and HS in CF HBE cells is shown in Figure 8B. Both
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Table 2.3: Pharmacokinetic Lung Clearance Parameter Values
Study kLT (min
−1) kDB(min−1)
NCF 0.0450±0.0085 0.0071±0.0005
CF HS 0.0393±0.0073 0.0105±0.0009
CF IS 0.0349±0.0076 0.0181±0.0012
CF Pediatric 0.0481±0.0173 0.0157±0.0014
Sakagami* [117] 0.022 ± 0.002 0.048 ± 0.003
Values from this study are shown with ± 95% confidence interval.
* PK model in isolated perfused rat lung. Three fluorescent markers used, but only the
parameter values for sodium fluorescein (F-Na) are shown since MWF−Na = 376 Da ≈
MWDTPA.
IS and HS additions increase functional area (p<0.05 and p<0.001, respectively). However,
HS increases functional area significantly more than IS (p<0.01).
2.5 DISCUSSION
The failure of the CF airway epithelium to secrete Cl− and absorb Na+ in a normal manner
results in a net osmotic gradient that favors rapid absorption of liquid from the ASL, resulting
in diminished MCC and an accumulation of dehydrated mucus in the airways. Nuclear
imaging methods have been developed to measure MCC and have been used as biomarkers
of therapeutic efficacy. A novel method that measures both MCC and ASL absorption has
been explored more recently [8]. This method involves the inhalation of radiolabeled particle
and small molecule probes (TcSC and In111-DTPA, respectively). The difference between
total DTPA clearance and TcSC clearance can be used to estimate the absorption of DTPA,
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Figure 2.14: FFCA determined in vitro in CF HBE cells is shown ± SEM (A)
Activated area is significantly greater between 10 µL and baseline (* p < 0.0005) and 2x10
µL and baseline (* p < 0.0005). Activated area is not significantly greater between hydrated
groups (p > 0.05). (B) The increase in FFCA after addition of HS in cell cultures is
significantly greater than IS (* p < 0.01).
and previous studies have demonstrated: (i) a positive and significant correlation between
DTPA and ASL absorption rates [65]; (ii) DTPA absorption response to the use of osmotic
therapies both in vivo and in vitro [8, 65].
This work describes a model developed to consider the basic mechanisms governing small
molecule and particle probe clearance from physiologically distinct compartments of the lung.
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The combination of these mechanisms is reflected in the imaging result. Compartment or
mechanism specific results provide additional insight into CF lung pathophysiology and ther-
apeutic mechanisms of action. They may also provide more sensitive and accurate predictions
of therapeutic efficacy than analyses of the composite imaging data as the compartmental
description incorporates the inherent time-correlation of mass transport within the model
structure.
2.5.1 Model Structure Selection and Analysis
The physically descriptive model includes central and peripheral lung compartments. The
central zone includes large airways, intermediate and small airways, and alveoli while the
peripheral zone includes only intermediate and small airways and alveoli [130], [133]. The pe-
ripheral zone includes both smaller airways and alveoli in a single compartment. The model
also includes compartments for the trachea and blood. As determined by Akaike Information
Criterion (AIC) [128] analysis, a quantitative metric that weights the model accuracy (as
measured by sum-squared error) against the cost of model complexity (quantified by the
number of parameters in a model), the most appropriate model given the timeframe of the
data assumed zero MCC from the peripheral compartment. Model rate constants describ-
ing MCC from the functional large airway compartment (kLT ), absorption from the small
airway/alveolar compartment (kDB), large airway absorption (kLB), and FFCA were fit to
the data. The fixed mathematical structure of the model is able to capture the dynamics of
both MCC and the absorption of DTPA in the lungs of all patient groups.
An alternative, and more highly parameterized, model than that shown in Figure 2 would
include parameter kDL as an MCC rate constant from compartment D to compartment L,
in addition to MCC rate constant kLT and absorption rate constants kDB and kLB. All ki-
netics were assumed to be first order. Furthermore, the initial dosing of probes was included
using a free dosing parameter (C/P), representing the ratio of radiopharmaceutical doses
delivered to the large airways and peripheral lung. Under the assumption that TcSC is not
absorbed in any lung region, the MCC curve was found to be bi-exponential, as suggested
previously [116]. However, regression and analysis of the model parameters via the MAT-
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LAB functions lsqnonlin (a nonlinear least-squares regression algorithm) and nlparci (an
algorithm that computes confidence intervals on estimated parameters from the covariance
matrix) yielded wide parameter confidence intervals, approximately ± 10 times the nominal
parameter value. By eliminating kDL the confidence intervals on parameter estimates are
tightened dramatically (the worst case parameter CI from the model herein is kLB in non-CF
subjects which has CI’s that are ±39% of the nominal value).
While a two-compartment model, like that proposed by Sakagami in [116], may be used
to describe clearance, the parameters may not be able to be estimated with confidence if
a physiological rate process captured by a parameter in the model is on the timescale of
the experiment, or longer. The 80-minute functional imaging session inherently limits the
confidence that can be derived for slower physiological processes. Therefore it is hypothe-
sized that the departure from monoexponential clearance seen in the retention curves could
be explained by a non-zero steady state value for pharmaceutical retention. While this is
aphysiologic over a period of days, an apparent non-zero baseline would manifest if a slow
clearance process was occurring and data collection was short by comparison to the half-life
of the clearance. This behavior can be realized in a number of ways in a kinetic model.
In the present study, it is most easily incorporated by adding a new compartment that has
no apparent MCC mechanism over the experimental timescale. Thus, while it is believed
that MCC in D can be observed on a longer timescale, its mechanism is considered to be
practically unidentifiable (i.e. there is insufficient data to inform this parameter) over the
timescale examined in this chapter [134]. The numerical and experimental efforts used to
identify this clearance effect are detailed in chapter 4.
The model structure presented in Figure 2, and its grounding assumptions discussed in
the Results section may fail to include mechanisms that could manifest on timescales longer
than the 80 minute imaging period. To address the question of model appropriateness on the
timescales of the data, the model was compared to the following alternative model structures
with AIC as the basis for quantitative comparison:
Case 1. Exclude kLB: DTPA absorption in L, represented by rate constant kLB, is not
appreciable over the 80-minute functional imaging timescale and should not be regressed to
achieve model fit
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Case 2. Include kDL: MCC in D, represented by rate constant kDL, is significant over
the 80-minute functional imaging study timescale
The AIC values of each case above, in comparison to the model in Figure 2, are given in
Table 2.4.
Table 2.4: AIC Values for Various Model Structures
Model Case 1 Case 2
NCF -2546.28 -2535.65 -2543.38
CF HS -2430.25 -2227.60 -2426.25
CF IS -2775.62 -2287.07 -2775.57
CF Pediatric -1858.37 -1597.47 -1854.37
The Akaike Information Criterion (AIC) is a metric for determining the most appropriate
model for a system, where better fit is balanced against a penalty for overparameterization,
such that more negative values are better. Total AIC is shown as calculated from Equation
7 for all cases: 1) exclude kLB from model structure; 2) include kPL in model structure.
These values demonstrate that the Figure 2 model displays the best combination of model
fit and parsimony for the data set from [8]. Parsimony was especially important for model
selection between the nominal case and Case 2, where the difference between AIC of the
two cases was less than ±1%. However, it is important to again note that there may in
fact be clearance mechanisms from D, LN , and LF that are not accounted for in this model
because of constraints on the ability to quantitatively resolve their effects with confidence
over the timescale of imaging. This is illustrated graphically in Figure 9, where it is clear
that the parameter kDL cannot be confidently identified as employed in Case 2 above. The
experimental and mathematical methodologies that can be used to identify kDL are discussed
in chapter 4.
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Figure 2.15: Least-squares solutions for model parameters in case 2 of Table ?? are
shown for comparison to the selected model with 95% confidence intervals for
four patient groups: Non-CF (NCF), CF HS, CF IS, and Pediatric CF (CP). (A)
MCC rate constant (kLT ) (min-1) reiterates that kLT is the same in all groups. (B) Fraction
(FFCA) of large airway with functional MCC. (C) Peripheral lung absorptive rate constant
(kDB) (min-1) and (D) large airway absorptive rate constant (kLB) are nearly identical to
their analogs in the selected model. (E) MCC rate constant (kDL) (min-1) from D to L
is clearly unidentifiable, and the nominal value is much smaller than kLT in each group.
Confidence intervals are also widened in all parameters directly related to MCC.
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2.5.2 Parametric Considerations
In non-CF subjects, FFCA is found to be < 1. The notion that not all of the surface of the
conducting airways has functional cilia is a novel finding in humans. Hoegger et al. [135]
recently report that even in the trachea, the most conductive airway, of newborn pigs without
CF ≈ 70% of particles clear in ten minutes and that those same particles are only actively
moving ≈ 80% of the time. While this timeframe is considerably shorter than the one in
the study, it has been established that particles can be retained in the conducting airways
of non-CF animals for a potentially significant amount of time. It would be reasonable to
assume that particles deposited deeper in the airways, like those in this study, would be
retained longer. This proives further reason to believe, in addition to the in vitro findings
presented here, that the estimation of FFCA as a model parameter is grounded in realistic
physiology.
Our model asserts that the rate of DTPA absorption (kDB) is increased in the peripheral
lung (small airway and alveoli) compartment of patients with CF as compared to non-CF
subjects. Hypertonic saline slows this rate to nearly non-CF levels. Previous in vitro studies
have related DTPA hyperabsorption to liquid hyperabsorption [65]. It is assumed that DTPA
hyperabsorption occurs via a paracellular mechanism, driven by increased paracellular liquid
absorption, as DTPA has no known transcellular route by which to absorb. Therefore, it
is likely that these current result reflects the basic liquid absorption defect associated with
CF. The aerosol delivery techniques utilized to deliver the radiopharmaceuticals targeted
large and small airways through a specialized breathing pattern both MCC and and absorp-
tion were observed, indicating airway - as opposed to alveolar - involvement. Additionally,
transient correction of the absorption defect would be expected after administration of an
inhaled osmotic therapy based on most current hypotheses of airway disease in CF [120].
However, the possibility of alveolar effects cannot completely excluded that may be related to
yet undocumented physiological differences between the alveolar regions of CF and non-CF
lungs.
The rate at which DTPA absorbs in the large airways (kLB) is similar to kDB in the
CF IS, CF pediatric and non-CF groups. However, while hypertonic saline decreases the
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value of kDB in patients with CF, it has no significant effect on kLB. MCC is the dominant
clearance mode in the large airways in both IS and HS cases. It has been shown in vitro that
HS modulates the FFCA of the airway epithelium and have shown in vivo that increased
MCC can be attained by modulating FFCA without requiring change in MCC rate. The
two rate constants in the central region (kLT and kLB) describe competing and correlated
processes, whereas FFCA describes a more macroscopic phenomenon. Therefore, it would
be expected that a change in one rate constant in L would induce a corresponding change in
the other. Between IS and HS days there is no change in kLT (the dominant process), so it
would not be expected a change in kLB either. However, due to the increase in FFCA, total
MCC increases in the central lung after HS inhalation, which results in less DTPA being
present and able to absorb in accordance with its unchanged rate constant. In effect, the
underlying rate of DTPA absorption is unchanged, but an increase in total MCC as a result
of increased FFCA leads to less DTPA being available for absorption and a smaller total
quantity of DTPA absorbed in the CF HS case. In the case of D, however, it is assumed that
there is no competing, certainly no governing, MCC term in D. Thus, conditions affecting
D must result changes in kDB.
2.5.3 Study Limitations
A primary limitation of the functional imaging method utilized is its inability to uniquely
discern airways and alveoli. Given the three dimensional nature of the lung architecture,
small airways and alveoli are likely to be included in any zone analyzed via 2D imaging.
The small sizes of these structures make them impossible to differentiate from each other
through direct imaging, though other physiological measurements (such as 24 hr MCC) may
help to differentiate their functional effects. The limited time scale of imaging (80 minutes)
in the current study may have also limited assessment of small airway mucociliary clearance.
Extended-duration imaging studies may yield additional data that can inform processes with
slower rates and model parameters such as kDL, which was excluded from the Figure 2 model
on AIC grounds.
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2.5.4 Physiological Implications
Our original study (see [8]) described significant differences in baseline whole lung DTPA
absorption when comparing CF and healthy subjects. MCC was decreased in the CF groups,
but not at statistically significant levels. This study finds that MCC is decreased (in a sta-
tistically significant way) in the CF IS group for t > 18 minutes. The difference between
these two findings arises from differences in the analysis tools used in this work versus the
endpoint analysis performed in [8]. The confidence intervals presented here are around the
parameters of the model, as opposed to being derived from statistical analysis of a final
retention value, as in [8]. The model parameters govern the entire time-course of clear-
ance, and thus are informed by the entire dynamic of the data given in [8]. The resulting
confidence-interval-derived envelopes in Figures 5 and 6 capture the uncertainty of each phys-
iologically descriptive parameter in the model. This is achieved by simulating the model at
all possible combinations of upper and lower CIs for each parameter and determining the
extreme values of model prediction at every time point. Hence, the CIs about the parame-
ters are used to generate physiologically, as opposed to empirically, informed predictions of
clearance behavior in each subject group population. The narrowness of the parameter CIs
indicates confidence in the model parameter estimates (in that they are well informed from
the dynamic data in [8]) and generates narrow prediction envelopes in each case, indicating
a physiological difference in MCC dynamics between patients with CF and non-CF subjects
that is not found via the previous endpoint-analysis methods.
Response to HS inhalation was apparent in terms of both decreased absorption and
increased MCC as compared to IS inhalation. These trends are reflected in the modeled
result. The model suggests that the observed increase in MCC following HS inhalation is
due to an increase in FFCA rather than an increase in MCC rate, and a detailed analysis
of this hypothesis using the in vivo imaging data is ongoing. The model also predicts that
FFCA is reduced in patients with CF as compared to the healthy population. This prediction
was used as a hypothesis about inducing a functional change in vivo that can be tested in
vitro. To further elucidate this phenomenon, and validate that such behavior is possible, in
vitro studies were performed with HBE cell cultures. A quantitative visual assay of ciliary
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movement demonstrated that a larger fraction of the cell culture surface was activated after
the addition of hypertonic saline vs. isotonic saline.
2.5.5 Clinical Relevance
Some previous imaging studies have shown significant differences in whole lung MCC be-
tween CF and non-CF subjects [19, 136] while others have not [22]. By ascribing a fixed
mathematical structure to the model, the clearance curves were constrained to a single fam-
ily of dynamical forms, which allows for more sensitive comparisons between the dynamical,
and also endpoint, behavior present from one patient group to another. This ultimately
increases the confidence in the model assertion that MCC is decreased in patients with CF
and can be increased by hypertonic saline inhalation and, subsequently, that the model offers
a better tool than statistical models for use in clinically gauging MCC.
Applications of this model may include the design of dosing regimens for agents targeting
changes in MCC and/or absorption. For example, the timeline of the effects associated with
an osmotic therapy (correction of liquid absorption defects) could be assessed independently
of the resulting secondary effects (recruitment of functional ciliated airway, large and small
airway clearance). Dosing timed in accordance with the duration of the counter-absorptive
effect may provide more continuous clearance from the lungs and patient benefit, though
outcome assessment is beyond the scope of the model at present. The model could also
be used to resolve the pharmacodynamics of medications with subtle, complex, or multiple
therapeutic effects, to the degree that these agents impact MCC and absorption.
2.5.6 Summary
Our physiologically motivated compartmental model is able to reproduce the clearance be-
havior of both large particle (TcSC) and small molecule (DTPA) radiolabeled probes as
informed by functional imaging data. The model asserts that liquid absorption rate is in-
creased in the peripheral lung of patients with CF as compared to non-CF subjects, and that
hypertonic saline will decrease the rate of absorption in patients with CF to near non-CF
levels. The model also attributes increased MCC induced by hypertonic saline treatment
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to an increase in airway surface area with functional ciliary clearance, as opposed to an
increased rate of clearance. The physiology inherent to the model structure and parameter-
ization allow for increased sensitivity in gauging the effects of hypertonic saline in vivo in
a real-time manner. This model should, therefore, be extendable to other treatments, both
present and future, that target the liquid hyperabsorption and MCC deficiency present in
cystic fibrosis.
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3.0 CELL SCALE MODELING OF LIQUID AND SOLUTE
HYPERABSORPTION IN CYSTIC FIBROSIS BRONCHIAL EPITHELIA
3.1 INTRODUCTION
Liquid volume regulation by human bronchial epithelia (HBE) is essential to maintaining
cell, tissue, and organ-level function in the lung [22]. In patients with cystic fibrosis (CF), the
most common life-shortening autosomal recessive disorder in caucasians, the Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) protein is absent or dysfunctional. This
causes dysregulation of ion transport at the airway surface, which leads to airway surface
liquid (ASL) depletion, mucus accumulation, and impaired mucociliary clearance (MCC)
[12]. Impaired MCC allows pathogens to establish chronic opportunistic infections in the
airways. Concomitant inflammation leads to airway damage and bronchiectasis resulting in
premature respiratory failure. Despite these multi-scale effects, however, at the most basic
level CF is a disease caused by abnormal cellular transport of ions and water.
In healthy epithelia, water, ions, and other solutes are transported in and out of cells
via a number of passive and active mechanisms [49]. In CF, deficient or absent Cl- and
HCO3
- secretion via CFTR have been identified as the primary anion transport defects
[135, 137]. Na+ hyperabsorption via dysregulation of the epithelial sodium channel (ENaC)
has been considered the primary cation transport defect [49], though recent studies have
called this into question [25]. Passive basolateral K+ transport is also affected [138]. Water
transport and volume regulation are also likely affected through failed CFTR interaction
with aquaporin-3 (AQP3) [52]. Passive water and solute transport occurs in the paracellular
space and is regulated by tight junction integrity, which may be diminished in CF airways
[139,140,141].
60
Historically, the active ion transport properties of HBE have been studied experimentally
in the Ussing chamber [32]. A number of mathematical models have characterized the ion
transport that occurs in the Ussing chamber: without liquid transport [87], in CF [55,88,89],
and comparing differences between CF and non-CF cells [16, 17]. In the Ussing Chamber,
current is only measureable when electrodes on the apical and basolateral sides of a cell
culture sample are submerged, which requires flooding the apical membrane of cultured
HBE [32]. There is evidence that both CFTR and ENaC currents are sensitive to ASL
volume [13, 88], implying that the function of these channels is not a true representation
of in vivo physiology in the flooded environment of an Ussing chamber and that it may be
more relevant to model HBE cell cultures under “thin-film” conditions. A model of thin-
film culture conditions was developed by Herschlag and colleagues [96] to capture purinergic
effects on ASL homeostasis, but it does not distinguish between types of ions. Warren et
al. [70] developed a thin-film model of Ca2+ effects on ion and liquid transport that does
not account for finite basolateral volumes, the auto-regulatory effects of the ASL volume, or
paracellular water transport.
Our model adds to those presently in the literature by accounting for the cellular com-
ponents of liquid and solute transport most relevant to CF. This includes apical chloride
transport through both CFTR and alternate channels such as calcium-activated chloride
channels (CaCCs) and members of the solute carrier family (e.g. SLC26A9) [3], apical
sodium transport through ENaC, and a linear description of basolateral Na+ and Cl- trans-
port. Paracellular transport of all components is also included to reflect the leakiness of
HBE, the extent of which is still debated [59, 61, 64]. The model incorporates the transport
of the radiopharmaceutical Tc99m-DTPA (DTPA), an in vivo functional imaging probe that
is representative of small molecule absorption. DTPA absorption is increased in the lungs
of patients with CF [8,21] and in CF HBE where it is strongly correlated with ASL absorp-
tion [65]. DTPA can only move through the paracellular pathway, and its absorption rate
characterizes paracellular flows and tight junction integrity [65]. DTPA transport across
the epithelium occurs through two mechanisms: (i) concentration driven diffusion; and (ii)
convection or “solvent drag” due to water flow through the tight junction [57].
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Presented here are the derivation and validation of a mathematical model of airway
epithelial ion and liquid transport considering the case of volume addition under thin film
conditions. Model-determined and channel-specific permeability coefficients are compared
for Cl- and Na+, trans- and paracellular liquid transport using DTPA as a surrogate, and cell
volume response in CF and non-CF epithelia. Treatment-relevant responses to hyperosmotic
solutions are also modeled. It is sought to parameterize disease-relevant components of liquid
volume regulation in CF. Furthermore, this model could provide insight into the mechanisms
by which airway depletion leads to reduced fractions of functionally ciliated airway, as has
been previously modeled and reported [1, 8]. It could then be mathematically coupled to
an airway scale model [1] by using disease-based parameterization to study the mucociliary
transport effects of CF that manifest from the cellular-scale processes.
3.2 MATERIALS AND METHODS
3.2.1 Model Development
The parameters defining model geometry are based on the assumption that cultures were
composed of a single layer of cells and that these cells were in the shape of rectangular
prisms.
Apparent apical surface areas of all the tight junctions (ATJ) and cells (AC) on the
filter (AF) are related mathematically. For a grid of rectangles m-by-n in dimension there
are 2mn-m-n interior borders (i.e., junctions). Thus, the expression for relative abundance
of junctions to cells is 2mn−m−n (junctions)
mn (cells)
which reduces to 2 (junctions)
(cell)
when mn is large.
Therefore, when there are a large number of cells on the filter it can be shown that ATJ can
be approximated by the following relationship:
ATJ = AF
2ATJ,1
AC,1
= AF
2DTJDC
(DTJ+DC)2
(3.1)
Here ATJ,1 and AC,1 are the areas of a single tight junction and cell for TJ (DTJ=60 nm)
and cell (DC=8 µm) diameter, respectively. AC can then be determined as the difference
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between ATJ and AF (AF=0.33 cm
2). Dynamic cell-volume behavior was captured solely by
allowing the cell height to change in response to osmotic influx or eﬄux of water, as would
be expected in columnar bronchial epithelia [9].
The transport of water from compartment i to j is driven solely by osmotic pressure
difference ∆pii,j:
∆pii,j =
∑
k
γk
nk,i
Vk,i
−
∑
k
γk
nk,j
Vk,j
(3.2)
Here nk,i is the number of moles of solute, k, which is divided by the volume of compartment
i and multiplied by osmotic coefficient γk. Because AC is assumed to be constant, the
height of the epithelium may be determined at any given time from the volume of the cell
compartment as hC(t)=VC(t)/AC. Initial cell height was specified to be 30.2 µm based on
values from the literature [16] but varies in response to osmotic and volumetric effects in the
system and accounts for the ability of the cells to change internal volume during simulation.
This allows us to determine the paracellular permeability of a solute k at any instance in
time as:
PkA,B(t) =
Dk
hC(t)
(3.3)
Paracellular permeability, PkA,B , is taken to be the diffusion coefficient (Dk) of species k
divided by the length of the paracellular pathway (i.e. cell height), which changes with time.
The absorption of DTPA is modeled based on its use as an in vivo analog for measuring
transepithelial liquid transport. DTPA absorption occurs through the paracellular pathway
and characterizes paracellular flows and tight junction integrity. Our experiments have also
shown that DTPA absorption is proportional to overall apical liquid absorption [65].
3.2.2 Model Structure
Based on the model schematic given in Figure 3.1, the equations governing liquid and solute
transport in HBE were established, defining mass balances for ASL (A), basolateral (B), and
cellular (C) compartments. Transport of water from compartment i to j is driven solely by
osmotic pressure difference, ∆pii,j, as described in Equation 3.2.
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The volumetric flux from any compartment to another is:
dVi
dt
= LPi,jVw
∑
j
(∆pii,j) (3.4)
Here, LP is the hydraulic permeability of the membrane separating compartments i and j, and
Vw is the molar volume of water (0.018 L/mol). By assuming that the cells in the culture are
neighboring rectangular prisms, it is also assumed that the apical and basolateral membrane
areas are identical. In reality the basolateral membrane area is at least 10-fold larger than
the apical membrane area (16-fold in the resting geometry of the model). This is because
basolateral transport proteins begin to appear in the membrane immediately adjacent to
tight junctions in the lateral intercellular space (LIS). Hence, the entire membrane area
across the tight junction away from the apical membrane is basolateral. As such, hydraulic
permeabilities of the apical and basolateral membranes are allowed to be equal (LPA=LPB,
thus it is denoted as LPC), though previous studies have found [9], and some [16] have applied,
order of magnitude differences between the membrane permeabilities.
Solute transport occurs via diffusion down a concentration gradient (given as a concen-
tration difference, ∆Cki,j = Cki −Ckj) between compartments, via active transport into and
out of the cell (Jact) and by bulk fluid convection in the paracellular space (Jconv). Thus,
overall solute transport in a given compartment is given by:
dnk,i
dt
=
∑
j
P ′ki,j∆Cki,j + Jk,acti,j + Jk,convi,j (3.5)
Here, P ′ki,j is the modified permeability (if volume-regulated; the true permeability, Pki,j ,
is used if not) of a membrane to a solute. These equations are applied to the appropriate
transport pathways illustrated in Figure 3.1 for Na+, Cl-, DTPA, and mannitol. A full list
of model state equations can be found in Appendix A and code to simulate the equations
in in Appendix B, but their function is summarized briefly below.
ENaC is the apical channel for transcellular Na+ transport, and is represented mathemat-
ically by an ASL-volume-regulated Michaelis-Menten expression that is maximally permeable
at high volumes. A linear regulator in the basolateral membrane drives intracellular Na+
concentration towards a homeostatic value of 23 mM. Cl- homeostasis is maintained at 44
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Figure 3.1: Schematic of the contributors to solute and liquid transport across the airway
epithelium represented in the model equations. Volumes (Vi) of the apical, basolateral,
and cellular compartments dynamically respond to changes in osmolarity. Terms describing
ENaC and CFTR respond to changes in apical volume according to first and second-order Hill
functions, respectively. Basolateral Na+ and Cl- fluxes are included to assure conservation
of mass. Mannitol (Ml) is included in the model to allow for the description of liquid and
DTPA absorption following hyperosmotic challenge. The inclusion of DTPA in the model
makes the terms describing paracellular and transcellular water transport mathematically
observable and provides a link between the physiological processes measured in vitro and in
vivo.
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Table 3.1: Initial conditions for the model compartments immediately following apical
Ringer’s addition. Initial apical volumes were determined from data, but solute concen-
trations were assumed to be similar regardless of post-addition volume. Cellular volume is
the total volume of the monolayer.
Apical Basolateral Cellular
Na+ (mM) 140 140 23
Cl- (mM) 119.6 119.6 44
Other Solutes (mM) 40.4 40.4 233
Water (µL) Measured 400 0.98
mM via action of a linear regulator in the basolateral membrane. These linear regulators
are surrogates for the homeostatic regulation that is accomplished by the Na-K-ATPase and
NKCC-cotransporter in biology [16, 17]. CFTR is an apical volume-regulated Cl- channel
modeled with a second-order Hill functionality that is maximally permeable at zero ASL
volume. ACC is an alternate, linear, constitutively active Cl- channel also in the apical
membrane of the model. DTPA and mannitol, another osmotic agent used in therapy, are
restricted to diffusion and convection through the paracellular space. Initial conditions for
Na+ and Cl- concentration and liquid volume in each compartment are given in Table 3.1.
3.2.3 Experimental Methods
CF and non-CF HBE cultures will absorb ASL following an apical volume challenge in order
to restore homeostasis [97]. It is also known that CF HBE hyperabsorb ASL and DTPA
relative to non-CF HBE when similarly challenged [49, 65, 97]. Experimental training data
for the model was obtained by observing the dynamics of liquid and DTPA absorption in
HBE cell cultures after a 10µL apical addition of Ringers solution and Technetium 99m-
labeled DTPA. Apical volume was determined over the course of the experiments using an
optical method described by Harvey and colleagues [97]. DTPA absorption was determined
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according to the methods of Corcoran and colleagues [65] concurrently with the volume
measurements. Primary HBE cultures from CF (11 donors, n=102 filters, > 6 filters per
donor) and non-CF (12 donors, n=93 filters, > 6 filters per donor) lungs removed at the
time of transplant were used for this model training data set. Estimates of net Na+ and
Cl- flux were determined from Ussing Chamber measurements of Na+ and Cl- currents (INa
and ICl, respectively) obtained according to the procedure in [65]. INa is calculated as the
amiloride sensitive short-circuit current (ISC). ICl is measured as the difference between
forskolin-stimulated and bumetanide-inhibited ISC under amiloride block. Transepithelial
electrical resistance (TER) exceeded 250 Ωcm2 for all cultures used. These cultures were
prepared using previously described methods and obtained through a protocol approved by
the University of Pittsburgh IRB [8].
3.2.4 Parameter Estimation
Model training was performed via Markov Chain Monte Carlo (MCMC) search for 9 free pa-
rameters that best fit the dynamics of liquid and DTPA absorption in HBE cells. The MCMC
algorithm used is that developed by Hogg: parallel tempering for estimation (ptempest)
[142]. The ptempest algorithm is freely available online (https://github.com/RuleWorld/
ptempest). In the simulations, least sum-squared-error (SSE) was the objective function
between simulation predictions and ASL volume (in µL) and DTPA absorption data (fitted
as retention in thousands of counts to scale it suitably versus ASL volume). The SSE can
be used as an estimate of the −log(likelihood) under the assumption of normal variance
in the data [129]. The resultant posterior parameter distributions for 8,000 swaps across 4
chains are presented in Figure 3.2. Constrained parameter refitting was performed in the
characterization of model-predicted responses to osmotic challenges in order to account for
the physiological changes that occur under such stresses. This was accomplished using the
Matlab ( c© 2015, The MathWorks, Natick, MA) function lsqnonlin.
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Figure 3.2: Posterior distributions of model parameters are given for base-10 (p) or log10
transformed values generated from Markov Chain Monte Carlo. Distributions are given along
either a linear or logarithmic abscissa.
3.3 EXPERIMENTAL AND SIMULATION-BASED FINDINGS
3.3.1 The mathematical model captures population absorption dynamics in CF
and non-CF HBE
We first examined whether model simulations were able to predict the absorption dynamics
of the ASL and DTPA. A 10 µL bolus of Ringers solution and DTPA was added to the apical
side of HBE cell cultures as described in Materials and Methods. Data demonstrated that
CF cells had decreased ASL volumes immediately after volume addition and all time points
through the 24 hours of the experiment (t-test, p<5x10-10), indicative of the characteristic
depletion of CF ASL. DTPA absorption was also significantly increased in the CF cells
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(p<5x10-10), which has been previously reported in in vitro experiments and in in vivo
functional imaging studies [21,65]. The distributions of all model parameters were generated
from model training via MCMC. Model simulations, using the best-fit parameter sets given
in Table 3.2, were able to capture the absorption dynamics of the ASL and DTPA as shown
in Figure 3.3. The model-predicted apical volume and DTPA trajectories were within the
standard error about the mean for all time points. Non-CF cells rapidly reabsorbed liquid
to return to homeostasis whereas CF cells demonstrated a slower but continued absorption
of liquid that exceeded that of non-CF cells over time.
In addition to good dynamic agreement between model output and experimental data,
the best-fit parameters determined via Monte Carlo search agreed well with those found
in the literature and are detailed in Table 3.2. The mean hydraulic permeabilities of the
cell in both CF (6.1x10-4 m/s) and non-CF (3.2x10-4 m/s) were similar to those reported
by Matsui and colleagues (2.4x10-4, CF; 0.96x10-4, non-CF) [9]. Additionally, the mean
maximum permeability of ENaC (6.3x10-8 m/s, non-CF; 2.5x10-8 m/s, CF) is of similar
magnitude to what has been reported in Ussing chamber experiments [56, 93] (2.3x10-8,
non-CF; 6.3x10-8, CF), which occur in flooded conditions where the Michaelis-Menten-type
switch governing ENaC in the model is nearly saturated. The thin-film model demonstrated
an opposite trend in ENaC permeability to the Ussing chamber experiment comparing CF
and non-CF cells. Paracellular water permeability was ten-fold greater in CF cells compared
to non-CF cells, which may indicate a defect in the barrier integrity of CF cells.
3.3.2 Validation of Model Structure and Dynamic Output
As validation of the estimates of liquid and DTPA absorption, it was sought to determine
whether the ion transport rates predicted by the model were similar to relevant physiological
measurements. The change in the amount of either Na+ or Cl- in the apical compartment in
the first hour after the liquid and DTPA addition was determined and the model-predicted
flux (µeq/cm2/hr) of each ion was computed. These flux estimates were compared to those
calculated from short circuit estimates in the Ussing Chamber, as shown in Figure 3.6A for
Na+ absorption and Figure 3.6B for Cl- secretion.
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Figure 3.3: Best-fit model trajectories and experimental data after 10 µL apical volume
addition to 6 non-CF (NCF)) and 6 CF lines. CF lines demonstrate apical dehydration
relative non-CF lines at the start and end points of the experiment (top panel, p<5x10-10).
Total volume absorbed in the model is 7.25 µL (38.4%) in the non-CF case lines and 6.91
µL (51.0%) in the CF lines. Non-CF cells rapidly return to homeostatic volumes, whereas
CF cells exhibit prolonged absorption that results in increased DTPA absorption (bottom
panel, p<5x10-11). Model-estimated DTPA clearance is 42.7% in non-CF cells compared to
65.0% in CF after 24 hrs. Error bars show experimental data ± SEM.
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Table 3.2: Model parameters were set according to values found in the literature (refer-
ences included) or determined via MCMC search for model training. Nonlinear least-squares
search was used under osmotically challenged conditions to account for stress responses that
can change transport rates. Abbreviations are transcellular (LPC) and paracellular (LPP)
hydraulic permeabilities, maximum ENaC (PENaC) and CFTR (PCFTR) permeabilities, and
the respective half-maximal Vmax and half-minimal Vmin for those channels. Constitutive
chloride permeability (PACC) and basolateral sodium (kNa) and chloride (kCl) rate constants
were also included in the parameter search. Best-fit values are given in lieu of means due to
distributional shape factors.
LPC
(m/s)
x10-4
LPP
(m/s)
x10-3
PENaC
(m/s)
x10-8
PCFTR
(m/s)
x10-8
Vmax
(L)
x10-6
Vmin
(L)
x10-6
PACC
(m/s)
x10-8
kNa
(s-1)
x10-5
kCl
(s-1)
x10-5
CF 4.57
*2.43
14.6 1.23
**6.3
- 214 - 0.554 107 7.47
Non-CF 2.40
*2.40
1.50 7.00
**2.3
5.50
**4.3,
***6.6
2.30 1.88 1.89 1.39 2.27
Ringers 2.76 11.4 1.94 5.50 2.30 1.88 1.25 1.39 2.27
Mannitol 6.34 5.64 4.54 5.50 2.30 1.88 7.35 1.39 2.27
Table 3.3: Citations are given for comparison of values to *, (52); **, (49), *** (18)
71
Maximum likelihood estimation functions for were generated for Na+ fluxes by fitting
the means and standard deviations of a lognormal and normal distribution summed together
with a fitted weighting factor to isolate and characterize the small secondary peak near 7
µeq/cm2/hr in the non-CF ensemble Figure 3.6A. The weighting factor was 0.98 in the non-
CF case and 1.00 in the CF case indicating that the primary peak in the non-CF case and
the only visible peak in the CF case are lognormally distributed as shown in Figure 3.4. The
large peak in the non-CF case is used as the basis of all further interrogation.
Figure 3.4: Ensemble distributions of model-predicted non-CF (top) and CF (bottom) Na+
fluxes. Both primary peaks are well-fit by lognormal distributions. The second peak in the
non-CF (NCF) distribution near 7 µeq/cm2/hr only contributes to 2% of the area in the
cumulative distribution function.
Figure 3.5 demonstrates that the Cl- flux distributions approximately normal. The non-
CF case has a minor left skew, but is approximately normal. The CF distribution is well-
approximated by a normal distribution. Both distributions include 0, and the CF distribu-
tion includes 0 within a standard deviation of the mean. This quantitatively recapitulates
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the representation of the CF absorptive phenotype given by Goralski and colleagues [23].
Comparisons of these flux values to data are presented in Figure 3.6.
Figure 3.5: The Cl- flux ensembles for non-CF (Top) and CF (Bottom) model predictions
are approximately normal. Both sets of distributions contain 0. Secretion rates are positive
in the apical direction.
These distributions are compared in the split violin plots of Figure 3.6A and B. Model
estimates for Na+ flux are similar to experimental values and those that have been reported
for airway epithelia [4,143]. Cl- secretion (Figure 3.6B) determined from forskolin-stimulated
ICl is significantly decreased in CF cells (p<0.05), as would be expected. While due in part to
absent Cl- transport through CFTR, the predicted permeability of the constituently active
alternate chloride channel (ACC) is also decreased in CF in the model (Figure 3.6C). Cl-
fluxes in CF as estimated by the model are also reduced and suggest that net Cl- absorption
occurs alongside liquid absorption in this open-circuit condition. That Cl- flux is either small
in terms of secretion (NCF) or absorption (CF) has been reported [23,136,143], particularly
under open-circuit conditions for CF [4]. Parameter ensembles for LPP were logarithmically
distributed for both CF and NCF model simulations, but CF paracellular hydraulic perme-
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ability is increased by an order of magnitude (Figure 3.6D). Mean transepithelial electrical
resistance (TER) was indicative of full differentiation for all cultures used in model training
and was statistically indistinguishable between CF and NCF (Figure 3.6E).
We next validated the model in cells from additional CF and non-CF airways. Model
response to volume addition in these 2 CF and NCF lines (n=4 filters per line) was compared
to experimental data without adjusting any parameter values that were previously derived
from the model training data. Only initial apical volume and DTPA counts were changed
as model inputs for these validations. Model predictions for both CF cell lines overestimate
liquid absorption at 24 hours (Figure 3.7A). It may be that there is a late-stage homeostasis
mechanism present in these lines that is diminished or unaccounted for in the model param-
eterization or structure. However, the CF lines chosen for validation were selected at their
earliest availability and displayed an unusually high starting volume for CF cells. As such,
the model should overpredict absorption because the model structure favors a return to near
homeostatic volumes as the mass balance allows. Model estimates for DTPA absorption
are accurate in both CF cases (Figure 3.7C). Model agreement with non-CF data is accept-
able ASL volume (Figure 3.7B), and the general strength of agreement between model and
DTPA data (Figure 3.7D) in the time points preceding the last indicates that the model is
well-suited to represent the bulk of behaviors present in the cellular system.
3.3.3 Effects of Osmotic Agents on ASL and DTPA Absorption in HBE
Because DTPA is only known to traverse the epithelial layer through the paracellular space,
its transport is only due to diffusive and convective flux. Paracellular convection of DTPA
was delayed experimentally by applying 10 µL of hypertonic fluid to the apical surface of non-
CF HBE. Two different hypertonic fluids, concentrated Ringer’s and mannitol in Ringer’s,
were selected because mannitol is not transported transcellularly like the ions in Ringer’s,
which we hypothesized would change the nature of the liquid transport dynamics observed.
Concentrated Ringer’s may be thought of as a surrogate for hypertonic saline, which is a
standard therapy in CF [22]. Inhaled powdered mannitol has also been shown to be thera-
peutic in CF [136]. As shown in Figure 3.8A and B, addition of either concentrated Ringer’s
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Figure 3.6: (A, B) Ion flux values from MCMC-generated model ensembles (violins) and ISC
measurements (boxes). The model predicts non-CF cells (NCF) have similar but increased
Na+ absorption compared to the data. Model and data are in strong agreement in the CF case
for Na+ absorption. No difference in Na+ flux is detected experimentally between CF and
NCF. (B) Cl- secretion is reduced in NCF and reversed (absorption) in CF model ensemble
predictions compared to experimentally determined forskolin-induced ICl. (C) CF cells have
markedly decreased constitutive chloride permeability (D) Paracellular permeability (LPP)
is significantly increased in CF. (E) Transepithelial electrical resistance is similar between
CF and non-CF cells.
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Figure 3.7: Model validation against experimental data demonstrates acceptable model
agreement in CF (A, C) and non-CF (B, D) HBE cultures. (B) In HBE 1, predicted ASL ab-
sorption is too rapid, though the DTPA prediction is in good agreement with the data. HBE
2 demonstrates acceptable agreement between model and data. Both CF lines demonstrate
strong agreement between model prediction and data, even in the case of DTPA absorption
in CF 2 where initial DTPA concentration is more than double the training set average (note
that axis scale is not the same for panels C and D). Error bars experimental data SEM.
Error bars are smaller than symbols where not distiguishable.
solution (450 mOsm) or 150 mOsm of mannitol to standard Ringer’s induced ASL swelling
and arrested paracellular convection of DTPA. Osmotically induced ASL expansion reached
a maximum after approximately 1 hour, at which point absorption began, introducing para-
cellular convection. This is illustrated in Figure 3.8B in the Ringer’s curve by an acceleration
of DTPA absorption. As osmolarities in all compartments are predicted to stabilize in less
than 1 hour (Figure 3.8C and D), convection decreased towards a solely diffusive regime.
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Cell volume dynamics (Figure 3.8E) were extremely fast (order <1 minute) compared to the
ASL dynamics, which agrees with the findings of Matsui and colleagues [9]. Cell volume ul-
timately recovers due to the homeostatic feedback mechanisms built into the model, though
at a slower rate than the initial volume response, which has been reported by Okada and
colleagues [95].
Model trajectories for the osmotic challenge conditions were generated from refitting the
model parameters via constrained nonlinear least-squares regression. Up to a five-fold [144]
change in model transport parameters from their baseline was allowed to result from the
cellular stress response after either addition of concentrated Ringer’s or mannitol (see Ta-
ble 3.2). Refitting is justified under this new case of hypertonic challenge because the cell
must act rapidly in order to preserve its volume and osmotic environment [144]. This will
necessarily change ion and water transport behavior through a combination of Ca2+ release
and channel trafficking [13,95] and osmotically activated water channels [144]. Particularly,
ENaC permeability should decrease [13, 95] and transcellular water permeability should in-
crease [144], which can be observed in Table 3.2. Simulated responses in Figure 3.8A and
B agree well with the data and also illustrate the different convective and diffusive mech-
anisms present after osmotic challenge. Additionally, mannitol decreased the absorption
of DTPA more than concentrated Ringer’s (p<0.01) and increased the steady state ASL
volume (p<0.05). Furthermore, model agreement with volume and DTPA profiles under a
previously untrained condition demonstrates the structural robustness of the model and its
ability to capture the underlying physics of the experimental system.
3.3.4 Other Considerations Regarding Cell-volume Regulation
Figure 3.8E demonstrated that cell-volume response occurs on a time-scale similar to that
reported by Matsui et al. [9]. A 150 mOsm hypertonic apical solution (of raffinose instead
of mannitol) was also applied to the lumen of cells in that study. Figure 3.9 shows that
the model can be refit to non-CF cell-volume data collected from that same study [9] by
increasing the initial “monolayer” height and varying LPP. Regression of the model over
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Figure 3.8: (A) by adding 10 µL of either 1.5x concentrated Ringer’s or Ringer’s and mannitol
solution apically to non-CF HBE, ASL volume increase is induced and paracellular DTPA
convection stops for approximately the first hour after addition resulting in slow initial
DTPA absorption (B). The subsequent decrease in ASL volume induces paracellular liquid
absorption and convection of DTPA, which accelerates its absorption. Model estimates are
in good agreement with the data. Mannitol reduces overall DTPA absorption (p<0.01) and
promotes increased steady state ASL volume (p<0.05) at 24 hours compared to hypertonic
Ringer’s. (C) and (D) Illustrate that the small disparity in terms of magnitude of initial ASL
volume increase was due to differences in inital osmolarities. (E) Cellular height decreases
rapidly in response to both hypertonic challenges on the same timescale as that reported by
Matsui et al. (2001).
these two parameters yielded a 95% confidence interval on monolayer height hc=[35.55,
37.58] µm and LPP=[1.576, 2.744]x10
-4 m/s.
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Figure 3.9: By only slightly changing the initial height of the monolayer and the hydraulic
permeability, the model is able to capture the data of Matsui et al. [9]. Envelope shows
region of 95% confidence in model dynamics given the other non-CF parameters from 3.2
The confidence envelope was generated from combinatorial selection of cell-height and
permeability 95% confidence bounds. The nominal initial value for height of 36.56 µm is a
reasonable value for the monolayer [9]. The absence of CF volume-response data motivated
the development of a simple, rapid method (as opposed to confocal microscopy or other more
involved methods [145, 146]) to measure cellular volume response. This method involved
detaching fully differentiated HBE cells from the transwell filters they are grown on and
plating them on a glass slide for video capture via bright-field microscopy. As a consequence
of detachment the cells become spherical, which minimizes their surface area to volume ratio.
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This allows for recognition via the circular Hough Transform in Matlab [147] as shown in
Figure 3.10.
Figure 3.10: Individual (even occluded) cells are detectable by the algorithm. Here four
non-CF HBE cells have been identified. Cilia are prominent on one of the cells.
The microscope used has the ability to perfuse various solutions over the surface of the
slide. In the case of a perfused anisosmotic solution, any change in cell volume can be
recorded over time and the resulting video can be analyzed frame-by-frame for each cell.
This is demonstrated for a normalized cellular volume-response comparison between CF and
non-CF cells in Figure 3.11, where cell-volume decrease was induced via perfusion with a
450 mOsm mannitol solution.
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Figure 3.11: Recordings of normalized cell volume over time are shown for n=3 CF and n=4
non-CF cells. No difference is observed in response between cells, but the performance of
the algorithm is verified.
No difference was observed between the CF and non-CF cells in terms of dynamics or
magnitude of response. This is to be expected for two reasons. The first, from the modeling
result, is that LPC of CF and non-CF cells are not expected to be different (see Table 3.2).
This also makes sense in terms of evolutionary fitness; cell-volume response must be tightly
regulated for survival, so even diseased cells would not be expected to have a noticeably
different volume regulatory response. Solely focusing on the validity of the model, similarities
in LPC between CF and non-CF cells should result in the similarities in cell-volume regulation
that we report here.
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3.3.5 Paracellular Convection of DTPA is Increased in CF Cells
Equation 3.5, when written for DTPA in the apical compartment, has no active or passive
flux terms into or out of the cell. Thus, the DTPA transport equation reduces to a two-term
form yielding the contributions of diffusion or convection to its transport at any instant:
dDTPAA(t)
dt
= Jdiff + Jconv
= −PDTPAA,BATJ
(
DTPAA(t)
VA(t)
− DTPAB(t)
VB(t)
)
+
DTPAA(t)
VA(t)
dVA(t)
dt
(3.6)
Equation 3.6 structurally matches the description of drug absorption in the intestine given by
Lennernas [148]. From equation 3.6 the contributions of diffusion and convection to DTPA
transport can be estimated individually. Model estimates for concentration driven diffusive
flux between CF and non-CF cells were similar despite the higher DTPA concentrations in
the CF cells that were associated with lower ASL volumes (Figure 3.12A). Differences in
convection between CF and non-CF were more apparent. The model predicted a threefold
difference in paracellular convection of DTPA between CF and non-CF cell cultures (3,179
vs. 913 counts, CF vs. non-CF in Figure 3.12B). Furthermore, approximately 38% of DTPA
absorption was estimated to be due to convection in CF cells, which is similar to experimental
values that we have previously reported [8]. It follows that total DTPA absorption was
increased in CF, implicating abnormal convective transport due to increased paracellular
water transport as the primary cause (i.e. solvent drag).
The equation governing water transport, Equation 3.7, between the ASL and the cell
or basolateral compartments can be split into separate terms in a manner similar to the
treatment of Equation 3.6:
dVA
dt
= Jtrans + Jpara = −LPA,BATJVw (piA − piB)− LPA,CACVw (piA − piC) (3.7)
Upon integration of the individual terms, illustrated in Figure 3.12C and D, model-estimated
transcellular water flux exceeded paracellular flux in the non-CF case, which has been exper-
imentally reported [63, 149], and nominally so in CF. Paracellular liquid flux was increased
threefold in CF. Diffusive driving force (Figure 3.12E) was initially increased in CF cells due
to the lower initial ASL volume present in those cultures, but decreased convection in the
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Figure 3.12: Figure 3.12 A comparison between model-predicted counts of DTPA either (A)
diffused or (B) convected in both CF and non-CF HBE. Diffusion is similar between the
two cell types (A), but DTPA convection is dramatically increased in CF (B). Transcellular
liquid flow (C) is predicted to be greater than paracellular liquid flow (D) in non-CF cells.
In CF cells, flows through both the para- and transcellular pathway are similar, though
transcellular flow is nominally increased. The increase in DTPA convection is explained by
the correlation between paracellular liquid flow and DTPA absorption (r>0.999, CF and
non-CF). CF cultures convect more DTPA because they demonstrate increased paracellu-
lar liquid flow as compared to non-CF cultures. The modest increase in diffusion in CF
cells is explained by the relative initial hyperconcentration of DTPA in CF cultures due to
dehydration present at the beginning of the experiments (E).
non-CF cells caused this disparity to diminish over time as DTPA in the non-CF ASL was
concentrated due to predominantly transcellular water absorption.
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In order to test whether paracellular integrity may be compromised in CF, a 10 µL bolus
of DTPA and Ringer’s was added apically and reversed the osmotic gradient of the mannitol
experiments in Figure 3.8 (i.e. OsmB,0=450 mOsm) in an additional 3 CF (n=6+4+6 filters)
and non-CF (n=6+4+5 filters) lines (TER > 250 cm2 for all lines). This osmotic gradient
drives rapid ASL absorption [9, 65], through both the trans- and paracellular pathways and
caused increased DTPA absorption in CF cells for all t>0 and in non-CF cells at t=24 hours.
DTPA absorption was again increased in CF cells without basolateral mannitol (Figure
3.13A, p<0.01) at 24 hours compared to non-CF control cells (Figure 3.13B) and in CF cells
exposed to basolateral mannitol at 8 and 24 hours (p<0.05, 0.01, respectively). Acceleration
of DTPA absorption due to the imposed gradient was measured as the difference in apical
DTPA retention between the control and gradient conditions at every time point (Figure
3.13C). The difference in absorption in the CF cells (control vs. basolateral mannitol) was
greater than that of the non-CF cells (control vs. basolateral mannitol) at 4 and 8 hours
(p<0.05), indicating that CF cells are more susceptible to further increased paracellular
absorption, congruent with the model-predicted barrier defect.
3.4 TREATMENT ANALYSIS AND DESIGN USING THE CELL-SCALE
MODEL
Up to this point, results relating only to the structure and dynamics of the airway epithelium
have been presented. As previously discussed in chapter 1, however, this knowledge regarding
structure and dynamics can also be used to control biological processes and design desired
responses [66]. In the context of disease treatment, control and design are similar in concept:
halt and reverse the progression of a disease using some treatment as an actuator. They tend
to differ in terms of actuation frequency, with control theory implementations for acute and
some chronic illnesses that require intensive or frequent care [77, 82] and optimal design
implementations for diseases where long-term treatment outcomes are the primary goal [76].
Airway dehydration in CF following rehydration is generally thought to occur on a time-
scale of 2-6 hours when ASL height (not volume) is measured in vitro [24, 49, 97]. Such
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Figure 3.13: Normalized DTPA retention (mean ± SEM) in CF (A) cells and non-CF (NCF)
cells (B). In A and B DTPA retention was measured in the presence of either an isosmotic
or a 450 mOsm (150 mOsm hyperosmotic) basolateral bath. DTPA absorption is increased
at 8 hours for CF challenge vs NCF challenge (*, p<0.05) and in CF controls vs. NCF
controls and CF challenge vs. NCF challenge at 24 hours (**, p<0.01). The difference
between control and challenge is significant (p<0.05) for all CF t>0, and NCF at t=24
hours (unmarked). Vertical dotted lines represent differences in retention between control
and challenge conditions that are significantly different between CF and NCF. (C) The
difference between the control and challenge condition is significantly increased in CF over
non-CF at 4 and 8 hours (∆, p<0.0.5) indicating an increased acceleration of DTPA transport
in CF due to the osmolarity gradient.
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time scales do not necessitate intensive monitoring and frequent (multiple per hour) treat-
ments. Furthermore, current hydrating therapies in CF like inhaled hypertonic saline require
cumbersome equipment and periods of time longer than taking a pill or using an asthma
inhaler. Thus, it is better to formulate model-based treatment as a long-term treatment
design problem instead of a control problem.
To begin, Tarran and colleagues have shown that there is a correlation between ASL
height and mucociliary transport velocity [49], and Figure 3.14 demonstrates that there is
also a positive correlation between ASL volume and FFCA.
Figure 3.14: FFCA is plotted against measurements of ASL volume for n=12 filters following
the apical addition of 10 µL of Ringer’s. The correlation is significant and consistent with
an intermediate volume range below the saturation point in Figure 2.14
.
While not mechanistic, this relationship underscores the idea that increasing airway hy-
dration (up to saturation) will improve MCC and thus patient health. So while a mechanistic
study of how FFCA, MCC, and hydration interrelate should be performed, a treatment de-
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sign that targets ASL volume should also be effective in improving MCC. Conversely, the
model should also be able to provide reasons for treatment failure to improve MCC.
3.4.1 Model Analysis of a Clinical Study
Goralski and Button [150] developed a cell-scale experimental model of aerosol deposition
on cultured HBEs. Using a nano-nebulizer they were able to provide a scaled down dose of
hypertonic saline with a deposition rate equivalent on a per surface area basis to that of the
standard Pari LC-star nebulizer. They reported that slower deposition rates induced less
cell-volume reduction while improving duration of hydration. They also noted that 4 hours
was the minimum interval that allowed for repeated dosing with equivalent rehydration as
the first dose. These findings provide two starting points for treatment design. The first, that
slow dosing might improve airway hydration and, thus, mucociliary clearance was tested in
a clinical study of nebulized HS given overnight (for 8 hours) via a nasal cannula and trans-
nasal pulmonary aerosol delivery (tPad) device designed by Parion Sciences Inc. The trial
and analysis were performed at the University of Pittsburgh to avoid conflicts of interest.
Results for that trial in terms of patient MCC and DTPA absorption are presented in the
next chapter (chapter 4). In brief, the study no difference in MCC or DTPA absorption in
HS vs. a sham treatment control day.
This study provided an opportunity to use the cell-scale model described above to identify
possible failure modes given that previous cell-scale experiments suggested the trial would be
successful. Patton and colleagues identified aerosol generation and particle deposition as the
primary challenges for inhalation therapy [151]. The aerosol generation of the tPad is well
characterized so the first focus was on the effect of deposition rate on airway hydration [152].
The simplest means of approximating deposition in the lung, which has enormous surface area
and heterogeneous topology [153], is to assume a uniform deposition rate throughout similar
lung regions. Based on the morphometry described by Weibel [153], functional imaging
scans, and known tPad output, a surface area normalized deposition rate was calculated for
HS in the bronchi (i.e. airway generations 1-10) of 70.1 pL/s. For 7% HS, this is equivalent
to 0.92 µmol/cm2/s of Na+, which is in excess of the model best-fit and median estimate for
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Na+ fluxes of 0.65 and 0.74 µmol/cm2/s, respectively. Since net Na+ absorption is required
for liquid absorption, it is expected that this rate to produce a hydrating effect over time.
Indeed, model predictions for this rate indicate as much across the ensemble of parameters
generated from ptempest, as seen in Figure 3.15.
Figure 3.15: Comparison of expected hydration in CF cells using either the surface area of
the first 10 airway generations to calculate a 70.1 pL/s or halved (35.1 pL/s) deposition
rate. Envelopes are generated from simulating the responses of the entire 8000 parameter
set ensemble from model training and give the median ASL volume prediction bounded by
its standard deviation.
But as seen from the other modeled case in Figure 3.15, halving the deposition rate does
not restore CF ASL volumes to resting levels seen in non-CF cells. This halving could easily
fit into the uncertainty about the total surface area where deposition occurred. Therefore,
it may simply be that not enough aerosol was delivered to the airway surface to induce
hydration.
Inherent to the assumptions is that half the total dose was deposited on an area equal in
size to the first 10 airway generations given estimates of a central to peripheral dosing ratio
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(C/P see [8]) of ≈1. It is possible that a larger proportion of bronchioles is represented in the
central region, however. If that were the case it would be expected that deposition rate per
surface area would decrease up to 10-fold in the extreme case that the first 16 generations
(Weibel limit of “conducting” airways) were used for the area estimate.
Furthermore, there is some uncertainty in terms of Na+ absorption rates. Some groups
have found Na+ absorption to be increased in CF [12, 13] while others report values closer
non-CF rates [25]. The variability of Na+ flux is also apparent in the model predictions
and data given above in Figure 3.6. Because of that, model-predicted sensitivity to Na+
absorption rates was also evaluated.
Ionic concentration in the aerosol and not the liquid volume carrying it is the primary
source of rehydration for osmotic therapies. Thus, whether or not increased (14%)saline
concentration could ameliorate these issues was tested as well. Each of these sources of
possible variation in therapeutic effect were tested via simulation using the model best-fit
parameter set for CF. The results of these simulations are shown in Figure 3.16.
A uniform deposition profile involving the first 16 airway generations is untenable for
successful hydration as no scenario with this assumption exceeds non-CF baseline hydration.
Sodium absorption rates ranging between the values and those of Boucher [4] have a smaller,
but observable effect on hydration. While 14% HS does substantially improve predicted
hydration, it is not able to counteract such a poor deposition profile, though it would be
able to counteract the reduced deposition case of Figure 3.15 as seen in Figure 3.17.
The uniform deposition assumption is not, however, the best means of informing the
model. Many computational fluid dynamics models (CFD) exist that describe the deposi-
tion patterns of aerosols as a function of size, flow condition, and lung geometry. That of
Martonen and colleagues [154] was chosen because it predicted the deposition pattern of the
tPad and that of Gerrity and colleagues [155] was selected as another point of comparison
for an airway generation-specific model of deposition and hydration. These CFD models
provide estimates of aerosol dose for each airway generation based on aerosol size.
These deposition models were utilitzed in a set of simulations of the cell-scale modeland
assume that the dose deposited in each airway generation is uniformly distributed over the
area of all branches in that generation [154]. For the following simulations ASL initial height
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Figure 3.16: Model predicted effects of deposition rate (volumetric rate/surface area) on
cell-culture ASL volume using either the total surface area of the first 10 (10G, solid) or 16
(16G, dashed) airway generations are shown alongside the effects of Na+ absorption rate.
Deposition amount in the bronchioles has a large effect on predicted efficacy, and sodium
(fast or slow) absorption has a smaller, noticeable, effect. Increased saline concentration
(14%) improves hydration.
was set to be 7 µm according to the literature [24, 97]. The analysis begins in Figure 3.18
by comparing the dynamic estimate of generational hydration to the static estimate of Sood
et al. [10] for ASL height added following fifteen minutes of inhaling isotonic saline via the
Pari LC-star (4 µm particle size).
Since the model includes the active liquid and ion transport occuring in the model and
the Sood et al. [10] prediction does not, ASL height added is decreased in every airway
generation in the model. However the profiles of ASL height vs. generation are similar
between models. This provides evidence that the model is suitable for making predictions
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Figure 3.17: Comparison of expected hydration in CF cells using either the ideal 70.1 pL/s or
halved (35 pL/s) deposition rate with 14%HS, which is predicted to be successful in restoring
hydration.
across airway generations and their specific deposition rates. Accordingly height response was
predicted at each generation for each deposition rate and particle size associated with the Pari
LC-star and extended analysis to the tPad with its reduced aerosol size and deposition rate.
Hydration profiles are given for each nebulizer at the airway generations most susceptible to
mucus accumulation and obstruction [11] for their respective treatment durations in Figure
3.19.
While hydration levels may seem high, it should be noted that this model does not
account for mucociliary clearance between generations that would be induced by upon airway
rehydration. The known acute action of HS after oral inhalation [150, 156] is evident in the
model prediction. For well hydrated generations like generation 7, the tPad is expected to
slow ASL resorption by about 30%. Generation 8 has sustained moderate hydration but
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Figure 3.18: The cell-scale, dynamic model (left) predicts similar patterns of ASL height
by airway generation to the previously published model by Sood et al., [10] (right) when
considering 7% HS delivery from a Pari LC-Star nebulizer. Heights are reduced overall in
the model based on inclusion of terms for liquid and Na+ absorption that reduce ASL height
over the 15 minutes of simulated delivery. Agreement is strong, and reduced heights at left
are justifiable given that liquid addition should cause some rapid volume resorption, even in
a fifteen minute time-frame.
the predicted deposition pattern for the tPad is such that generations beyond it are not
substantially hydrated. This issue is predicted to be solvable by using 14% HS instead 7%,
where the added osmotic drawing power overcomes the inherent ability of the lower airways
to absorb added Na+. This is one possible design suggestion posed by the generational
modeling result.
However, the uniform deposition assumption can be reapplied to a sequential treatment
involving both the Pari LC-star and the tPad. Orally inhaled HS provides an acute treatment
effect that the long-term deposition period of the tPad is meant to fix. By “priming” the
lungs with a quick, hydrating dose of HS with an oral nebulizer, the tPad operates on airways
in a pre-hydrated state and can be thought of as a hydration maintenance device in the same
way an IV drip might be used instead of a bolus. This concept is not limited to HS alone.
It was noted in Figure 3.8 that mannitol has a longer residence time in the ASL due a lack
92
Figure 3.19: Model-predicted hydration of the bronchi where obstruction has been found to
begin [11] given anatomically informed deposition rates for either a 1.5 µm (tPad, solid) or
4 µm orally inhaled aerosol (Pari LC star, dashed, [10]). Acute hydration is predicted for
oral inhalation of 7% HS, but not for the tPad. 14% HS (+) provides pronounced hydration
at generation 9 beyond that of 7% in the tPad.
of cellular transport pathways that translated to more long-term and robust hydration and
reduced solute absorption. Figure 3.20 compares the efficacy of 7% HS alone to oral HS and
either extended delivery 7% HS or 20% mannitol at half of the ideal tPad deposition rate.
Figure 3.20 illustrates priming the airways with a proven, though acute, inhaled osmotic
therapy may allow for extended therapeutic benefit via the tPad or a similar extended
delivery device. The benefit may be extended even further using more durable osmotics, like
mannitol, or by reducing Na+ absorption with ENaC blockers.
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Figure 3.20: Three ASL volume profiles (median with SD envelope) are shown for cell-culture
response to area-normalized deposition rates of either the Pari LC Star alone (magenta) or
followed by the tPad at the reduced deposition (RD) rate (yellow). Combination therapy with
a rapidly inhaled “priming” dose is able to maintain hydration for an overnight time duration
for either HS or mannitol (cyan). However, the absence of cellular transport pathways for
mannitol provides sustained hydration.
3.5 SUMMARY
Previous mathematical models of airway epithelia have considered liquid and solute trans-
port in varying degrees of mechanistic detail. Typically models have been designed around
Ussing chamber conditions [16,17,55,88,89], which are flooded in comparison to physiological
(thin-film) conditions. The model represents an advancement in that it accounts for paracel-
lular transport and includes dynamic apical, basolateral, and cellular compartments under
thin-film conditions. These conditions recreate the conditions in the human airway, allowing
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the model epithelium to establish a homeostatic ASL at an air-liquid interface. By consider-
ing the effects that ASL and cell volume have in terms of regulating solute and liquid flux in
an HBE culture system, structurally robust model that recapitulates experimental findings
has been constructed. Previous models also typically solve the algebraic electrophysiological
transport relationships involving Kirchhoff’s laws ( [55, 88]) and/or use high-order repre-
sentations of ion transporters, particularly in the basolateral membrane [16, 70]. Instead,
lumped kinetics were used for basolateral transport and apical transport terms that preserve
physiological phenomena (e.g. volume regulation) in the equation structure. The result is
a simplified model of epithelial solute and liquid transport that captures ASL and DTPA
absorption dynamics with model parameter and species flux values that reflect those found
in the literature. Furthermore, the model also explains physiological observations regarding
the routes of water transport in non-CF and CF HBE, namely that there is more paracellular
transport in CF epithelia than non-CF epithelia.
Using an identical model equation structure for both populations, we were able to identify
different parameterizations for CF and non-CF cell cultures that give rise to different ASL
and DTPA absorption dynamics. It was estimated that Na+ flux (thus, ENaC permeability)
is similar between CF and non-CF cells (Figure 3.6A), which is in agreement with some
experimental studies that have found that ENaC is not necessarily hyperabsorptive in CF
[25, 157] but contradicts the findings of some previous experimental and modeling studies
[17,93] conducted under Ussing chamber conditions. Ussing chamber measurements from cell
lines used for the training set indicate transepithelial Na+ flux as calculated from INa values
are similar in CF and non-CF. Ussing Chamber experiments, where ENaC transport kinetics
are essentially saturated, are difficult to extend to thin film conditions. However, the model
is structured such that PENaC represents the saturated permeability of ENaC. It is shown
in Table 3.2 that the estimates for PENaC are similar to those in the flooded conditions of
Ussing Chamber studies [56,93]. The model calculations for mean Na+ flux in both CF and
non-CF cells are between the lower (0.74 µeq/cm2/hr, [87]) and upper (2.15 µeq/cm2/hr, [4])
bounds found in the literature. In the case of CF in particular, the model-predicted Na+ flux
demonstrates excellent agreement with the value calculated from the data, which is evidence
of the physiological relevance of the model.
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We also calculated via the model that Cl- flux is decreased in CF to the point of inversion
from secretion in the non-CF case to absorption in the CF case. Indeed, the model estimates
for Cl- flux are reduced in comparison to values calculated from the Ussing Chamber data.
However, the Ussing Chamber estimates of Cl- flux are based on the difference between ISC
under bumetanide inhibition and the ISC of forced Cl
- secretion following forskolin stimu-
lation. Resting Cl- fluxes must be smaller than the forskolin stimulated values, and open-
circuit studies have shown that low secretive or even absorptive Cl- flux may occur [4, 23].
The model-estimated permeability of the constitutively active (i.e. not volume-regulated)
chloride channel was also analyzed in the model, PACC. We found that PACC is decreased
in CF HBE in addition to the absence of CFTR function (Figure 3.6C). This agrees with
findings from Ussing Chamber experiments that ICl is decreased in CF HBE, which may
be in line with the findings of Bertrand and colleagues [3], who suggest that SLC26A9 is
a constitutively active Cl- channel whose function is diminished by dysfunction in CFTR.
Accordingly, it may be that the model demonstrates that the hyperabsorptive dynamics that
arise in CF are due, at least in part, to the absence of constitutive Cl- transport brought on
by the absence of CFTR regulatory presence in addition to the loss of its chloride channel
function.
The major factor contributing to differences in absorption dynamics between CF and non-
CF epithelia is hydraulic permeability (Figure 3.6D, Table 3.2), which the model describes
as being 10 fold higher in CF. The model cellular hydraulic permeabilities in non-CF and
CF cells are close to literature values [9] derived from similar thin-film experiments. They
indicate that CF cultures are more permeable to both trans- (only ˜2x) and paracellular
(˜10x) water flows. TER is a metric of epithelial junction integrity, in terms of permeability
of ions through the paracellular space that is measured in the Ussing Chamber. There was
no difference in TER between CF and non-CF cells (Figure 3.6E). However, this does not
necessarily speak to the permeability of water through the cellular junctions in an open-
circuit, thin-film experiment like that on which the model was trained. It could be that
water transport kinetics vary greatly between the Ussing Chamber and thin-film conditions,
which more closely mimic the airway environment. It is also possible that a decrease in
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paracellular resistance was balanced by an increase in transcellular resistance due to the lack
of Cl- conductance through CFTR.
We also validated the model using four additional cell lines (2 CF and 2 non-CF, Figure
3.7). The effective use of the best-fit parameters generated by MCMC during model training
demonstrates that these parameters and their distributions are representative of the respec-
tive CF and non-CF cell populations, implying that cell parameters from a “new” subject
would fall within these ranges.
In order to demonstrate appropriate model response to osmotic challenges, 10 µL of
either 450 mOsm concentrated Ringer’s or mannitol+Ringer’s solutions was added with
DTPA to the ASL of non-CF HBE. Model parameters were refit, resulting in the best-fit
values given in Table 3.2. The subsequent apical hyperosmolarity induced ASL swelling
(Figure 3.8A) as the ASL volume increased (up to t≈1 hour). DTPA transport was slowed
due to abrogated convection, as illustrated by the visible downward deflection in the slope of
the concentrated Ringer’s curve (Figure 3.8B). Dilution and experimental variability caused
small differences in initial ASL osmolarity (Figure 3.8C and 5D), resulting in more swelling
in the Ringer’s-only condition. Model-predicted changes occur rapidly, and maximum cell
shrinkage occurs on a similar time-scale as reported by Matsui and colleagues [9] (Figure
3.8E). Mannitol increased steady-state ASL volume and reduced DTPA absorption as com-
pared to concentrated Ringer’s. Mannitol is not actively transported through cells; it can
only diffuse through the paracellular pathway, which is comparatively slow. The residence
time for mannitol and therefore its osmotic effect in the ASL was longer than the residence
time of the ions of Ringer’s solution, which are actively transported by epithelial cells. There
was also no appreciable difference in osmotic volume response between CF and non-CF cells
(Figure 3.11).
Our training data corroborates previous reports, both in vitro [65] and in vivo [8], that
DTPA absorption is increased in the CF airway. Using the mathematical description of
DTPA absorption from the ASL, it is possible to probe the relative contributions of diffusion
(Figure 3.12A) and convection (Figure 3.12B) that lead to this increased DTPA absorption in
CF. Concentration driven diffusion differences diminish during the experiment as the larger
transcellular liquid absorption in non-CF cells “concentrates” DTPA in the ASL relative
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to CF cells (Figure 3.12E). The model predicts that convective transport explains approxi-
mately 80% of the increase in DTPA absorption seen in CF vs. non-CF cells. Furthermore,
convection accounts for 20% of total DTPA absorption in non-CF cells, increasing to nearly
40% in CF cells, which is close to experimentally observed values [8]. The model also suggests
that the majority of liquid absorption occurs through the transcellular pathway in both CF
and, particularly, non-CF cells (Figure 3.12C). This agrees with previous reports [149] that
transcellular, namely aquaporin-mediated, water transport exceeds the volume of transport
that occurs in the paracellular space.
In order to test the model prediction that paracellular permeability is increased in CF
cells, a basolateral osmolarity gradient was imposed favoring increased ASL absorption. In
so doing, this accelerated DTPA absorption at all time points (2-24 hours) in CF cells and
at 24 hours in non-CF cells. CF cells in both the control and challenge conditions absorbed
DTPA faster than non-CF cells (Figure 3.13A and B). Moreover, the acceleration induced
by the gradient was greater in CF cells than non-CF, verifying the model predictions that
paracellular permeability is increased (i.e. barrier integrity is diminished) in CF cells.
There are two disease-relevant implications of this work to CF:
1. According to the MCMC-estimated ion fluxes and related Ussing Chamber measurements
(Figure 3.6), the depletion of CF ASL originates in dysfunctional ion transport and
subsequent dysregulation of liquid transport through epithelial cells.
2. Paracellular liquid transport is increased in CF vs. non-CF HBE, leading to the increased
convective and total absorption of DTPA observed in CF (Figures 3.12 and 3.13). Para-
cellular transport does not exceed that of the transcellular route, but possible structural
deficiencies indicated by the model paracellular permeability (Figure 3.6C) suggest its
contribution is significant in terms of overall liquid absorption.
CFTR has been shown to regulate not only ion transport but also liquid transport via
interactions with AQP3 in airway epithelial cells [52]. This could explain the parametric
and dynamic transport differences observed in this work. It has also been reported that
structural and functional defects (e.g. connexin 43 mistrafficking or impaired cytoskeletal
interactions) exist in the tight junction of CF cells [139,140,141], which would further explain
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the aforementioned threefold increase observed in paracellular transport. This abnormality
is distinguishable from transcellular transport through the model, which describes these
transport mechanisms independently, in concert with the experimentally known cellular ion
and liquid transport defects in CF.
Because the model is able to distinguish between paracellular and transcellular liquid
and solute transport in HBE cells, it follows that transport in the airways in vivo could be
described by the physiological equations developed herein. MCC and DTPA absorption in
the lungs of subjects with and without CF [1,8] has been previously observed and modeled.
That model provided a physiological explanation for the deficient MCC observed in patients
with CF and a mechanistic description of DTPA absorption. It also demonstrated the
therapeutic effect of hypertonic saline on both MCC and DTPA absorption
This work represents a mechanistic description of DTPA and liquid transport. Further-
more, it is a system of ordinary differential equations that are less computationally expensive
to solve than the differential algebraic equation-based models in the literature. The reduced
complexity of the model in terms of active ion transport, particularly that of Na+, is also use-
ful for more rapidly identifying patient-specific parameters and designing patient treatment
and dosing strategies in real time on its own or merged with a lung-scale model.
We have shown the utility of the model in diagnosing possible causes of treatment failure
for the tPad system for overnight HS delivery via nasal cannula. It was determined that
insufficient saline deposition is the most likely explanation for why the study was negative
(see Figures 3.15 and 3.16). Simulations presented in Figure 3.17 and Figure 3.19 suggest
that 14% hypertonic saline may hydrate intermediate airways more effectively than 7%.
However, they also suggest that priming the airways with a short (20 min) pre-hydrating
dose of HS via the Pari LC-star or similar device may allow the tPad maintain ASL hydration
for the duration of overnight treatment. Figure 3.20 illustrates this point as well suggesting
that mannitol may be a more durable therapeutic than HS, which is similar to the result
presented in 3.8. Ultimately, these results demonstrate that the cell-scale model is a useful
explanatory and predictive tool that is well-positioned for rigorous optimal treatment design.
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4.0 PARAMETER IDENTIFICATION: METHODS AND MOTIVATING
CASES
4.1 OBSERVABILITY AND IDENTIFIABILITY IN SYSTEMS MODELS
Parameter identification is one of the most important problems in systems modeling, and is
only complicated by the complexities and nonlinearities present in biological models. Cobelli
and DiStefano [158] describe the concept of identifiability as one primarily focused on the
uniqueness of solutions to the problem of parameter estimation. They define a “structurally
identifiable” model as a model with a unique solution to the parameter estimation problem
[158]. As evidenced by the models presented in previous chapters, this estimation problem is
often ill-posed with many more unknown parameters in the vector θ than model equations,
and the observables, y(t), often come in the form of noisy data. In this case, the estimation
problem can be posed as an optimization problem. In the case of modeling dynamic data,
the objective function, F , is usually a variant of minimizing the sum squared error (SSE)
between model fit and data. A standard variance-weighted form of the SSE is given in (4.1):
min
θ
F =
m∑
i
n∑
k
1
σ2(tk)
(yˆ(tk, θ)− y(tk))2 (4.1)
The variance, σ(tk)
2, of the data is used to weight the squared difference between the
model value of the i = 1, . . . ,m states, yˆ(tk, θ, and the value of the observable given data
at k = 1, . . . , n points in time, t. The most standard means of optimization using this
objective function is regression [134,159,160]. For a linear optimization problem the solution
and the confidence in that solution is exact [134]. Solutions for nonlinear models or even
nonlinear optimization problems (i.e. the final model of chapter 2) are rarely guaranteed
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to be in closed form, and characterizing the confidence in those estimates introduces the
subject of “practical identifiablity” [134, 160]. Raue and colleagues [160] define a model
parameter θi as practically identifiable if finite confidence intervals can be placed on the
optimal estimate, θ∗i . A parameter is said to be “structurally unidentifiable” if it has infinite
confidence intervals [158,160,161]. The parameter kDL from the lung-scale model of chapter 2
is a relevant example of a “practically unidentifiable” parameter (see Figure 2.15). It has
finite confidence intervals, but there is insufficient information to map mucociliary clearance
in the model state D to observable data (either distal or whole-lung counts) in a way that
provides confidence intervals that exclude 0 and negative values. That is, even though the
data is such that the lung-scale model structure is observable, the data for D are not sufficient
to say that kDL is different from 0 (i.e. ineffectual).
This concept of observability is also important in modeling. Cobelli and DiStefano [158]
provided a detailed review of the concepts of identifiability and structural identifiability in
the face of model observability questions. They borrow the definition of observability in the
linear case from Kalman [162]:
dx1
dt
= A11(t)x1(t) +B1(t)u(t)
dx2
dt
= A21(t)x1(t) + A22(t)x2(t) +B2(t)u(t)
y(t) = C1(t)x1(t)
Where x1 is an m1-vector and x
2 is an m −m1 vector, u is the control input, and A11,
A21, and A22 are the submatrices representing the state effects on state dynamics. Note that
the y outputs x1 dynamics are affected by the x1 states but not the x2 states. Thus, a system
is observable if a system of equations can be specified from its state equations that relates
each state to either another state or an output. Restated, a system is completely observable
if its state variables, x, are not split into two groups wherein one group (i.e. x2) has no effect
on either the other states or the outputs. Thus, for a linear system of m states, if the Linear
Observability Matrix O = [C,CA,CA2, ..., CAm−1]′ is of rank m, the system is observable.
In the nonlinear case, the observability matrix is developed from higher order Lie deriva-
tives of y(x), L n(y(x)) [163]. If we let f = A(x) ∗ x, and y = C(x) ∗ x, and assume Bu = 0,
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the Nonlinear Observability Matrix, ONL is determined as follows [164] from the Lie bracket
sequence:
L 0(y) = y
L 1(y) = ∇(y)f
L 2(y) = L 1(y)f
...
L n(y) = L n−1(y)f
Where ONL is ultimately:
ONL = ∇

L 0(y)
L 1(y)
...
L m−1(y)

And ∇ is the Jacobian with respect to the states, x.
As an example, the lung clearance model of chapter 2 can be shown to satisfy the
observability criteria. Note that for the Tc-SC model the absorption parameters are kLB =
kDB = 0, thus the change in the whole-lung count output is due only to MCC from LF,
so we have one relationship. The change in D is also observable via its own measurement
as defined by the P box from imaging, so we have another. LN is observable due to the
observability of LF and D to which LN is related algebraically in Laplace space. As such,
the model is observable. Conveniently, the same model structure when applied to DTPA is
also observable but only because of the observability of the Tc-SC model. Since we can set
the values for the MCC rate constants at the values obtained in estimated Tc-SC clearance,
absorption is strictly observable based on data from D and also L since FFCA is known.
It is interesting to note that this model, while completely observable, is not totally
identifiable. This possibility is discussed by Cobelli and DiStefano [158] and is another
way of defining the case of practical unidentifiability [160]. Specifically, while MCC in D is
technically observable in the mathematical sense, the rate constant that governs its dynamics,
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kDL, is ill-informed by the data. In the case of kDL, selection of time points for gathering
data is the primary issue with identifiability; MCC in D is known to be detectable on the
order of hours [116], but there are only 80 minutes of data to inform the clearance constant.
Data sparseness can also be a cause of unidentifiability [134], but we show this is not the
case - and that it is the former point discussed - later in this chapter. However, it is useful
to first discuss the available methods of parameter estimation and identification including
those used in this disseration.
4.2 METHODS FOR PARAMETER ESTIMATION AND
IDENTIFICATION
Parameter identification is commonly performed via regression, which can be applied in
linear and nonlinear models using gradient-based methods. Newton-Raphson methods are
the simplest of this class of search. Most common to this dissertation, however, is the
trust-region-reflective method that is built in to the Matlab function lsqnonlin ( c©2013, The
MathWorks, Natick, MA). These methods require the computation of the Jacobian J = dF
dθ
of the model states at every iteration, which is computationally expensive for large systems.
So-called quasi-Newton methods approximate the Jacobian or Hessian H = d
2F
dθ2
in order to
improve computational performance. An example of this type of solver that is used in this
dissertation is the interior point optimizer ipopt, which employs the the Broyden-Fletcher-
Goldfarb-Schano (BFGS) algorithm [165].
The general assumption of (4.1) is that the minimum solution set in all of parameter
space, called the global optimum, is the true solution to the estimation problem. While
there is some debate regarding whether true global optimality is essential in the identification
problem in biology [166], it is useful to explain how it can be obtained. Gradient-based
methods on their own can only guarantee that the solution achieved is globally optimal if
the optimization is formulated as a linear program (LP) or quadratic program (QP). In part,
this is because gradient-based methods require a convex objective surface for convergence,
which are guaranteed in these formulations. Gradient-based solvers tend to fail for nonlinear
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programs (NLPs) because NLPs are rarely globally convex, but they require an initial guess
in order to determine an optimal value for a given parameter. Thus, the goodness of the
solution provided by these methods for NLPs is heavily reliant upon the quality of the initial
guess. With an infinite number of guesses any algorithm achieve global optimality [167].
For most models with any degree of physiological detail, such methods are only useful for
verification of nonconvexity. As a next step, Raue and colleagues propose that the sparseness
afforded by Latin Hypercube sampling (LHS) is a strong method for generating an ensemble
of initial guesses for an optimization algorithm [168]. An additional benefit of LHS is that it
is highly parallelizable; a single guess and subsequent optimization routine can be assigned
to a dedicated computational core or thread for independent simulation in parallel with other
optimizations in the hyperspace. There is still no guarantee that any solution is globally
optimal, but this method has the benefit that deterministic assignment of initial conditions
is computationally cheap and good solutions can generally be found [168]. Deterministic
programs that solve NLPs to global optimality (if needed) also exist (e.g. BARON [169]
and KNITRO [170]), but may still struggle in optimizing the systems of highly nonlinear
differential equations that often arise in biology.
In many cases, particularly those with a high degree of nonlinearity, stochastic methods
for parameter identification may be useful [166] and some can be shown to provide guaranteed
convergence in finite time [142]. In a similar manner to LHS, these methods can randomly
sample values in parameter hyperspace for determination of the objective function value, but
they iteratively improve fit through statistical biasing instead of a gradient-based search - be
it through evolutionary “fitness” [171], simulated annealing [172], parellel tempering [142]
or otherwise. Papers by Moles, Mendes, and Banga [166] and by Raue et al. [168] provide
a broad survey of such algorithms for the interested. Another such method that is used
in the second case study of this chapter is the Affine Parallel Tempering Markov Chain
Monte Carlo (APT-MCMC) method developed by Zhang and colleagues [173]. This is a
Markov Chain Monte Carlo variation of the Metropolis-Hastings algorithm that applies an
affine transformation during likelihood calculations for improved performance. Stochastic
and deterministic methods both rely on the assumption that the global solution is the best
(i.e. “real”) solution. In the stochastic sense, however, the “real” solution is the most
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likely solution. As stochastic simulations progress, the history of objective function values
at sampled locations in parameter space preserves an estimate of the likelihood function L .
Confidence intervals on parameters can be calculated directly from this likelihood estimate.
Thus, it is a benefit of stochastic simulations that the parameter estimation algorithm itself
simultaneously provides information regarding the practical identifiability of the model.
An estimate of the likelihood can be obtained for deterministic cases as well using F
from 4.1 as the measure of L . The Fisher information matrix is one methodology that is
commonly used in systems biology [174]. Rooney and Biegler [159] provided an outline for
developing a joint confidence region between two model parameters that was exploited for
one and two parameters by Word and colleagues [175]. The confidence regions or intervals
for p parameters are generated by finding θ∗ that satisfies the optimization problem 4.1 and
then solving for each of the θi that provide the maximal distance from θ
∗
i that does not
exceed the given confidence value α from the likelihood ratio (LR) test [176], as formulated
in 4.2.
maximize
∑
i
(θi − θ∗i )2
s.t. LR = 2[log(L ∗)− log(L )] ≤ χ21−α,p
(4.2)
χ21−α,p is the χ
2 value for confidence at the 1 − α level for p number of parameters. If
the solution to 4.2 is found iteratively for a single parameter, θi, by increasing the distance
(θi − θ∗i )2 in a stepwise manner until the LR constraint is violated, the contour generated
in the objective space of 4.1 over all examined θi is equivalent the Profile Likelihood (PL)
described by Raue and colleagues [134]. Profiling the likelihood in this manner provides
the confidence intervals of 4.2 for all practically identifiable parameters while also revealing
structural unidentifiabilities and nonlinearities in the objective space [134,160]. PL methods
have been shown to be more computationally efficient than stochastic Monte Carlo methods
in general [168]. Even so, the lack of guarantee or even detail with regard to global opti-
mality in the former case may justify the use of stochastic analysis. Specifically, stochastic
algorithms like MCMC provide not only the likelihood estimate for each parameter but also
allow for analysis of parameter-parameter correlations from the marginal distributions gen-
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erated. A comparison between PL and a Markov-Chain Monte Carlo (MCMC) method in
identifying the parameters of the model from chapter 2 will be the focus of a case study in
the fourth section of this chapter. Before that, however, the generation of the PL algorithm
used for that purpose within the open source optimization package Pyomo, will be discussed.
4.3 AN OPEN SOURCE PACKAGE FOR PARAMETER LIKELIHOOD
ESTIMATION
4.3.1 The Pyomo Model Profile Likelihood Estimation (PyMPLE) Package
Pyomo [177] is an algebraic modeling language (AML) that is designed to exploit the bene-
fits of the programming language Python, namely its high-level, object-oriented nature and
expanse of available open source packages and libraries. Pyomo is itself open source and
available to anyone with a Python installation, making it more accessible than most other
licensed AMLs, including AMPL [178] and its solvers, with which Pyomo can also inter-
face. As their name might suggest, AMLs are not well-suited for the solution of differential
equations, though it is generally possible through tedious effort [179]. Others have devel-
oped their own methods for optimizing certain classes of dynamic systems [180]. For this
reason, Pyomo has recently become more appealing to dynamicists with the advent of the
pyomo.dae package [179]. This package automates the discretization of Pyomo Var() type
variables and their dependent DerivativeVar() type variables into an algebraic approximation
of each differential equation. It supports standard and backward finite difference transfor-
mations, collocation on finite elements, and custom discretization schemes for integration.
The pyomo.dae package is capable of solving partial differential equations (PDEs) and dif-
ferential algebraic equations (DAEs), and the same methods can be used to solve systems of
ordinary differential equations (ODEs), like those presented previously in this dissertation.
This combination of easy-to-generate solutions to dynamical systems within a powerful opti-
mization framework makes pyomo.dae an ideal platform for high-performance identification
in systems engineering and systems biology.
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Currently, pyomo.dae will only optimize a model parameter or parameter set without
generating direct information about practical identifiability. Asympototic confidence inter-
vals can quickly be calculated from the covariance, C, and the Hessian, H, since C = 2H−1,
according to 5.3.
CIθi = θ
∗
i ±
√
χ2(α, p)Ci,i (5.3)
For most quasi-Newton methods such as ipopt [165], the Hessian is already approximated
by the algorithm. While fast, this approximation of the CIs is not always good, and can
be improved by calculating parameter likelihoods [134, 159]. Word and colleagues [175]
set a precedent for using likelihood-based techniques within the Pyomo framework using a
dynamic model of the seasonality of infectious diseases. That work was performed prior to
the release of the pyomo.dae package. Consequently all of their discretization and estimation
techniques were developed in a custom implementation for their model. Since pyomo.dae is
now available to automate the discretization transformations of differential equations, the
goal of the work that follows in this chapter is to also automate the analysis of parameter
identification via profile likelihood.
Described herein is the Pyomo Model Profile Likelihood Estimation (PyMPLE) package.
PyMPLE works in concert with pyomo.dae as a standalone module and class in Python.
Instantiation and execution of the PyMPLE class and its methods and attributes is accom-
plished via a run file.py script that imports the module and provides requisite arguments
for PyMPLE and the pyomo.dae model. An example of a run file and the pyomo.dae model
it runs are given in Appendix C, as is the full code of PyMPLE itself. The outline of the
process by which profile likelihoods are obtained is presented in Figure 4.1
The PyMPLE class has six methods:
1. PyMPLE. init is the initialization method for an instance of the class
2. PyMPLE.get CI is the method that sequentially calculates the profile likelihood and
confidence intervals of model parameters for a given α value.
3. PyMPLE.ebarplots generates a matplotlib bar plot with errobars at the upper and lower
CI for each model parameter.
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Figure 4.1: The algorithmic flowchart for generating PL analysis via PyMPLE.
4. PyMPLE.plot PL Plots the profile likelihoods of each profiled parameter in θ and returns
the figure handle containing the graphs.
5. PyMPLE.plot trajectories generates graphs of the dynamic state trajectories for each
solution instance from the profiling algorithm and returns the figure handle containing
the graphs.
6. PyMPLE.pop pays homage to the built-in Python method of the same name that re-
turns and deletes the final element of a list by returning the final elements of the upper
and lower profile arrays (i.e. the upper and lower bounds) of one or more requested
parameters.
Each of the methods except for PyMPLE.pop uses the numpy numerical package, and
the graphing methods use the Seaborn and matplotlib graphing packages. Methods 3-6
can only be used upon completion of the PyMPLE.get CI method execution. A detailed
description of the argument structure of these methods is contained in the code provided in
Appendix C.
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4.4 PYMPLE EXAMPLE: A MODEL OF THE VAN DE VUSSE
REACTION IN A CSTR
The Van de Vusse reaction scheme [181] is a widely used [182,183,184] chemical engineering
model for the study of nonlinear reaction systems. It has the following structure:
A →
kAB
B →
kBC
C
2A →
kAD
D
(4.2)
Where cyclopentadiene (A) is converted to the desired product cyclopentanol (B) with
byproducts of cyclopentanediol (C) and dicyclopentadiene (D). Under the assumption that
the reaction is carried out in an isothermal CSTR with only A in the feed, there is no need
for an energy balance and the mass balances for the system become:
V
dCA
dt
= F (CAf − CA)− V kABCA − V kADC2A
V
dCB
dt
= −FCB + V kABCA − V kBCCB
V
dCB
dt
= −FCC + V kBCCB
V
dCD
dt
= −FCD − 1
2
V kADC
2
A
(4.3)
We set the inputs F
V
= 4/7min−1 and CAF = 10
mol
L
and the rate constants kAB =
5/6min−1, kBC = 5/3min−1, and kAD = 1/6 molL−min . This served as a numerical basis for
demonstrating the functionality of PyMPLE as well as some key concepts regarding iden-
tifiability, observability, and their relationship to experimental design. We simulated the
system of equations over 10 minutes of dynamics using ode15s in Matlab, so that a clear
steady state was achieved in the data following start-up. Normal random error (µ = 0,
σ = 0.1) was added to each of the state-value vectors in time. This noisy data was pre-
served for re-optimizing the parameters under a number of observability and data-richness
conditions as follows in the next section.
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4.4.1 Analysis and Model Identification
We generated a model of the system using the pyomo.dae package to discretize the differential
equations of our model. As a first example we fit the concentrations of all model states over
time while attempting to identify θ∗ as the set of model rate constants given the initial guesses
{kAB,0, kBC,0, kAD,0} = {1/2, 5/2, 1/3}. Using 110 finite elements per state - one for each
time-point - and a backwards finite difference transformation we fit the model parameters
to the data using the ipopt solver. The state trajectories given the optimal parameter set
are plotted over time in Figure 4.2.
Figure 4.2: Model fit to full data set is excellent for each of the four model states.
In this case, the model is fully observable.
f = A(x)x =

−F
V
CA − kABCA − kADC2A
−F
V
CB + kABCA − kBCCB
−F
V
CC + kBCCB
−F
V
CD − 12V kADC2A

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y = Cx =

CA
CB
CC
CD

Its nonlinear observability matrix is:
ONL = ∇

L 0(y)
L 1(y)
L 2(y)
L 3(y)
 =

1 0 0 0
0 1 0 0
0 0 1 0
0 0 0 1
−kAB − 2A kAD 0 0 0
kAB − FV − kBC 0 0
0 kBC − FV 0
A kAD 0 0 − FV
(kAB + 2A kAD)
2 + 2 kAD
(
kAD A
2 + kAB A− FV
)
0 0 0
−kAB (kAB + 2A kAD)− kAB
(
F
V
+ kBC
) (
F
V
+ kBC
)2
0 0
kAB kBC − FV kBC − kBC
(
F
V
+ kBC
)
F
V
2
0
−kAD
(
kAD A
2 + kAB A− FV
)
−A F
V
kAD −A kAD (kAB + 2A kAD) 0 0 FV
2

Which is rank m = 4. Thus the system is observable.
This is an intuitive result because each state is directly informed by data, and the problem
is well-posed with a rich dataset. It is not surprising that under these conditions the rate
constants are all practically identifiable as demonstrated in the profile likelihoods of Figure
4.3. θ∗ is similar to the known values of the parameters (see Table 4.1).
The observability of the model given the full data set translates, in this case, to full
identifiability of the kinetic rate constants. It also has an effect on the quality of the es-
timation of state dynamics. To account for this, when the PyMPLE algorithm solves the
model dynamics for each parameter set during profiling it also stores the trajectory values as
a dictionary of arrays that represent the entire ensemble of model simulations which can be
plotted. In this first case, each model state has data to inform its dynamics, and the narrow
range of state trajectories in Figure 4.4 reflects this.
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Figure 4.3: Profile likelihoods (blue lines) of the kinetic rate constants when all states are
measured. Each parameter is identifiable at a 95% confidence level (red line). Optimal values
(green dot) are close to the “true” values (purple dot) used in data generation.
Table 4.1: Estimates of reaction rate constants with true values given for comparison to the
full and reduced data set examples.
Parameter Full Data No C or D True Values
kAB (min
−1) 0.848 0.749 0.833
kBC (min
−1) 1.677 1.401 1.667
kAD (
mol
L−min) 0.174 0.202 0.167
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Figure 4.4: Trajectories for each model are given. The dynamics are similar within each
state and to the state behavior in the data across the ensemble of simulations.
4.4.2 Identification of an Unobservable Model
All of the components of the Van de Vusse process are chemically similar, which may pose
multiple difficulties including sensor detection of individual component concentrations. In
the hypothetical case that measurements of only A and the desired product B are taken, the
model states C and D become unobservable. Thus, the new vector field y is:
y = Cx =

CA
CB
0
0

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This has multiple effects in terms of model performance. The first is demonstrated in
Figure 4.5, where values for C are underestimated while the values for D are overestimated.
Figure 4.5: Model fit to A and B is excellent, however, data for C and D were not used in
the objective function, and model fit falters accordingly.
The nonlinear observability matrix is:
ONL = ∇

L 0(y)
L 1(y)
L 2(y)
L 3(y)
 =
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
1 0 0 0
0 1 0 0
0 0 0 0
0 0 0 0
−kAB − 2A kAD 0 0 0
kAB − FV − kBC 0 0
0 0 0 0
0 0 0 0
(kAB + 2A kAD)
2
+ 2kAD
(
kADA
2 + kABA− FV
)
0 0 0
−kAB (kAB + 2A kAD)− kAB
(
F
V + kBC
) (
F
V + kBC
)2
0 0
0 0 0 0
0 0 0 0

Is rank m = 2, proving the system is non-observable.
That C and D are unmeasured also affects parameter identifiability. As illustrated in in
Figure 4.6, parameters kBC and kAD are unidentifiable from zero. Furthermore, θ
∗ estimates
are worse than the full data case, as shown in Table 4.1. Confidence intervals on the estimates
are substantially wider in the unobservable case as well.
Figure 4.6: Profile likelihoods (blue lines) of the kinetic rate constants given only data for A
and B. Only kAB is identifiable at a 95% confidence level (red line). Optimal values (green
dot) are further from the true values (purple dot) than in the observable case.
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These results demonstrate that observability affects identifiability in a meaningful way,
but its effect on state estimation may be even more meaningful. This is demonstrated in
Figure 4.7 in the trajectories for C and D. As a direct consequence of not being able to identify
kBC and kAD as different from 0, there is no ability to estimate the concentrations of C and as
being different from 0 at any point in time. Furthermore, the range of possible concentrations
generated during profiling precludes the possibility of accurate state estimation.
Figure 4.7: Trajectories for each model are given. Trajectories for unobservable states C and
D cannot be confidently differentiated from a zero-dynamics case, and span a wide range of
possible dynamic forms.
These findings motivate the following conclusions. The first is that observability and
identifiability are interrelated despite the fact that neither is a necessary condition for the
other [158]. Stemming from that concept is the notion that an ill-posed optimization problem
can lead to poor performance if insufficient thought is given to data collection during ex-
perimental or process design [185]. This may be even more important for biological systems
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where scale, complexity, and ethics greatly constrain the type and frequency of measure-
ments. To that end, this example shows that PyMPLE is useful in providing analysis of
process identifiability and observability. However, it should also be demonstrated that PyM-
PLE can serve the same function in biological models.
4.5 IDENTIFICATION OF A LUNG-SCALE MUCOCILIARY AND
ABSORPTIVE CLEARANCE MODEL
We continue the study of identifiability and observability in systems with a case study
of in vivo clearance model of chapter 2. Data for the model comes from a more recent
clinical trial involving patients with Cystic Fibrosis (CF). The trial involved determining the
efficacy of slow (as opposed to orally inhaled), continuous, overnight delivery of nebulized
hypertonic saline (HS) through a nasal cannula. This follows from unpublished findings that
reducing the deposition rate of HS can prolong airway surface liquid (ASL) hydration in
human bronchial epithelial cell cultures. HS has been shown to be effective in treating the
mucociliary clearance (MCC) and ASL hyperabsorptive defects that bring about CF lung
disease [1, 8, 22].
The trial examined clearance every 2 minutes for the first 90 minutes following the
inhalation of Tc99m-Sulfur Colloid (TcSC) and In111-DTPA (DTPA) as described in [8].
Additional images were obtained at 180 and 360 minutes to assess whether MCC in the
distal lung, which is known to be slow [1] could be determined from later data points. The
result is an extended-duration, though more sparsely measured, data set than that of [1].
MCC was determined from functional imaging of Tc-SC clearance, as it is a large particle
that is not absorbable into the bloodstream. Absorption (ABS) was determined as the
normalized difference between Tc-SC and DTPA retention. Initial counts in the central (C0)
and peripheral (P0) lung were also estimated for both TcSC and DTPA.
Parameter identification was performed via two methods. The first utilized APT-MCMC
[173]. This approach requires simultaneous optimization of the MCC and ABS parameters,
making the model unobservable for DTPA. The second employed a variation of the PyM-
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PLE package in the pyomo.dae environment that was modified to allow for the sequential
MCC then ABS parameter identification scheme described in chapter 2. This section will
focus more on the comparison of the two methodologies than the study result itself, which
was null. We find that both methods, despite differences in observability and tradeoffs in
terms of computational cost and information gained, are generally capable of identifying
the model with similar results in untreated patients with CF. However, the observability
and deterministic nature of the pyomo.dae model structure provide better computational
performance.
4.5.1 Problem Formulation
4.5.1.1 APT-MCMC Because the APT-MCMC algorithm is stochastic, there is no
way to perform an unbiased sequential optimization routine in the same manner as the
deterministic method used in chapter 2. That is, there is no way to determine optimal MCC
parameter (kLT , kDL, FFCA) values prior to the generation of the posterior likelihoods. Only
a combinatorial search involving each parameter set from the MCC posteriors could supply
an unbiased basis for the ABS parameter search, and that would be far too computationally
expensive. Instead we pose the following objective function for fitting whole lung clearance
of TcSC and DTPA to the equations 2.3-2.7 for each probe simultaneously:
min
θF
P∑
p=1
2∑
i=1
46∑
k=0
1
σ(k)2
(yˆi(tk, θ)− yp,i)(tk))2
s.t. θLi ≤ θ∗i ≤ θUi ∀i ∈ Θ
yi = LF,i + LN,i +Di ∀i ∈ Y
(4.4)
The SSE is obtained on the HS day and also the control day for P=12 matched patients
over 47 time points. APT-MCMC allows for parameter bounds, which is the first contraint.
Finally there is the algebraic relationship between the whole-lung clearance of TcSC and
DTPA. APT-MCMC automatically performs a log-transform of the states and the data for
evaluation of the objective function. The algorithm was run with 100 “walkers” on each
of four chains. Walkers were allowed 25 steps before a swap was executed between chains,
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and 10000 swaps were performed for each optimization attempt for a total of 108 model
simulations.
4.5.1.2 PyMPLE The objective function in pyomo.dae is similar to that of APT-MCMC,
with the addition of constraints related to the backward finite difference solution and the
partitioning of θ = {θTcSC , θDTPA}. The deterministic nature of pyomo.dae allows for the
minimization of the objective for TcSC first for the MCC parameters:
min
θTcSC
F
12∑
p
46∑
k=0
1
σ2k
(yˆTcSC(tk, θTcSC)− yp,T cSC(tk))2
s.t. xj(0) = g(0) ∀j ∈ X
dxj,f
dt
=
xj,f − xj,f−1
∆xj,f
∀j ∈ X, f ∈ E
∆xf = A(θTcSC)xf ∀j ∈ X, f ∈ E
θLTcSC,i ≤ θ∗TcSC,i ≤ θUTcSC,i ∀i ∈ Θ
The first constraint requires that the initial condition of each state is a function, g, of
the dosing parameters. The second constraint is the backward finite difference constraint for
every state j in X at every element f in E. The third is the difference approximation to the
state equations at each element. A similar problem is then posed for the DTPA data and
the ABS parameters:
min
θDTPA
F
12∑
p
46∑
k=0
1
σ2k
(yˆDTPA(tk, θDTPA, θTcSC)− yp,DTPA(tk))2
s.t. xj(0) = g(0) ∀j ∈ X
dxj,f
dt
=
xj,f − xj,f−1
∆xj,f
∀j ∈ X, f ∈ E
∆xf = A(θDTPA, θTcSC)xf ∀j ∈ X, f ∈ E
θLDTPA,i ≤ θ∗DTPA,i ≤ θUDTPA,i ∀i ∈ Θ
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The difference in formulation between APT-MCMC and PyMPLE provides an interesting
comparison between the performance of a global solver in an ill-posed case and a local solver
under better conditions.
4.5.2 Model Fit to Data
The ODE models were fit to the data and likelihoods were generated using APT-MCMC.
The resulting ensembles and median trajectory for TcSC and DTPA clearance on the HS
and control (Sham) days from the APT-MCMC experiments are shown in Figure 4.8.
Figure 4.8: APT-MCMC ensembles of whole-lung TcSC (top) and DTPA (bottom) clear-
ance. Model estimates capture the data and variance (mean+ SD). Ensembles are a random
selection of 105 APT-MCMC simulations of 106 total post-burn-in.
Ensemble medians are in generally good agreement with the data. The low estimate
for TcSC on the HS day is mostly due to one patient with high deposition. They were not
excluded from the fitted data for matching purposes with the Sham day. The variance of
the ensemble is in good agreement with the data except for the TcSC-HS case where the
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same high-deposition patient was the only patient with a manifestly different profile than
the others. Model fits via APT-MCMC are acceptable on the whole.
In accordance with the methodology outline in Figure 4.1, the model was also fit using
pyomo.dae and the solver ipopt to determine a single set of optimal parameter values. Model
output and fit to data are shown in Figure 4.9.
Figure 4.9: Pyomo estimates of TcSC (top) and DTPA (bottom) clearance. Model agreement
with data is strong. Of note is the similarity between data sets, indicating the null result of
the clinical trial.
The pyomo.dae fit is in strong agreement with the data on both study days. The model
was not fit to normalized data, but they are presented in this manner to show the strong
similarity in clearance due to both MCC and absorption on both study days. TcSC fits
on the HS day produce a low estimate of initial TcSC counts for the same reason as APT-
MCMC; one patient had a high deposition day that was not reflected in other patient data
sets. Fits via pyomo.dae are also acceptable.
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4.5.3 Comparison of Likelihood Estimates from APT-MCMC and PyMPLE
Herein the maximum likelihoods and likelihood functions calculated for each parameter in
the lung clearance model are compared. APT-MCMC has the benefit of computing the
entire likelihood function at the same time that it performs the parameter search. It also
provides information that can be used to determine marginal distributions, which cannot
be obtained from profile likelihoods. However, the profile likelihoods are typically faster to
compute. Regardless, it is first useful to compare the estimated likelihoods for both methods
before analysis of their computational performance. Such a comparison is given for the large
airway parameters in Figure 4.10. Optimal values and algorithm performance metrics are
given in Table 4.2
Figure 4.10: Large airway clearance parameters and their APT-MCMC distributions (top
row) or profile likelihoods for HS (middle) and Sham (bottom) days. Agreement is strong
in all cases for both methods except for kLT on the Sham day (bottom left). This difference
is likely due to a single anomalous patient that drives underestimation by APT-MCMC on
the Sham day on population grounds. A lack of difference between days indicates ineffective
treatment for promoting large airway clearance.
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Table 4.2: Kinetic parameter estimates for MCMC and PL (as maximum likelihood) tech-
niques. Deposition parameters were also estimated. Literature values are from Markovetz
et al. [1] where trust-region-reflective estimation was used. Time to convergence is given for
each method. APT-MCMC is parallelizable, but the estimations for both APT-MCMC and
PL occurred on a single 2x Xeon core.
Day or
Source
kLT × 102
(min−1) FFCA
kLB × 103
(min−1)
kDL × 103
(min−1)
kDB × 103
(min−1)
TcSC
L0/D0
(C/P)
Time
(min)
MCMC HS 0.83 0.35 3.37 2.27 1.77 1.03 299
Sham 1 0.38 2.77 2.07 1.75 1.35 310
PL HS 1.23 0.43 3.41 2.94 84.2 1.26 19.2
Sham 12 0.52 2.66 4.4 7.13 0.87 13.9
Lit. [1] 3.5 0.53 - 2.8 1.8
1.5
1.3
-
Parameters are identifiable by both methods. They also agree on nearly every estimated
parameter except for kLT on the Sham day, which is estimated to be an order of magnitude
greater than other values for that parameter. With respect to the model dynamics and
those apparent in the data, this larger value seems more reasonable (the pyomo.dae model
fit to TcSC on the sham day is excellent). It may simply be, then, that one individual with
much slower clearance dynamics biased the model fit on the HS day for both APT-MCMC
and pyomo, resulting a lower estimated value of kLT . Regardless, the high degree of overlap
between most of the likelihood estimates for large airway parameters is an encouraging result.
A similar illustration is presented in Figure 4.11 for the two D parameters, kLB and kDB.
The likelihoods for CTc, the initial TcSC counts in the central region of the imaging scan as
defined in [8], are also given.
The distal airway parameters have a clear maximum likelihood as estimated by APT,
but are only identifiable by PyMPLE. This is again likely due to the observability of the
system. Weak identifiability of kDB in the HS day is evident in the distributions and the
spread of its PL. This may be due to HS producing a hydration effect in the distal lung [1]
that is confounded with the relatively slow estimate of kLT . CTc was bounded more tightly in
the pyomo.dae (data mean±SD) solution than in APT-MCMC. However, poor performance
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Figure 4.11: Small airway clearance parameter and initial TcSC central deposition (right
column) estimates. Agreement is strong except for kDB on the HS day, which is likely a
compensation for the slow MCC brought about by the small values of kLT estimated for
HS. Distal MCC constant kDL is identifiable in the Sham case using PyMPLE. Deposition
estimates are much less variable using PyMPLE.
of APT-MCMC in estimating the deposition is further evidence that the observability of the
PyMPLE model is beneficial, since observability is a state property. This notion would also
explain the differing estimates for the deposition parameters that are illustrated in Figure
4.12.
While consensus is shared between the maximum likelihood estimates of APT-MCMC
and PyMPLE, the shapes of the likelihood functions for deposition values do not agree
between methods. Particularly, peripheral deposition values (PTc and PIn) are practically
unidentifiable in APT-MCMC case, whereas all parameters are identifiable using PyMPLE.
The bimodality in PTc and the discontinuity in PIn profiles in the HS case are known to arise
in cases with insufficient data [134]. This is a reasonable explanation in the case of initial
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Figure 4.12: Initial TcSC peripheral (left column) and DTPA deposition estimates. Agree-
ment is good in terms of maximum likelihood estimates, but likelihood shape agreement is
varied.
conditions because of the small sample size for each study day. Even still the identifiability
of these parameters is notable.
4.5.4 APT-MCMC and PyMPLE Comparison
In general both methods, APT-MCMC and PyMPLE, were in agreement about optimal pa-
rameter values. However, PyMPLE outperformed APT-MCMC in terms of demonstrating
the practical identifiability of clearance and deposition parameters. Admittedly, the design
of the clinical trial favors PyMPLE, given that an observable model structure cannot be
formulated for APT-MCMC. PyMPLE computationally outperformed APT-MCMC. This
is demonstrated in Table 4.2 by order-of-magnitude improvements in terms of completion
speed. It should be noted again that APT-MCMC is a highly parallelizable algorithm, but
fairness in benchmarking required operation on a single core for comparison with PyMPLE.
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Parallelization would obviously improve completion time for APT-MCMC, possibly reducing
times to nearly identical values. However, each profiling operation in PyMPLE is indepen-
dent from the others, providing an opportunity for parallelization that will be implemented
in future versions of the code. Even so, the benefits of APT-MCMC include estimates of
parameter-parameter correlation that can greatly aid in model reduction efforts when dealing
with models of greater complexity than this parsimonious model [186].
4.6 SUMMARY
Overall, these case studies should demonstrate that observability is critical to identifiability.
Even in the case where 106 simulations in a global solver (APT-MCMC) are performed,
parameter identification is hindered by state unobservability. The global solver was outper-
formed by local optimization in the pyomo.dae environment using the ipopt solver (a local
optimizer) and likelihood estimation via the PyMPLE package. In fairness, the marginal dis-
tributions and other meta-parametric results from MCMC methods are often useful. They
provide a wealth of population based information that profile likelihoods cannot. Thus, given
our findings we conclude with the following. Profile likelihoods are a useful and rapid means
to assess practical identifiability and may also be useful to precondition stochastic global
solution algorithms in the case that more populational information is desired. Furthermore,
experimental design is critical to model performance. This is not a new concept, but we
believe that our examples add emphasis to the similar statements made by others in this
field, particularly those who perform optimal experimental design [185, 187, 188], which we
have not covered here. Finally, we have developed an open source means of assessing both
the identifiability of dynamic models. The PyMPLE package, the utility of which has been
demonstrated in this chapter, is free to use for anyone.
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5.0 SUMMARY AND FUTURE WORK
5.1 CONTRIBUTIONS
This dissertation presents mathematical models of airway transport processes at multiple
scales and the disease that subsequently arises in the lungs of patients with Cystic Fibrosis.
Particularly, these models have focused on identifying and understanding the hyperabsorp-
tion of the small-molecule probe DTPA in CF cell cultures and airways and the relationship
between its hyperabsorption, airway dehydration, and MCC failure. Models of lung-scale
hyperabsorption and MCC were developed and analyzed. The outcomes indicated that in-
creases in the model parameter definining the fraction of functional ciliated area (FFCA)
in the airway were associated with improvements induced by HS inhalation therapy. The
need to better understand the mechanisms of DTPA hyperabsorption at the lung scale mo-
tivated the development of a cell-scale model of liquid and solute transport. This model
suggests that DTPA hyperabsorption is due to increased paracellular liquid absorption in
CF. It has also been used to explore modes of treatment failure and options for remediation.
Finally a model parameter identification package was developed within the Pyomo modeling
environment that will provide rigorous model identification and dose-schedule optimization
programs within the same coded framework.
5.1.1 Lung-scale Model of MCC, ABS, and Treatment Response
A number of PK models exist for inhaled therapies [101,104,105,106,107,108,109,110,111,
112], but only a few [116, 118] provide physiological detail regarding clearance differences
in lung regions. The two-compartment lung model of Sakagami was successful in fitting
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functional imaging data of whole-lung clearance from the study by Locke et al. [8] but
could not be reconciled with data regarding regional specificity. A new model structure was
proposed that partitioned the large airways that are the source rapid MCC dynamics into
sections with and without functional MCC. This partition coefficient, FFCA, was estimated
with other clearance parameters and found to allow model agreement with dynamic and
regional deposition imaging data [1].
The validity of adding such a parameter was tested experimentally via a newly developed
imaging algorithm in airway cell cultures. It was shown that hydration increases the FFCA
observed in cell-cultures and has a saturating dose-dependency [1]. In vivo, the model
structure best depicting the imaging outcomes included increases in FFCA associated with
HS inhalation and rate constants for mucus clearance from the large airways that were
otherwise similar in treated and untreated CF subjects and controls. Thus the inhalation
of an osmotic treatment appears to recruit new regions of previously inactive or halted cilia
rather than increasing the ciliary beat frequency. Absorption in large and distal airways was
found to have an increased rate constant for all CF cohorts, but the rate constant for distal
absorption, kDB was decreased by HS treatment. Due to the similarity in scale between the
MCC rate constant in the distal airways kDB and the duration of the imaging study, kDB was
not identifiable as different from 0. The model itself provides a rapid method of assessing the
efficacy of hydrating therapies, and the FFCA assay developed for use in cell-culture may be
useful as a high-throughput marker for prospective therapies. Finally, characterizing DTPA
absorption provides a potential surrogate for liquid absorption and also provides a potential
estimate of the clearance of chemically similar inhaled small molecule therapeutics. The
model may thus be useful as a detailed PK model structure for other inhaled compounds.
5.1.2 Cell-scale Model of Airway Liquid and Solute Transport
Some attention has been given to the modeling of airway transport at the cellular scale.
Much of this interest is directed at the study of ion-transport in the Ussing Chamber [?, 16,
17, 87, 88, 89]. While the Ussing Chamber remains an essential experimental device in the
field of epithelial transport, it requires flooding of the lumen of cultured cells [32]. For airway
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epithelia this is not physiologically accurate. HBE cells transport ions and liquid in concert in
order maintain a sufficient ASL volume at the air-liquid interface. Models of this “thin-film”
condition have also been developed with varying degrees of detail and focus [70,96]. However,
none so far have accounted for paracellular transport while accounting for multiple ions and
ion transport proteins relevant to CF. The cell-scale model presented in this dissertation is
meant to fill this gap in the literature.
Furthermore, the model is intended to explain in detail why DTPA is hyperabsorbed in
both the CF lung [8, 65] and in CF HBE cells [21]. The physiologically relevant parame-
terization and structure of the model revealed two transport pathways as possible culprits.
First, constitutive Cl- permeability, hence transport, is predicted to be decreased in CF cells.
This result is similar to the implications that Bertrand and colleagues have made regard-
ing SLC26A9 function in CF [3]. The second is that paracellular hydraulic permeability
and liquid transport, thus solute convection, are greatly increased in CF cells. This could
possibly be due to irregular interactions between CFTR and structural proteins [141, 189]
or inflammation [140], or a combination of the two. Exploration of how CFTR interacts,
via indirect signaling, its PDZ motif, or by other means with other proteins and how those
interactions affect cell structure and transport is warranted in order to better understand
these predictions.
While the cell-scale model provides predictive insight regarding the origins of hyperab-
sorption in CF, it can also be used to study other processes that involve perturbation of
the ASL. In the case of osmotic therapies, the model can be used to predict and design
successful treatments as well as diagnose failure modes for unsuccessful therapies. The latter
was applied to explain the most likely cause of a failed clinical trial for nasal, overnight
delivery of 7% HS. Orally inhaled HS is a standard of care in CF, but has been shown to
have a transient affect in improving MCC [156]. In vitro experiments [150,152] have shown
that extended delivery periods at a slower rate provide extended hydration duration and
better epithelial response. By administering HS nasally overnight, it was thought that the
same effects could be achieve in patients. The study result thus required an explanation. Of
all possibilities, insufficient HS deposition was found to be the most plausible explanation,
including greater than predicted Na+ absorption. Possible model-predicted solutions to ad-
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dress this failure mode were explored. One predicted solution required an increase in HS
concentration to 14%. Modifications to delivery protocol were also suggested. By combining
a priming step of rapid oral HS inhalation to prehydrate the airways with an immediately
subsequent overnight treatment involving nasally administered HS, hydration is predicted to
persist for the entire treatment period. The same effect can be achieved with a 20% mannitol
solution, which would likely absorb more slowly from the airways potentially extending the
duration of the therapeutic effect. These dose designs have not yet been optimized, but they
could be posed in such a manner as to allow for optimal scheduling and dose rates.
5.1.3 Pyomo Model Profile Likelihood Estimation (PyMPLE) Package
Model identification is a critical aspect of systems research in general, with systems biol-
ogy and medicine being no exception [134,158,160,168,175,185]. The ability to confidently
predict and bound system dynamics is vital when modeling systems as complex as those in
biology. It would be otherwise impossible to design robust treatments without a characteri-
zation of system uncertainty. Assessment of the practical identification of model parameters
can be performed via a number of methodologies, both deterministic [134, 168, 175] and
stochastic [142, 166, 168]. Stochastic methods, such as APT-MCMC, can provide excellent
characterization of globally optimal parameters and their practical identifiability. More im-
portantly they can provide information regarding parameter-correlations. However, they are
generally more computationally taxing and operate on black-box models [166]. Deterministic
methods can suffer from identification inaccuracies inherent to nonlinearities in biology but
have the advantage of providing a direct relationship between model structure, dynamics,
and parameters [168].
This dissertation has presented a deterministic modeling tool for parameter identifica-
tion. The Pyomo Model Profile Likelihood Estimation (PyMPLE) package exploits the
open-source and high performance Pyomo optimization environment, particularly the re-
cently developed pyomo.dae package and its utility in optimizing dynamic models. PyM-
PLE is implemented as a Python class object. Its identification method employs the profile
likelihood [134] as a means of determining the practical identifiability of model parameters.
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The method allows for the calculation of confidence intervals (from the profiles themselves)
and the generation of an ensemble of model state trajectories during the profiling procedure.
The capabilities of PyMPLE were demonstrated in two case studies. In the first, reaction
rate constants were profiled for the Van de Vusse reaction [181] carried out in a CSTR. The
case study showed that PyMPLE is capable of accurately estimating and profiling the three
parameters of the model in a well-posed case with ample data. This case also used the esti-
mation algorithm and graphing methods in PyMPLE to illustrate the dramatic effect that a
data-sparse problem can impose on the quality of the estimates of model states. The second
case study compared the stochastic APT-MCMC algorithm [173] to PyMPLE for estimating
and identifying the parameters of the MCC and ABS model from [1]. For this relatively com-
pact model, PyMPLE provided faster estimates and demonstrated practical identifiability of
all parameters. This includes the slow, distal-to-large airway MCC constant kDL that was
previously unidentifiable in patients with CF [1], though it lacks the parameter-parameter
correlation information that can be obtained from APT-MCMC. These two examples com-
bine to illustrate the utility of PyMPLE for parameter estimation in dynamic and static
models in Pyomo.
5.2 FUTURE WORK
The above work represents the first efforts in collaboration to bring the analytical and design
utility of systems biology and medicine into the field of Cystic Fibrosis research. It is
intended to be a part of the groundwork for addressing the treatment of patients with CF
in a rigorous, patient-specific manner. The following are suggestions for ongoing or future
work in CF systems medicine.
5.2.1 Updates and Maintenance of PyMPLE
As an open source language, effort is expected to be made by Python users toward making
software freely available to the community. For that reason, PyMPLE will ultimately be
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made available on a code repository such as GitHub. Prior to distribution, a few key updates
should be made to include better error checking and exception handling. Presently the
PyMPLE.get CI method only catches errors thrown in the solver call via a general statement
that stops the current branch of the profile and moves to the next. Catching specific errors
and returning information to the user should be implemented shortly. A “second-chance”
method that does not immediately exit the profile branch might be useful for situations
where sharp non-convexities exist in the profile that pose a difficulty for most solvers.
5.2.2 Additional Components in the Cell-scale Model
The parsimony of the cell-scale model presented in this dissertation is one of its appealing
traits. However, ions other than Na+ and Cl- may also play an important role in cell-
volume and ASL homeostasis, particularly in other disease states. Manzanares and colleagues
[51, 190] have indicated that K+ transport is an important component for ASL hydration
in CF and non-CF cells. It also has implications in asthma [51] and inflammation. K+
could be added as a model state in each compartment [16, 17]. Additionally, many of the
cellular ion transport pathways are pH dependent [?]. Characterization of pH would require
the addition of H+ and HCO3
- as model states. Other more specific anion channels such
as TMEM16A [191], SLC26A4 (pendrin) [33], and a directed focus on SLC26A9 [3] could
be useful as well. The addition of these components to the model has been attempted with
success in fitting model training data. However, difficulty ensuring numerical stability (see
[?,88]) alongside physiological state dynamics and steady state concentrations was evident in
simulation results that used the basic descriptions of ion transport from the cell-scale model
when more species than Na+ and Cl- are added.
More success has been achieved in adding K+ to the model when also adding complexity
to the model terms describing ion transport. When using the NKCC and Na-K-ATPase
terms from [53] and [54], respectively, the model is able to fit the training data, though not
as well as in chapter 2. APT-MCMC was used with penalties added for severe excursions
from homeostatic cell concentrations. Model fit to data with the equations are given in
Appendix B.
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Garcia et al. made considerations for feasible search spaces given electrophysiological
relationships and assumptions regarding paracellular permeabilities that allowed them to
avoid the numerical cost associated with the solution of the algebraic electrical relations
(see [16] and its supplement). The cell model in this dissertation currently uses the Stokes-
Einstein diffusion coefficients as a basis for dynamic paracellular permeabilities, so adoption
of a similar approach may provide more accurate results than the penalties applied above.
However, the assumption of paracellular permeabilities may be inadvisable given the implied
susceptibility of the paracellular space to changes in parameter values in CF from the cell
model result in this dissertation. Another approach is to solve the DAE system using py-
omo.dae and PyMPLE to estimate parameters including paracellular permeabilities. These
estimates could then inform a set of APT-MCMC simulations given more rigorously obtained
values for paracellular permeability. Such a model could be useful for studying either Ussing
Chamber or thin-film in open or short-circuit conditions.
5.2.3 Optimal Treatment Design at the Cell-scale
The resorption of the ASL begins as soon as an inhaled treatment is completed. Assuming
that greater than minimum necessary hydration was achieved and that there is a range
of ASL volumes at which MCC can occur, there will be a period of time that MCC will
be improved even as ASL volume recedes. This range of ASL volumes is referred to as a
therapeutic window in pharmacokinetic (PK) studies, and is useful for treatment design.
The CF curve in Figure 5.1 is helpful in illustrating the therapeutic window concept using
bolus additions of isosmotic Ringer’s as “treatments.”
If the SEM about the final non-CF ASL volume is taken to be the therapeutic window,
then the dosing schedule in Figure 5.1 is successful in maintaining therapeutic efficacy. The
model response in the CF case has not been formally optimized, but it does achieve thera-
peutic window maintenance in addition to a number of other quality of life improvements:
there are relatively few treatments per day, which is good for patient convenience, and treat-
ments occur no more frequently than every four hours. Because we have a mathematical
model of the ASL volume regulatory system, a treatment objective, and heuristics that can
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Figure 5.1: Unoptimized dosing strategy for maintaining CF ASL volumes within the SEM
window about the HBE final volume. A bolus is given initially and starting at 8 hours three
successive hydrating boli every four hours maintain ASL hydration above the non-CF steady
state volume. Other conditions are identical to the training case of Figure 3.3
serve as formal constraints we may pose the dose scheduling problem in formal optimization
language. The ODE model and its interaction with decision variables is nonlinear and the
number of doses is an integer variable, making this a mixed-integer nonlinear programming
(MINLP) problem. Even under the relaxed case of partial dosing (instead of at a prescribed
amount), the ODE framework of the model requires that the drag variables in the para-
cellular space be binary, which also adds a mixed-integer component to the problem. This
problem, given yet without solution, can be posed as equation 5.2.3.
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min
N(k)
K∑
k=0
1
σ2(k)
(VˆA,CF (θ, u(tk))− VA,NCF (∞) + λ)2 + ΓDN
s.t.
dx
dt
= Ax(t) +Bu(t, N)
y(t) = Cx(t)
Windowlower ≤ λ ≤ Windowupper
N ≤ 6 N = 0, . . . , 6
tk − tk−1 ≥ 4 t ∈ IR
Here λ is a slack variable that allows for some window about the non-CF steady state
volume. N is the number of treatments per day, which cannot exceed six. And the treatment
at time k can be no closer to the previous k than 4 hours. The formulation is similar to
the zone-control formulation of Muske and Rawlings [192]. Modeling-specific languages like
Pyomo can use solvers like ipopt to solve problems of this class efficiently and rigorously.
5.2.4 Individualized Patient Characterization and Treatment
While much of this work has focused on fitting models to whole samples of patient data,
individual patients differ in terms of disease severity and treatment response. Part of the
variability is certainly due to the variation present in the more than 2,000 known mutations
in CFTR [45]. However, there is also known variation within patient subpopulations of the
same genotype. This is illustrated in Figure 5.2 where the cell-model is fit to ASL volume
and DTPA data in cells cultured from individual patients after lung transplant.
Model parameters were fit within a five-fold range of the nominal CF parameter set for
the cell model. All patients have the most common mutation, ∆F508 (∆F), on at least
one allele. Homozygotes for ∆F (left columns) are known to have significant lung disease,
but the two homozygotes in Figure 5.2 have characteristically different ASL absorption
dynamics from each other with similar DTPA absorption profiles. Patients with a G85E
mutation are expected to have severe disease, and these patient cells are similar in ASL
and DTPA dynamics to the top ∆F patient. The patient with the often less severe G551S
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Figure 5.2: Volume absorption (left) and DTPA absorption (right) in cell cultures varies
across and even within patient genotypes (panel titles as allele 1/allele 2).
mutation is similar to the other, less absorptive ∆F patient. Ivacaftor is now available to
patients with this and other gating mutations and the ivacaftor-lumacaftor combination is
available to ∆F homozygote patients [40]. However, the benefit of the osmotic therapies
that have been examined in this dissertation is that they are mutation agnostic, and can be
applied to any patient with a dosing schedule that could theoretically be tailored specifically
to them. This gives rise to the notion that the cell-scale and lung-scale model may be used
in concert to determine absorption and MCC characteristics associated with genotypes and
individual-specific phenotypes.
This is the focus a recently awarded NIH grant (U01HL131046) award that used some
of the modeling results presented in this dissertation as preliminary findings in support of
the application. That study will use human nasal epithelial (HNE) cells from patients with
CF and single-mutation biological parents of the CF subjects to inform a cell-scale model of
individual absorption characteristics. HNE cells are ciliated and similar to other epithelial
cell types in experimental and modeling results [17, 93]. The HNE results will be compared
to functional imaging MCC and ABS measurements to determine possible bench-to-clinic
correlations.
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A similar comparison between HNE and imaging data and modeling will also be made
using measurements obtained from a clinical trial comparing inhaled powdered mannitol to
7% HS as a therapy for CF. Mannitol has been demonstrated to increase MCC in patients
with CF [136], and is an approved therapy in Europe and Australia. The cell model results
have suggested that mannitol may be a more durable therapy than HS, and if that were
demonstrated through in vivo studies it would be an important validation of the utility of
the cell-scale model. However, the ultimate goal of the comparison between cell and lung-
scale results is the development of a multi-scalar model-based treatment design and decision
support system to personalize treatments for patients with CF. Such a decision support
system would be implemented with the very same goal as the entirety of this dissertation:
to provide full health and quality of life for each and every patient with Cystic Fibrosis.
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6.0 MIXED-METHODS ANALYSIS OF THE EFFECT OF CUSTOMER
VOICE ON PRODUCT DESIGN
6.1 INTRODUCTION
Success following graduation now requires more than just technical savvy from engineering
students [193]. Engineers entering the workforce today must be more than technically pro-
ficient. They must be able to exhibit qualities similar to an entrepreneurial mindset, (i.e.
the ability to work in a dynamic, creative, team-based environment while remaining aware
of current and future market demands for a given class of products) [194, 195]. Purzer and
colleagues [195] note that this mindset translates to an awareness of the societal value of
a product within a self-efficacious and leadership focused perspective regarding the design
task. Though the definition of an entrepreneurial mindset varies to some extent, each of
these traits has been identified as an element of such a mindset, and regardless of definition,
much focus is being directed toward instilling an entrepreneurial mindset in engineering stu-
dents [193,194,196,197,198]. Companies require innovative thought, personal initiative, and
market awareness from the incoming workforce to stay competitive [199]. Meeting this chal-
lenge requires creative and critical thought and adaptability to the ever-changing needs of the
customer base, which are essential components of the entrepreneurial mindset [200,201,202].
Indeed, it is imperative that the entrepreneurial mindset be fostered in the engineering
classroom [203] for either entrepreneurial or “intrapreneurial” (i.e. the entrepreneurial ten-
dencies of an employee within a company that they do not own) purposes [204, 205]. For
this reason, it is crucial to gain an understanding of how different pedagogical methods can
further the development of an entrepreneurial mindset in students while still in the col-
lege environment. Byers et al. [193] suggest encouraging creativity, flexibility, and technical
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acumen to foster entrepreneurial tendencies, whereas Kriewall and Mekemson [202] suggest
that acquaintance with business principles including meeting customer needs is essential to
developing entrepreneurial engineers. Bodnar, Clark, and Besterfield-Sacre [194] through a
literature review were able to capture an engineering-specific definition of entrepreneurial
mindset. Particular to this definition is the notion that engineers must also account for
technical aspects in addition to market demands when approaching design. In the present
work, the focus is on a pedagogical method of increasing awareness of customer needs at an
early stage of engineering education.
The field of entrepreneurship education, specifically in engineering, is relatively young
[196, 203]. However, much focus has been given to understanding the customer voice since
Akao (1978) first opened the door to that concept nearly 50 years ago [206, 207, 208]. Pro-
ducing a technically sound design that meets customer needs is one of the great challenges
of engineering product design. Lin and colleagues [209] have stated, “Understanding cus-
tomer voice and enhancing design characteristics which meet customer requirements and
thus increase product competitiveness are the challenges for designers.” Furthermore, it
must be understood that the map between a potential user’s mental model and the de-
signer’s concept have to match in order for quality design to occur [210]. The ability to meet
this challenge, when fostered in engineering undergraduates, will contribute to a technically
savvy engineering workforce with a higher potential for creative and entrepreneurial design,
per the definition of Rae [211]. Therefore, it is posited that teaching customer-focused de-
sign is beneficial for developing entrepreneurial tendencies within the minds of engineering
students.
Students who are na¨ıve to the realities of customer and marketplace demand and their
importance to successful design have only preconceptions to serve as a guide, and those
preconceptions may very well be incorrect [212]. These preconceptions can range from the
nature of the final design to the precise meaning of design in a given field and can even
include their conception of customer knowledge base. Any of these three forms of student
misconceptions as suggested by Chi et al. [213], whether incorrect, inconsistent, or incom-
patible with the nature of customer needs and voice, pose an obstacle to effective customer
focused design. However, if they are easily correctable (i.e., incorrect or inconsistent with
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prior knowledge), it would be useful to know whether they can be corrected more quickly at
an early stage in student progression through a degree program.
The challenge, then, is understanding how to effectively instill a customer focus in engi-
neering students while dispelling misconceptions regarding customer desires. As it stands,
engineering students in colleges today do not relate well to traditional engineering pedagogy,
such as the direct transmission model, which has remained the norm for the past few cen-
turies [214]. The current generation of students is looking for a curriculum and educational
approach that uses advanced classroom technology and active learning to engage them in
the learning process [214, 215]. A novel approach that can be used to engage students in
the engineering product design process in a professional context are engineering epistemic
games [216,217].
Epistemic games are founded on epistemic frame theory [218]. This theory posits that the
formation of “communities of practice” - groups of practitioners with similar problem-solving
styles - is essential for learning to solve the most challenging problems in a discipline [218,219].
Moreover, the concept that every community of practice has its own culture with unique
skills, knowledge, values, identity, and epistemology that constitute its epistemic frame is
the basis of the “epistemic frame hypothesis” [219,220,221].
Epistemic games are simulations that allow students to act as practitioners in a simulated
real-world environment while gathering data on students’ development as practitioners within
a given epistemic frame [219]. In engineering epistemic games, students role play as interns
for a virtual company and are tasked with a real-world design problem to engage them in
the engineering design process. Within the engineering epistemic game Nephrotex [219],
students are tasked with designing a dialysis membrane for therapeutic blood ultrafiltration.
The design process involves the participation of multiple students (i.e., design teammates)
and a design mentor as students progress through design activities. These activities occur in
stages referred to as “rooms” in which the students play through a specific task. The interns
are advised by virtual employees in the company’s research and development team (either
simulated or played by student volunteers) during each of these activities. The internship
and product design culminate in the selection of a final design, written justification for the
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selection of that design, and an oral or poster presentation of the design to other teams and
the course instructor.
The implementation of Nephrotex has been shown to increase student engagement [219]
and positively impact the intent of women in first-year engineering programs to persist in an
engineering discipline [222]. Its utility in fostering entrepreneurial mindset was previously
investigated [197]. Taking this further, we evaluate in this work the effect of the implemen-
tation of a focus group within Nephrotex for its possible effects on product performance with
an emphasis on customer desired attributes. Customers can add their voice to the design
process through the focus group, one of the most widely employed tools in market analy-
sis [223]. In the context of epistemic game research, the focus group also provides a controlled
environment in which to probe initial student interest in terms of focus group participant
selection from a pool of customer types and ultimate student response to both internal and
external stakeholder (i.e. customer) requests. By implementing a focus group within a vir-
tual internship for sophomore and senior engineering students the goal is to gauge whether
exposure to end-customers within the early stages of the design process yields a quantitative
change in the final design specifications in terms of product performance in the marketplace
and/or quality. Even though students may not specifically focus on reducing cost to meet
customer needs, decreased final product cost is associated with the exposure to external
stakeholders in the focus group.
6.2 RESEARCH QUESTIONS:
The following three research questions were investigated through quantitative analysis in
this chapter:
1. Is there a direct relationship between information sought by students relevant to final
design specifications during an external customer focus group and the attributes of the
final design in the virtual internship Nephrotex?
2. Does the incorporation of an external customer focus group within Nephrotex influence
any specific attribute of the final designs generated by student groups?
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3. Does the incorporation of an external customer focus group within Nephrotex raise or
lower the overall quality of student designs?
Complementing the quantitative analysis of the effect of a focus group in a virtual in-
ternship, including its effect on end customer desired attributes, is a qualitative analysis
of student design process. Qualitative analysis was selected as a research methodology to
better understand how and why students chose a certain design process and how it relates to
customer needs. Furthermore, a qualitative description of student design process may help
explain the quantitative effects observed from customer input as part of a focus group. In
this work, a grounded theory framework is developed and used in order to identify themes
in student responses as a starting point for analysis.
Furthermore, the differences in design conception between sophomores and more experi-
enced seniors are also examined. Student selection of questions and responses to information
gained from the focus group were evaluated across academic levels. Specifically compared
were what types of customers were selected for the focus group and questions were asked of
focus group members by sophomores and seniors.
The following research questions are answered by the analysis of the student responses.
• Is an external customer focus group within a virtual internship environment associated
with specific product attribute or customer themes?
• Do senior engineering students have different pre-conceptions of the customer?
6.3 METHODS:
6.3.1 Study Design
Nephrotex was implemented in the spring semester of 2014 in two sophomore-level sections
(57 students each) and one senior-level section (89 students) as part of a series of design
courses in the Chemical Engineering undergraduate program at the University of Pitts-
burgh. One sophomore section played through a version of Nephrotex that incorporated two
additional activities pertaining to a focus group that provided those students with external
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stakeholder (i.e. end-customer) insight. The Nephrotex game allows for the customization
of four components of each membrane design: membrane polymer, polymerization process,
processing surfactant, and carbon nanotube percentage (see [219], Figure 3 for a complete
description of the design space). The selections made for each of these four components are
taken as inputs to the design process, and the resulting outputs are five quantified metrics of
design performance: marketability (in anticipated units sold), cost (in $), and three techni-
cal metrics – flux (m3/m2/day), blood cell reactivity (BCR, ng/mL), and reliability (hours).
These output values for each final design were compared between the focus group (FG)
and non-focus group (NFG) sections. Cost was considered to be a non-technical attribute,
and marketability was considered as both technical and non-technical because economic and
ergonomic considerations are vital for the production of a marketable product.
Lecture periods for the course utilized both direct transmission and active learning meth-
ods. The Nephrotex virtual internship took place over the course of 10 consecutive weeks
in a 15-week semester. Play-through of the virtual internship occurred during the scheduled
class period for one hour per week where students were assigned to one of 10 teams com-
posed of either 5 or 6 students. Tasks assigned to the students within the internship that
were not completed in the allotted time were completed outside of classroom hours. The
internship culminated in the presentation of each student-group’s final membrane design in
poster format. Proper human subjects approval was obtained prior to the conduct of this
study.
6.3.2 Assessment of Final Membrane Designs
Assessments were made on the performance metrics of each final design according to the
built-in design criteria of the Nephrotex software, and comparisons were made between
those of the section with the added focus group and the non-focus group section, referred to
as FG and NFG, respectively.
Quality of the final design was also assessed relative to thresholds for each of the five
output categories based on the framework developed by Arastoopour and colleagues [224].
Four graduated thresholds per output were used. These were described to the students
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in uniform detail as either suggested or required performance levels according to requests
from internal Nephrotex “employees,” henceforth referred to as “internal consultants.” The
designs were given a point for each threshold - minimum, medium low, medium high, and
maximum - with minimum receiving one point and maximum receiving four points. Thus,
a “perfect” design that met the maximum threshold (given in Table 6.1) in every output
category would receive a 20 point quality score. However, the maximum possible score for
any actual design in the design space was 18 due to design space constraints. Students were
unaware of this quality framework during the design process, so while design requests were
made by the internal consultants, the design process by which they arrived at a final design
was open-ended.
Table 6.1: Thresholds for design outputs
Threshold BCR Flux Cost ($) Marketability
(Units)
Reliability
(hr)
Minimum 110 10 165 250,000 1.5
Medium low 90 12 150 350,000 3
Medium high 55 13.5 100 550,000 4.7
Maximum 45 16 75 650,000 5.5
6.3.3 Design of Focus Group
The focus group was implemented to determine whether design input from stakeholders
external to Nephrotex (i.e. customers) could be mapped to a resulting design output. To that
end, the focus group was designed to work in concert with the existing play-through structure
of the internship to ensure an otherwise equivalent (in terms of information conveyed and
time required) gameplay experience for both sections. The focus group “room” of play
was designed to elicit input from five simulated external stakeholders: a dialysis patient, a
nephrologist, a hospital administrator, a Medicare assistant, and an industry thought leader.
The questions that students could ask of each stakeholder and the subsequent stakeholder
responses were pre-established within the game framework by the authors of this work. These
questions and responses were sent to a practicing nephrologist independent of this work for
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Figure 6.1: Schematic of stakeholder/customer and question selection process for the focus
group interview.
review. The full set of questions and answers available to students in the focus group section
is provided in Appendix C.
Students in the FG section were told to select two of the five external stakeholders (i.e.,
end customers) to participate in their focus group and were allowed to strategize prior to
the focus group within their team as to who and what questions would be best to ask. They
were then allowed to ask each stakeholder three questions from a bank of ten about their
opinion relating to the design of dialysis membranes (see Figure 6.1). Students discussed
the focus group responses to question findings with their team members. At the completion
of the virtual internship, all questions that students asked of external customers were sorted
into the performance relevant categories (i.e. marketability, BCR, reliability, flux and cost).
6.3.4 Assessment of Student Submissions
The qualitative work was directed toward determining differences in student design process
when they are exposed to customer voice through focus groups, which may ultimately lead to
differences in design output. These qualitative assessments were performed via an analysis of
student notebook submissions to provided reflection questions within the virtual internship
Nephrotex. Each question asked during the focus groups was also quantitatively reviewed.
The number of times each customer was selected by a student design team was counted and
the normalized results were compared between the sophomore and senior sections. A list of
questions asked of the students is published in Appendix D. Students also submitted final
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designs that were assessed for quality according to the methodology in [?]. This allowed
for determination of whether qualitative differences between groups resulted in quantitative
differences in design performance.
6.3.5 Grounded Theory Framework Development
Grounded Theory was the primary analysis methodology used in this work [225]. Grounded
theory frameworks are generated through iterative reduction of the set of observed themes in
all analyzed responses. Recurrent or study-relevant themes are retained through subsequent
iterations until a concise representation remains. In the case of this virtual internship,
common themes are expected to be in line with technical terms found in dialysis. Thus,
a coding scheme was generated that measures how interrelated the occurrences of specific
themes are (e.g. membrane flux and customer knowledge).
Furthermore, this tool will be useful in understanding what student perceptions of the
design process are regardless of academic level, and specifically between sophomores and
seniors in this case. The perceptions could relate to value of information gained/to-be-
gained. They could also relate to the importance of the information gained relative to
patient care supply chain, whether it is regarding end-users like patients or nephrologists
or intermediate stakeholders like hospital administrators, Medicare providers, or third-party
industry members.
The themes (also referred to as categories) for assessing student responses within the
focus group rooms as well as descriptions and quoted examples of occurrences of each theme
in this study are given in Table 6.2.
Each student response from the focus group rooms was double-coded for Inter-Rater
Reliability (IRR) purposes. The two coders were trained to categorize student responses
according to the items in Table 6.2 by reviewing 10 randomly selected responses from the pool
of 394 valid responses, reconciling differences, and retraining on another 10 responses. The
remaining 374 responses were used to determine the IRR, which was found to be substantial
across all responses (Cohen’s = 0.669) [23]. The frequency of each category or combination of
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Table 6.2: Categories and subcategories with their notebook responses. Grammatical errors
by students are denoted with [sic].
Category Subcategory Description Example
Focus Group (FG)
Useful Finds the FG useful “The customer focus group was useful in
determine [sic] what attributes are most
important to the customer and therefore
what we should focus on when designing
the product.”
Not Useful Did not find the FG useful “Our focus groups did not address too
much information.”
Customer
Role Student-perceived customer role as as
end user or otherwise
“[Patient] doesn’t pay for his treatment
but would love to use the best possible
product.”
Needs Identified customer needs as price or per-
formance constraints
“The nephrologist is on more of a budget
and will not spend more than 80.”
Knowledge
High Student believed insight could be ob-
tained from customer
“[Patient] gave us knowledge on how of-
ten he had to have treatments. . . ”
Low Student believed little knowledge could
be gained from customer
“Half of the questions asked where [sic]
outside of their expertise and was [sic]
left unanswered.”
Utility
Compared Student compares the value of responses
given by two or more customers
“Depending on if we focus on the in-
home or clinical patient, some of these
responses may not be valuable.”
High Customer responses were useful to the
student
“I found the industry leader more useful
that [sic] the patient.”
Low Customer responses were not useful to
the student
“From the Medicare Government Assis-
tant, she had no useful information other
than that Medicare has an $80.00 cover-
age on dialysis cost.”
Attributes
Technical Technical attributes (e.g., BCR, Flux, or
Reliability) were mentioned (counted in-
dividually)
“The industry leader was concerned with
a balance between reduced pain and
flux.” (BCR and Flux)
Marketability Marketing and/or marketability were
mentioned
“A low cost product may not be the
best advice from a marketability per-
spective.”
Cost Cost was mentioned “It was clear from the responses that
most of the customers care about the
membrane being cheap and efficient.”
Expectations Met Expectations of the FG or customer were
met/exceeded
“This is what was expected by the in-
ternal consultants. They basically pre-
dicted each answer.”
Not Met Expectations of the FG or customer were
not met
“My responses are rather disappoint-
ing.”
categories of interest was recorded. Differences in frequencies between sections were assessed
using z-tests of proportions and/or effect sizes measured by the odds ratio (OR).
6.3.6 Statistical Analysis
Statistical analyses were performed in Matlab ( c© 2013 The MathWorks Inc., Natick, MA)
using either the ttest (a Student’s or matched t-test), ranksum (Wilcoxon rank-sum), or
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corr (determination of either the Spearman or Pearson correlation statistic) functions, using
an alpha level of 0.05 for statistical significance in all cases. Due to small sample sizes,
statistical tests include both parametric and non-parametric equivalents such as the Pearson
and Spearman correlation coefficients as well as the t-test and Wilcoxon rank-sum test.
6.4 QUANTITATIVE RESULTS
This section presents the quantitative results relating to customer input in the virtual in-
ternship Nephrotex based upon each of the first three research questions. The quantitative
results reflect analysis performed only on the sophomore sections.
6.4.0.1 RQ1: Is there a direct relationship between information relevant to final design
specifications obtained from an external customer focus group and the attributes of the final
design in the virtual internship Nephrotex?
Figure 6.2 shows the box-plot of the number of questions asked by each student group
pertaining to each output parameter. Students asked more cost-related questions than other
question-types with some overlap in the upper tail of both the flux and BCR categories.
Additionally, averaging the number of questions asked in each category over all the
groups demonstrated that students ask significantly more cost-related questions versus any
one technical-related question (p<0.05). This may indicate that cost was a highly-valued
metric in the minds of students.
To determine if apparent interest had a direct relationship to design output values, the
relationship between questions asked during the focus group and achievement/performance
on the final design was investigated. Correlation coefficients were calculated between the
number of questions asked per metric and the corresponding final design metric (e.g. BCR)
value. These results are given in Table 6.3 and showed no significant correlations. This
indicates that there was no correlation between the number of questions asked for any of the
metrics and their associated performance level in the final team design.
148
Figure 6.2: Number of cost, BCR, reliability, and flux-related questions asked by each group
in FG section.
Table 6.3: Correlations for each of the four metrics of the final design versus the number of
questions asked.
Value vs. #Questions BCR Reliability Flux Cost
R2 0.0402 0.0192 0.0281 0.0039
p-value (Pearson) 0.579 0.703 0.643 0.863
p-value (Spearman) 0.553 0.621 0.794 0.788
6.4.0.2 RQ2: Does the incorporation of an external customer focus group within Nephro-
tex influence any specific attribute of the final designs generated by student groups?
Adding the data from the NFG section to the analysis and comparing final design metrics,
including marketability, between the NFG and FG sections allowed us to investigate whether
the external customer focus group within the Nephrotex virtual internship influenced any
specific attribute of the final designs generated by the student groups, such as reliability or
flux. The results of this comparison are given in Table 6.4.
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Table 6.4: Comparison of final design metrics between FG and NFG sections.
Marketability Cost Reliability Flux BCR
NFG FG NFG FG NFG FG NFG FG NFG FG
average 7.50E+05 6.40E+05 135 114 10.7 9.7 15.6 16 42.2 47.77
std. dev. 1.35E+05 2.37E+05 10.8 15.1 2.5 1.7 1.3 1.4 16.1 14.1
p-value 0.222 0.002 0.305 0.526 0.421
It was determined that the cost of the final design was significantly less in the section with
the focus group even after adjusting for multiple comparisons using Bonferroni’s correction,
and was the only metric that demonstrated any significant difference (p<0.05/5). In terms
of effect sizes, there was a large decrease in marketability due to the focus group (Cohen’s d
= 1.15), but the impact on cost was even larger (d = 2.45) [226].
6.4.1 RQ3:
Does the incorporation of an external customer focus group within Nephrotex raise or lower
the overall quality of student designs?
An overall quality score was calculated as described in the Methods by summing the
number of stakeholder thresholds met for each design. The resulting score had a possible
range from 0 to 18. Across all groups who produced devices, the mean overall quality score
was 14.95, with a minimum of 13 and maximum of 17.
An independent samples t-test showed no significant difference (p > .277, t(28)=-1.415)
in overall quality scores for devices chosen by the FG section (mean = 15.3, SD= 1.77) versus
the NFG section (mean = 14.6, SD= 0.84).
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6.5 DISCUSSION OF QUANTITATIVE FINDINGS
These results suggest the following:
There was not a direct relationship between questions asked in the focus group and
students’ priorities in device design, where priority was established according to the quan-
titative value of a given aspect of the final design. That is, students did not focus more on
the outcomes that they asked more questions about. However, they did ask about cost more
than any other issue.
Teams that were exposed to a focus group made lower cost devices than those that were
not. Since there was no correlation between student interest and value of device design
criteria, it may be that exposing students to customer voice is responsible, at least in part,
for this difference.
The quality of devices was not different when comparing focus group and non-focus group
teams. Therefore, on average, students in both sections produced equally viable designs.
Given the decreased cost of designs by focus group teams, and that decreased cost meets a
consumer need, the focus group may have achieved these ends by increased attunement to
customer voice. Therefore, the exposure of students to customer needs via a focus group
may improve the design process by preserving design quality while decreasing cost.
These results show that customer exposure through a focus group can encourage a high-
quality, lower-cost design within an epistemic game environment. This result has implications
for structuring engineering pedagogy to develop the entrepreneurial mindset of students at
an early stage of education. As Pahl and colleagues [208] noted, “The market price and oper-
ating costs are the most important criteria for a customer when selecting between competing
products and processes.” Thus, the lower cost associated with the designs in the focus group
section suggests that simulating interactions with external stakeholders in an educational
context may help with encouraging the development of an entrepreneurial mindset. The
prospect of enhancing an aspect of entrepreneurial mindset through the incorporation of end
customer exposure within design experiences in the classroom is important for the future to
attain the goal of creating more entrepreneurially minded engineers.
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6.6 SUMMARY OF QUANTITATIVE FINDINGS
It was demonstrated that while students who participate as interviewers in a customer focus
group show interest in both the technical and cost attributes of a product design, there is
at this preliminary stage no evidence of a direct relationship between their interest level
and the performance of the design in various areas, including cost and reliability, possibly
because students may not ask about matters in which they already have a knowledge-base,
a hypothesis that will be examined qualitatively in the next portion of this dissertation.
However, students in the focus group section produced final designs that were less expensive
than the designs produced in the section without a focus group. Based on this result, it
may be inferred that exposing design students to end customer input processes may yield
increased awareness towards customer needs, including cost. It appears that this does not
sacrifice the technical performance of the final product based on analysis. This suggests
the need for including elements or activities leading to increased customer focus within
the design process while not sacrificing on design quality, both of which may help develop
amongst students’ traits inherent to an entrepreneurial mindset.
6.7 QUALITATIVE RESULTS
6.7.1 Results and Discussion
6.7.1.1 RQ4: is an external customer focus group within a virtual internship environ-
ment associated with specific product attribute (i.e. BCR, flux, reliability, cost, marketabil-
ity) or customer themes? This research question examines only the sophomore sections,
particularly the section that played through Nephrotex with a focus group (FG). First the
sophomore FG notebook responses were categorized using our grounded theory framework in
Table 6.2. Table 6.5 shows the total and relative frequency in descending order of percentage
response for each category was mentioned during the FG module, indicating the students’
focus on the particular category. The mentions of individual technical attributes (flux, BCR,
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and reliability) are also reported. The percent of students with response describes how many
students mentioned the category at least once.
Table 6.5: Categorized notebook responses
Code Category Frequency % of Students with Response (/54)
Attributes – Cost 49 78%
Customer – Needs 43 74%
Attributes - Technical 36 67%
Flux 24 44%
BCR 25 46%
Reliability 9 17%
Customer – Role 20 35%
Attributes - Marketability 9 15%
There was a nominally higher percentage of cost-related responses compared to technical
(78% vs. 67%), but the difference was not significant (p=0.20, z-test) and the effect size
was small (OR = 1.16) [226]. Additionally, the cost and technical attributes were mentioned
together 48% of the time as exemplified below with the appropriates code from Table 6.2 in
brackets following the quote.
• “In summary, the customer focus group concluded that flux and cost are the most im-
portant values to them” [attributes – flux, attributes – cost]
• “Cost and flux were the two most important concerns cited by the customer targeting
session.” [attributes – flux, attributes – cost]
• “The manufacturing engineer completely agreed with the nephrologist because he thinks
that cost and reliability are most important.” [attributes – reliability, attributes – cost]
These findings that two-thirds or more of students mentioned technical or cost attributes
and that responses like the ones above were given by approximately half of the students
indicate that no substantive difference in student focus between cost and technical matters
existed. These results demonstrate that while cost may be an important individual design
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parameter to the students, it did not outweigh overall technical performance in terms of
student focus.
Using data gathered from these same student sections, it was previously found that the
number of questions that a given student asked about cost during the focus group had no
relation to the final cost of the product, but exposure to customer voice during a focus group
was associated with lower cost designs [?]. Our current finding that those same students did
not have increased interest in cost relative to technical attributes coincides with our previous
assessment that customer exposure alone is associated with lower cost designs. There was,
however, significantly (p<0.0005) increased interest in cost over each individual technical
metric, with medium to large effect sizes (OR = 1.77 and OR = 1.69) for flux and BCR,
respectively, and very large effect size for reliability (OR = 4.59). It was observed that
there was no significant difference when balancing cost with overall technical performance
however cost was prioritized over individual technical performance elements. As both cost
and technical performance are known to be important factors to the customer, the number
of times students mentioned either cost or technical attributes in the same submission as
customer needs were also evaluated. Examples of this occurring are given for mention of
customer needs alongside technical attributes, cost, and marketing, respectively below with
coding for each snippet in brackets:
• “They [nephrologist] would not be happy with a lower flux because with so many patients
they need a dialysis that can be completed in an efficient amount of time.” [attributes –
flux, customer – needs]
• “The nephrologist said that they were willing to spend no more than $80 per membrane.”
[attributes – cost, customer – needs]
• “They also posessed [sic] no brand loyalty at all. This is very valuable data, because now
we need to establish a brand name.” [attributes – marketing, utility – high, customer –
needs]
Students tended to associate customer needs with both cost and technical aspects of the
design more so than marketability, as presented in Table 6.6.
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Table 6.6: Frequency mentions of both customer needs and a design attribute in tandem.
Combining Code Frequency of Category % of Students (/54)
Customer – Needs
50 61%
Attributes - Technical
Customer – Needs
55 67%
Attributes - Cost
Customer – Needs
8 10%
Attributes – Marketability
The difference between the number of times cost or technical attributes were mentioned
in combination with customer needs was not significant (p=0.28, z-test), and the effect size
was small (OR = 1.09). Students also mentioned cost or technical attributes in combination
with customer needs far more than marketability and customer needs (OR = 6.7 and 6.1,
respectively).
6.7.1.2 RQ5: Do senior engineering students have different pre-conceptions of the cus-
tomer? The results of the analysis of focus group customer selection are given in Figure
6.3.
As demonstrated in this figure, sophomores demonstrated increased (p<0.05) focus on
end-users (i.e. patients and nephrologists) compared to seniors, as shown by the frequency
of focus group questions asked. Additionally, the expected fraction of questions asked was
0.2 for each external stakeholder given the five customer types, assuming zero bias going into
the focus group. However, sophomores asked a significantly different (p<0.05) proportion
of questions to each stakeholder except for the industry thought leader (p=0.13), with the
larger proportions dedicated towards the end users of the product. Seniors asked more evenly
of each stakeholder, only asking the patient an increased fraction of the time (p= 0.02). This
may indicate that seniors have an increased awareness of the full scope of a product’s cus-
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Figure 6.3: The distribution of customers interviewed. Each bar represents the fraction of
times each customer was interviewed relative to the other stakeholders. Differences between
sections were significant in the case of the nephrologist and hospital administrator (p<0.05).
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tomer base or supply chain. Recognizing the diversity of customer needs is important to
understanding the customer and their within the design process. This finding may indicate
that senior students have developed that recognition to a greater extent. Explaining what
may be the source of this difference in focus could reveal a method to develop students’ recog-
nition of the entire consumer base at an earlier stage of their education. To further explore
this hypothesis, senior submissions were categorized using our grounded theory framework.
This allowed us to compare the design processes used by seniors and sophomores, as well as
their pre-conceptions of the customer base. The frequency of occurrence of each theme that
demonstrated statistically significant differences between seniors and sophomores based on
a z-test for proportions is presented in Figure 6.4.
Seniors addressed important design attributes, including cost, technical, or marketability,
to a greater extent than the sophomores did. Technical emphasis by seniors was primarily
focused on flux, with decreased emphasis on BCR and reliability. Seniors did not, however,
find the focus group or its participants as useful or as knowledgeable as the sophomores
when comparing the fraction of responses that stated FG utility was high. In the case of the
seniors, their expectations were not met relatively less (i.e. their preconceptions were less
often wrong). For example, some responses to that end are given below:
• “The industry thought leader’s answers confirmed much of what I already knew.” [ex-
pectations – met]
• “[The focus group] was of some value but the cost could have been assumed front [sic]
he [sic] beginning.” [attributes – cost, expectations – met]
This may indicate that seniors have an experiential knowledge base from which to draw
when designing a product, which could have been gained either through coursework or co-op
assignments or internships (hence their reduced perception of focus group utility).
It could be assumed that the seniors’ relative knowledge base is more extensive and
would ultimately provide an advantage in terms of final design quality and the ability to
meet customer needs. However, there were no differences between final design performance
of the seniors and sophomores in the FG section. The sophomore FG section had nearly
equivalent cost ($112 vs. $111.3) and quality (15.3 vs. 15.6) as the seniors did, whereas it
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Figure 6.4: Responses that demonstrate significantly different proportions between senior
and sophomore students that participated in a focus group.
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has been reported above that students that did not perform a focus group have increased
cost for similar quality. This may indicate that the sophomores may have experienced an
informative event during their participation in the virtual internship that corrected any false
preconceptions they may have had or lacked in regards to customer focused design. This
could, in turn, have allowed them to achieve similar results to the seniors, who may have had
an informational advantage over the sophomores prior to the course due to more experience
or training. In order to test this hypothesis the sophomore FG section responses regarding
their expectations of the customer types were reviewed. Sophomore expectations were met
more often than not (30%, not shown in Figure 2 vs. 22%, although there was considerable
mention (26% of students in both classes) of customers lacking an understanding of the
technical attributes of the design. Two examples are given below. The first was in response
to the in-home patient answer to the question, “What values did you have in mind when
considering the flux of the membrane you use for dialysis?”
• “I noticed that the patient is unaware of the specifications and technical requirements of
a membrane.” [knowledge – low]
And the second:
• “The patient did not understand what blood cell reactivity was so that was a small
problem. He did say his insurance pays for it so cost is not an issue to him. Having a
low blood cell reactivity will make his day more comfortable. Also he spends about 3
hours a week. That would mean he wants a decent flux and reliability.” [knowledge –
low, attributes – BCR, attributes – cost, attributes – flux, attributes – reliability]
Which was a student entry in response to receiving patient answers for the questions,
“Are you willing to sacrifice an efficient membrane for a membrane that reduces blood cell
reactivity?” and, “Are you willing to spend over $100 on a hemodialysis membrane?”
Based on these responses and naivety, it may be that sophomores entered the focus group
lacking understanding about the design elements that are important to specific external
stakeholders and which stakeholders are most appropriate to reach out to when seeking
information on a proposed design element. Analysis of sophomore responses and final product
design, particular in terms of the quality-cost interplay of the design, indicates that the focus
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group may have increased sophomore awareness of the design space, as evidenced by the
similar quality and cost between sophomore and senior final designs, hence the closing of
the observed gap in end-user knowledge depicted in Figure 6.3. Moreover, it was previously
reported that the focus group in Nephrotex was associated with lower cost designs for the
sophomores. Now it is reported that those costs as similar to those of more experienced
senior students, who achieved qualities nearing the maximum. It may then be that the
similarities in terms of cost and design quality between senior and sophomore FG designs is
due to information gained by exposure to the customer voice, as had previously hypothesized.
A stronger validation of this claim would require a longitudinal study of the sophomore
students, wherein it is tested whether the non-focus group section attains the same level of
their FG peers through educational experiences within their degree program.
6.7.2 Study Limitations
The study presented could be hindered by sample sizes. The sophomore classes were nearly
identical in size (56 and 57 students) and 54 students recorded responses in the FG section.
There were 82 seniors, allowing for ten sophomore teams per section and 15 senior teams.
Thus, analyses performed on team-generated results are more likely to face sample size issues
with regard to statistics.
Another limitation to this work relates to the pre-constructed questions and responses
built into the focus group design. The space from which students could draw questions
relevant to their design was constrained in a manner that may not be reflective of what they
might ask in a true industrial setting. This could be remedied by an open question format;
however, this is difficult to regulate within an epistemic game environment. It would be
possible to further determine student valuation of the design metrics through qualitative
analysis of the notebook logs students maintained during these activities. This work is
currently underway and should serve as useful feedback for future iterations of the customer
focus group design as well as additional insight into the students’ design processes.
This study and all analysis within was performed with chemical engineering class sections
that participated in Nephrotex during the 2014 spring semester at one university. Since
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no year-over-year, qualitative analysis of the impacts of focus groups on student design
processes and outcomes has been performed at this point, it may be difficult to generalize
these results. In order to more meaningfully characterize the differences and similarities
observed between sophomores and seniors, a study tracking the state of students’ mindsets
would have to be performed over the duration of their engineering education. Therefore,
these results obviate a need for long-term studies regarding the development of aspects of
an entrepreneurial mindset. This could include research into the effects of solely classroom
or industrial experiences and the two in combination. These findings provide a basis for
continued research in this area.
6.8 SUMMARY
In this work, a mixed methods approach was used to assess quantitative and qualitative
outcomes in terms of customer focused design in response to a focus group in the virtual
internship Nephrotex. The quantitative results described a cost decrease without a decay in
quality for a sophomore section that was exposed to a focus group vs. one that did not. In
order to provide a more detailed explanation of the student design mindset that may have
driven this difference, a grounded theory framework was developed to determine possible
differences in design processes that occur with the introduction of a customer focus group to
a virtual internship. Analysis of student responses based on this framework has shown that
sophomores who engage in a focus group during the virtual internship Nephrotex showed
(statistically) equal focus on cost versus technical measures of design performance during
the focus group. Despite this, design cost was lower in the section that participated in a
focus group, with no decrease in quality, which was described in detail in the first portion of
this chapter. This indicates that customer voice may be an important factor in decreasing
product cost, which provides additional support for results observed in the qualitative portion
of the analysis.
In terms of other differences in the design processes that occurred with the focus group
sections, sophomore students prioritized their interviewing of customers within the focus
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group towards end users, such as the patient and nephrologist. Furthermore, qualitative
analysis of sophomore responses demonstrated that they found utility in the focus group (30%
of participants) but did not necessarily believe that the customers had useful knowledge of the
relevant design attributes (17% of participants). Sophomores may have been able to use the
focus group to correct any misconceptions about the important elements of customer focused
design, resulting in a more customer-friendly (i.e., lower cost) product. Such realizations may
have contributed to the equivalent quality and decreased costs associated with the designs
of sophomores who participated in a focus group.
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APPENDIX A
CODE FOR SIMULATING THE CELL- AND LUNG-SCALE MODELS
A.1 EQUATIONS OF THE CELL-SCALE MODEL
The following state equations were used for model simulations in chapter 3
Volumes:
dVA
dt
= LPCACVw(piA − piC) + LPPATJVw(piA − piB) (A.1)
dVB
dt
= LPCACVw(piB − piC)− LPPATJVw(piA − piB) (A.2)
dVB
dt
= −LPCACVw(piA − piC)− LPCACVw(piB − piC) (A.3)
Na+:
dNaA
dt
=
−PENaC
Vmax
VA
+ 1
(
NaA
VA
− NaC
VC
)− PNaA,BATJ(
NaA
VA
− NaB
VB
) + Jconv,Na (A.4)
dNaB
dt
= PNaA,BATJ(
NaA
VA
− NaB
VB
) + kNa(
NaC
VC
− NaC,∞
VC,∞
− Jconv,Na (A.5)
dNaC
dt
=
PENaC
Vmax
VA
+ 1
(
NaA
VA
− NaC
VC
)− kNa(NaC
VC
− NaC,∞
VC,∞
) (A.6)
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Cl-:
dClA
dt
= PCFTR(1− 1
Vmin
VA
2
+ 1
)(
ClA
VA
− ClC
VC
) +PACC
ClC
VC
−PClA,BATJ(
ClA
VA
− ClB
VB
) + Jconv,Cl
(A.7)
dClB
dt
= kCl(
ClC
VC
− ClC,∞
VC,∞
) + PClA,BATJ(
ClA
VA
− ClB
VB
)− Jconv,Cl (A.8)
dClC
dt
= −PCFTR(1− 1
Vmin
VA
2
+ 1
)(
ClA
VA
− ClC
VC
)− PACCClC
VC
− kCl(ClC
VC
− ClC,∞
VC,∞
) (A.9)
Mannitol:
dMlA
dt
= −PMlA,B
(
MlA
VA
− MlB
VB
)
+ Jconv,Ml (A.10)
dMlB
dt
= PMlA,B
(
MlA
VA
+
MlB
VB
)
− Jconv,Ml (A.11)
DTPA:
dDTPAA
dt
= −PDTPAA,B
(
DTPAA
VA
− DTPAB
VB
)
+ Jconv,DTPA (A.12)
dDTPAB
dt
= PDTPAA,B
(
DTPAA
VA
− DTPAB
VB
)
− Jconv,DTPA (A.13)
A.2 ADDITION OF POTASSIUM TO THE MODEL
The previous equations were expanded with the model addition of potassium by removing
the linear basolateral regulation terms from (A.5, A.6, A.8, and A.9 and replacing them with
the NaKP rate equation (νNaKP ) of Lindenmayer and colleagues [54]:
νNaKP = νpump,max
(
NaC
NaC +Kint,Na(1 +KC/Kint,K)
)3(
KB
NaB +Kext,K(1 +NaB/Kext,Na)
)2
(A.14)
164
And the NKCC rate equation (νNKCC) of Miyamoto and colleagues [53]:
νNKCC = νNKCC,max
(
NaB
NaB +KCONa
)(
KB
KB +KCOK
)(
ClB
ClB +KCOCl,1
)(
ClB
ClB +KCOCl,2
)
−νNKCC,max
(
NaC
NaC +KCONa
)(
KC
KC +KCOK
)(
ClC
ClC +KCOCl,1
)(
ClC
ClC +KCOCl,2
)
(A.15)
And adding a calcium concentration-dependent (fixed at 0.09 mmol/VC for the sim-
ulations) term for K+ transport through the large conductance potassium channel (BK)
from [70]:
PBK =
1
1 + KBK
CaC
1.7 (A.16)
The changes are reflected as follows:
Na+:
dNaB
dt
= PNaA,BATJ(
NaA
VA
− NaB
VB
)− 3νNaKP + νNKCC − Jconv,Na (A.17)
dNaC
dt
=
PENaC
Vmax
VA
+ 1
(
NaA
VA
− NaC
VC
) + 3νNaKP − νNKCC (A.18)
Cl-:
dClB
dt
= kCl(
ClC
VC
+ 2νNKCC + PClA,BATJ(
ClA
VA
− ClB
VB
)− Jconv,Cl (A.19)
dClC
dt
= −PCFTR(1− 1
Vmin
VA
2
+ 1
)(
ClA
VA
− ClC
VC
)− PACCClC
VC
− kCl(ClC
VC
− 2νNKCC (A.20)
K+:
dKA
dt
= PBK(
KA
VA
− KC
VC
)− PKA,BATJ(
KA
VA
− KB
VB
) + Jconv,Na (A.21)
dKB
dt
= PKA,BATJ(
KA
VA
− KB
VB
) + 2νNaKP + νNKCC − Jconv,K (A.22)
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dNaC
dt
= −PBK(KA
VA
− KC
VC
)PBK(
KA
VA
− KC
VC
) + 2νNaKP − νNKCC (A.23)
Simulation and fitting of the model equations to the same data as in chapter 2 resulted
in the fits in Figure A1
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Figure A1: Model fits to ASL volume and DTPA with added K+ and more detailed transport
mechanisms.
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APPENDIX B
MODEL EQUATIONS
B.1 CODE FOR SIMULATING THE LUNG-SCALE MODEL
The code below will accomplish the integration of the model of chapter 2 in MatLab. There
is also a version written in C for MCMC simulations.
1 % InVivoModel − i t i s f o r the in vivo model
2 % pre − i t comes be f o r e the p l o t t i n g rou t ine
3 % par f r a c − a l egacy name f o r models that in c lude FFCA
4 % t − need a time vec to r
5 % k − need a parameter vec to r
6 % CR − need to prov ide the f r a c t i o n o f dose in the C reg i on
7 % PR − need to prov ide the f r a c t i o n o f dose in the P reg i on
8
9 f unc t i on [T, In , Tc ] = InVivoModelpre par f rac ( t , k ,CR,PR)
10 % k many pa t i en t s . Genera l ly only one because naive poo l ing
11 f o r i t e r =1:1 : l ength (k ( : , 1 ) )
12 dose = 100 ; % percentaged dose could be normal ized too
13 gens = 3 ;
14 inputs = ze ro s ( gens+2 ,1) ;
15 f = k ( i t e r , 2 ) ; % FFCA
16 pe r i = PR( i t e r ) ∗dose ; % s e t s D dosage
17 cent = CR( i t e r ) ∗dose ; % s e t s P dosage
18 inputs (1 ) = cent ∗ f ; % L F pa r t i t i o n
19 inputs (2 ) = cent ∗(1− f ) ; % L N pa r t i t i o n
20 inputs (3 ) = pe r i ;
21 inputs ( gens+1) = 10 ;
22 inputs ( gens+2) = 0 ;
23 inputs ( gens+3) = 0 ;
24
25 f o r n=1:1:2
26 i f n==1 % Indium DTPA model
27 [T, y ] = ode23s (@InVivoModelODE parfrac , . . .
28 t , inputs , [ ] , k ( i t e r , : ) ) ;
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29 In ( : , : , i t e r ) = y ;
30 e l s e % TcSC model
31 k ( i t e r , 3 ) = 0 ;
32 k ( i t e r , 4 ) = 0 ;
33 [T, y ] = ode23s (@InVivoModelODE parfrac , . . .
34 t , inputs , [ ] , k ( i t e r , : ) ) ;
35 Tc ( : , : , i t e r ) = y ;
36 end
37
38 end
39 end
40 f unc t i on dy = InVivoModelODE parfrac ( t , y , k )
41 dy = ze ro s (6 , 1 ) ;
42
43 kLT = k (1) ;
44 kDL = 0 ;%k (3) not i d e n t i f i a b l e
45 kLB = k (4) ;
46 kDB = k (3) ;
47 FFCA= k (2) ;
48
49 FL = y (1) ;
50 NL = y (2) ;
51 D = y (3) ;
52 T = y (4) ;
53 B = y (5) ;
54
55 dy (3) = −kDB∗D −kDL∗D;
56 dy (1) = −kLT∗FL − kLB∗FL + FFCA∗kDL∗FL;
57 dy (2) = −kLB∗NL + (1−FFCA) ∗kDL∗FL;
58 dy (4) = kLT∗FL;
59 dy (5) = kLB∗(FL + NL) ;
60 dy (6) = kDB∗P;
61 end
62 end
B.2 CODE FOR SIMULATING THE CELL-SCALE MODEL
The following C code will integrate the cell-scale model when mexed in Matlab with a helper
function rhs.h.
1 /∗
2 ∗∗ FILE : rhs . c
3 ∗∗
4 ∗∗ Requires a parameter vec to r with va lue s
5 ∗∗ f o r a l l the names in the d e c l a r a t i on
6 ∗∗/
7
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8 /∗ math ∗/
9 #inc lude ”math . h”
10 /∗ model header ∗/
11 #inc lude ”model . h”
12 /∗ headers f o r u s e f u l mathematical f un c t i on s ∗/
13 #inc lude ” f unc t i on s . h”
14
15 //#de f i n e max(a , b) ( ( a ) >= (b) ? ( a ) : (b ) )
16
17 /∗ User de f ined RHS func t i on ∗/
18 i n t rh s func ( r e a l t ype t , N Vector x , N Vector xdot , void ∗ f d a t a )
19 {
20 /∗ l o c a l v a r i a b l e s ∗/
21 s t r u c t func t i on da ta ∗ data ;
22 s t r u c t model parameters ∗ par ;
23
24 /∗ ca s t f da t a to ’ f unc t i on da ta ’ type ∗/
25 data = ( s t r u c t func t i on da ta ∗) f da t a ;
26
27 /∗ get po in t e r to parameters , d i s turbance and con t r o l s t r u c t u r e s ∗/
28 par = data−>par ;
29
30 /∗∗∗ USER DEFINED CONTENT STARTS HERE ∗∗∗/
31
32 /∗ Reass ign parameters to th ing s with names that don ’ t need po i n t e r s ∗/
33 double Oia0 , OsmA0, Vb0 , Nac0 , Clc0 , Oib0 , OsmB0, Ac , Vc0 , Oic0 , OsmC0, Va0 ,
Atj ;
34 double Lpc , Lpp , Penac , Pcftr , Vmax, Vmin , Dna , Dcl , Dml , Ddp , NCF, kna , kc l ,
Pcacc ;
35 double Vm, Pcc , Tcc , Oia , Oib , Oic , OsmA, OsmB, OsmC, Eh i l l , Ch i l l , Lpb , Bcc ;
36 double hc , Pna , Pcl , Pml , Pdp , AD, BD, Va , Vb, Vc , Nacss , Clcss , Tab , Tba , Tca
, Tcb ;
37
38 /∗ I n i t i a l Condit ion Constants ∗/
39 Oia0 = par−>Oia0 ;
40 Nac0 = par−>Nac0 ;
41 Clc0 = par−>Clc0 ;
42 Oib0 = par−>Oib0 ;
43 Ac = par−>Ac ;
44 Vc0 = par−>Vc0 ;
45 Oic0 = par−>Oic0 ;
46 Atj = par−>Atj ;
47
48 /∗ Pos s i b l e to Fit Paramters ∗/
49 Lpc = par−>Lpc ;
50 Lpp = par−>Lpp ;
51 Penac = par−>Penac ;
52 Pc f t r = par−>Pc f t r ;
53 Vmax = par−>Vmax;
54 Vmin = par−>Vmin ;
55 Dna = par−>Dna ;
56 Dcl = par−>Dcl ;
57 Dml = par−>Dml ;
58 Ddp = par−>Ddp ;
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59 NCF = par−>NCF;
60 kna = par−>kna ;
61 kc l = par−>kc l ;
62 Pcacc = par−>Pcacc ;
63 Lpb = par−>Lpb ;
64
65 Penac = 100∗Penac ; /∗ Convert m/ s to cm/ s ∗/
66 Pc f t r = 100∗ Pc f t r ;
67
68 Dna = 100∗Dna ;
69 Dcl = 100∗Dcl ;
70 Dml = 100∗Dml ;
71 Ddp = 100∗Ddp ;
72
73 Lpc = 100∗Lpc ;
74 Lpp = 100∗Lpp ;
75 Lpb = 100∗Lpb ;
76
77 Vc0 = Vc0/1000 ;
78
79 OsmA= (Oia0 + ( Naa + C l a ) + Mla ) /( Va /1000) ; /∗ mOsm∗/
80 OsmB= (Oib0 + ( Nab + C lb ) + Mlb ) /( Vb /1000) ;
81 OsmC= (Oic0 + ( Nac + cC l ) ) /( Vc /1000) ;
82
83 Va = Va /(1000) ;
84 Vb = Vb /(1000) ;
85 Vc = Vc /(1000) ;
86
87 Vm = 0 . 0 1 8 ; // cmˆ3/mM
88 Tcc = Lpc∗Ac∗Vm∗1000 ;
89 Pcc = Lpp∗Atj∗Vm∗1000 ;
90 Bcc = Lpb∗Ac∗Vm∗1000 ;
91
92 Eh i l l = 1/((Vmax/Va)+1) ;
93 // Eh i l l = h i l l (Va , 1 , Vmax) ;
94 Ch i l l = (1−1/(pow( (Vmin/Va) ,2 )+1) ) ;
95 // Ch i l l = h i l l (Va , 2 , Vmin) ;
96
97 hc = Vc/(Ac) ;
98
99 Pna = (Dna/hc ) ; /∗ m/s Na+ pa r a c e l l u l a r pe rmeab i l i t y Inte rp from Li+ ∗/
100 Pcl = (Dcl/hc ) ; /∗ m/s Cl− p a r a c e l l u l a r pe rmeab i l i t y Wilke−Chang ∗/
101 Pml = (Dml/hc ) ; /∗ m/s Mannitol p a r a c e l l u l a r pe rmeab i l i t y Bashkatov ∗/
102 Pdp = (Ddp/hc ) ; /∗ m/s DTPA pa r a c e l l u l a r perm from Stokes−Eins t e in ∗/
103
104 /∗ Determine drag d i r e c t i o n a l i t y ∗/
105 AD = (OsmA<OsmB?1 : 0 ) ;
106 BD = (OsmA>OsmB?1 : 0 ) ;
107
108
109 Clcs s = 0 . 0 4 4 ; //Clc0/Vc0 ;
110 Nacss = 0 . 0 2 3 ; //Nac0/Vc0 ;
111
112 // p r i n t f (”AD i s %f ” , OsmA) ;
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113
114 Tca = Tcc ∗(OsmC−OsmA) ∗1e−3;
115 Tcb = Bcc ∗(OsmB−OsmC) ∗1e−3;
116 Tab = Pcc ∗(OsmB−OsmA) ∗1e−3;
117 Tba = Pcc ∗(OsmA−OsmB) ∗1e−3;
118
119 DOT Va = −Tca∗1 e3 − Tab∗1 e3 ;
120 DOT Naa = −Penac∗ Eh i l l ∗Ac∗( Naa /Va− Nac /Vc) − Pna∗Atj ∗( Naa /Va−
Nab /Vb) − Naa /Va∗Tab∗AD + Nab /Vb∗Tba∗BD;
121 DOT Cla = Pc f t r ∗Ch i l l ∗Ac∗( cC l /Vc−Clcs s ) ∗NCF + Pcacc∗Ac∗ cC l /Vc −
Pcl∗Atj ∗( C l a /Va− C lb /Vb) − C l a /Va∗Tab∗AD + Clb /Vb∗Tba∗BD ;
122 DOT Mla = −Pml∗Atj ∗( Mla /Va− Mlb /Vb) − Mla /Va∗Tab∗AD + Mlb /
Vb∗Tba∗BD;
123 DOT DTPA = −Pdp∗Atj ∗( DTPA /Va− DTPB /Vb) − DTPA /Va∗Tab∗AD +
DTPB /Vb∗Tba∗BD;
124 DOT Mlb = Pml∗Atj ∗( Mla /Va− Mlb /Vb) − Mlb /Vb∗Tba∗BD + Mla /
Va∗Tab∗AD;
125 DOT Vc = Tca∗1 e3 − Tcb∗1 e3 ;
126 DOT Nac = Penac∗ Eh i l l ∗Ac∗( Naa /Va− Nac /Vc) − kna ∗( Nac /Vc−Nacss )
;
127 DOT cCl = −Pc f t r ∗Ch i l l ∗Ac∗( cC l /Vc−Clcs s ) ∗NCF − Pcacc∗Ac∗ cC l /Vc +
kc l ∗( Clcss− cC l /Vc) ;
128 DOT Vb = Tcb∗1 e3 + Tab∗1 e3 ;
129 DOT Nab = kna ∗( Nac /Vc−Nacss ) + Pna∗Atj ∗( Naa /Va− Nab /Vb) −
Nab /Vb∗Tba∗BD + Naa /Va∗Tab∗AD;
130 DOT Clb = Pcl∗Atj ∗( C l a /Va− C lb /Vb) − kc l ∗( Clcss− cC l /Vc) −
C lb /Vb∗Tba∗BD + C l a /Va∗Tab∗AD;
131 DOT DTPB = Pdp∗Atj ∗( DTPA /Va− DTPB /Vb) − DTPB /Vb∗Tba∗BD +
DTPA /Va∗Tab∗AD;
132
133 DOT DIFF = Pdp∗Atj ∗( DTPA /Va− DTPB /Vb) ;
134 DOT CONV = − DTPB /Vb∗Tba∗BD + DTPA /Va∗Tab∗AD;
135
136
137
138 /∗∗∗ USER DEFINED CONTENT ENDS HERE ∗∗∗/
139
140
141 /∗ Al l done . RHS eva lua t i on i s loaded in to vec to r xdot . ∗/
142 re turn (0 ) ;
143 }
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APPENDIX C
PYMPLE CODE AND EXAMPLES
C.1 CODE FOR PYMPLE
The following is the code for PyMPLE as it is written on April 7, 2017.
1
2 # −∗− coding : utf−8 −∗−
3 ”””
4 Created on Fr i Mar 4 13 : 36 : 36 2016
5
6 @author : Matthew Markovetz
7
8 This can remain umodi f ied i f you so choose . As long as you s t ru c tu r e your
model
9 module and run− f i l e in the same format as provided in the example f i l e , t h i s
10 wonderful p i e c e o f code need never s ee the l i g h t o f day .
11 ”””
12
13 import numpy as np
14 import s c ipy as sp
15 from pyomo . env iron import ∗
16 from sc ipy . s t a t s . d i s t r i b u t i o n s import ch i2
17 from numpy import copy
18
19 c l a s s PyMPLE:
20 ”””
21 params becomes the i n i t i a l parameter guess , which i s the optimal s o l u t i o n
22
23 model becomes the pyomo ConcreteModel ( ) that you are opt imiz ing
24
25 ob j e c t i v e becomes the r e f e r e n c e ob j e c t i v e f o r the l i k e l i h o o d r a t i o
26
27 pnames becomes the l i s t o f s t r i n g s o f parameter names
28
29 bounds i s the bounds f o r the parameters
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30
31 s t a t e s becomes the l i s t o f model s t a t e or Var ( ) names
32
33 hard t e l l s PyMPLE i f i t should (True ) or should not ( Fa l se ) p r o f i l e
34 beyond the bounds o f a parameter
35 ”””
36
37 de f i n i t ( s e l f , params , model , ob j e c t i v e , pnames , bounds , s t a t e s ,
38 hard=False ) :
39 s e l f . popt = params
40 s e l f .m = model
41 s e l f . obj = ob j e c t i v e
42 s e l f . pkey = pnames
43 s e l f . bounds = bounds
44 s e l f . hard bounds = hard
45 s e l f . s t a t e s = s t a t e s
46
47 de f get CI ( s e l f , p f ixed , data , maxSteps=100 , s t e p f r a c =0.01 , s o l v e r=’ ipopt ’
,
48 nfe =150 , alpha =0.05) :
49
50 # Get Conf idence I n t e r v a l s
51 c t o l = maxSteps
52 s e l f . c t o l=c t o l
53
54 s t a t e s d i c t = d i c t ( )
55 # r e s u l t s e s = d i c t ( )
56
57 # I n i t i a l i z e
58 parup = copy ( s e l f . popt )
59 pardn = copy ( s e l f . popt )
60 parub = copy ( s e l f . popt )
61 par lb = copy ( s e l f . popt )
62 parkey = s e l f . pkey
63 upkey = [ ]
64 dnkey = [ ]
65 v a r d i c t = d i c t ( )
66 o b j d i c t = d i c t ( )
67
68 # Def ine Step s i z e and the parameters to be p r o f i l e d
69 def SF = copy ( s t e p f r a c )
70 pf ixCI = copy ( p f i x ed )
71
72 ob j CI = s e l f . obj
73 ndat , npat = np . shape ( data )
74
75 i=0
76 e r r = 0 .0
77 pstep = 0 .0
78
79 f o r j in range ( l en ( p f i x ed ) ) :
80 i f s e l f . hard bounds :
81 lower bound = s e l f . bounds [ j ] [ 0 ]
82 upper bound = s e l f . bounds [ j ] [ 1 ]
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83 e l s e :
84 lower bound = 0 .0
85 upper bound = f l o a t ( ’ I n f ’ )
86
87 i f p f i x ed [ j ]==0:# Do some f i r s t −pass i n i t i a l i z a t i o n
88 pf ixCI [ j ] = 1
89 df = 1 .0#len ( p f i x ed )−sum( p f i x ed )
90 e t o l = ch i2 . i s f ( alpha , df )
91 parup = copy ( s e l f . popt )
92 next up = s e l f . popt [ j ]
93
94 # Enter the upper p r o f i l e arm
95 whi le i<c t o l and err<=e t o l and next up<upper bound :
96 pstep = pstep + s t e p f r a c [ j ]∗ s e l f . popt [ j ]
97 parub [ j ] = s e l f . popt [ j ] + pstep
98 parup [ j ] = s e l f . popt [ j ] + pstep
99
100 i tername = ’ ’ . j o i n ( [ parkey [ j ] , ’ i n s t up ’ , s t r ( i ) ] )
101 t ry :
102 i t e r i n s t , i t e r r e s = s e l f .m( data , s o lve r , nfe , pf ixCI ,
103 parup , s e l f . pkey ,
104 bound=s e l f . bounds )
105 except ValueError as e :
106 z = e
107 pr in t ( z )
108 i = c t o l
109 cont inue
110
111 # in s t an c e s [ i tername ] = i t e r i n s t # these get very big
112 # r e s u l t s e s [ i tername ] = i t e r r e s # they tend to slow th ings
down
113 s t a t e s d i c t [ i tername ] = [ [ va lue ( g e t a t t r ( i t e r i n s t , i ) [ j ] )
114 f o r j in i t e r i n s t . t ] f o r i in s e l f . s t a t e s ]
115
116 e r r = 2∗( l og ( va lue ( i t e r i n s t . obj ) ) − l og ( ob j CI ) )
117 v a r d i c t [ i tername ] = [ va lue ( g e t a t t r ( i t e r i n s t , parkey [ i ] ) )
118 f o r i in range ( l en ( parkey ) ) ]
119 o b j d i c t [ i tername ] = value ( i t e r i n s t . obj )
120
121 #adjus t s tep s i z e i f convergence slow
122 i f i >0:
123 prevname = ’ ’ . j o i n ( [ parkey [ j ] , ’ i n s t up ’ , s t r ( i −1) ] )
124 d = np . abs ( ( l og ( o b j d i c t [ prevname ] ) −
125 l og ( o b j d i c t [ i tername ] ) ) ) / l og ( o b j d i c t [ prevname ] ) /
s t e p f r a c [ j ]
126 e l s e :
127 d = e r r
128
129 i f d<=0.01:
130 pr in t ( ’ ’ . j o i n ( [ ’ S t ep s i z e i n c r ea s ed from ’ ,
131 s t r ( s t e p f r a c [ j ] ) , ’ to ’ ,
132 s t r (1 . 05∗ s t e p f r a c [ j ] ) ,
133 ’ with prev ious p value : ’ , s t r ( parup [ j
] ) ] ) )
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134 s t e p f r a c [ j ] = 1 .05∗ s t e p f r a c [ j ]
135 e l s e :
136 s t e p f r a c [ j ] = s t e p f r a c [ j ]+def SF [ j ]
137
138 pr in t ( ’ ’ . j o i n ( [ ’ f i n i s h e d UB i t e r a t i o n ’ , parkey [ j ] , s t r ( i ) ,
139 ’ with e r r o r : ’ , s t r ( e r r ) ,
140 ’ and parameter change : ’ , s t r ( pstep ) ] ) )
141 i f e rr>e t o l :
142 upkey . append ( itername )
143 pr in t ( ’ Reached upper CI ! ’ )
144 e l i f i==cto l −1:
145 parub [ j ] = np . i n f
146
147 next up = s e l f . popt [ j ] + pstep + s t e p f r a c [ j ]∗ s e l f . popt [ j ]
148 i f next up > upper bound :
149 pr in t ( ’ Reached parameter upper bound ! ’ )
150 i+=1
151 i=0
152 e r r =0.0
153 d=0.0
154 pstep=0.0
155 pardn = copy ( s e l f . popt )
156 s t e p f r a c [ j ] = def SF [ j ]
157 dneps=1e−10
158 next down = s e l f . popt [ j ]
159
160 # Enter the lower p r o f i l e arm
161 whi le i<c t o l and err<=e t o l and next down>lower bound :
162 pstep = pstep − s t e p f r a c [ j ]∗ s e l f . popt [ j ]
163 par lb [ j ] = s e l f . popt [ j ] + pstep
164 pardn [ j ] = s e l f . popt [ j ] + pstep
165
166 i f pardn [ j ]<dneps :
167 pardn [ j ]=dneps
168 par lb [ j ]=dneps
169 i tername = ’ ’ . j o i n ( [ parkey [ j ] , ’ inst down ’ , s t r ( i ) ] )
170 t ry :
171 i t e r i n s t , i t e r r e s = s e l f .m( data , s o lve r , nfe , pf ixCI ,
172 pardn , s e l f . pkey , bound=s e l f
. bounds )
173 except ValueError as e :
174 z = e
175 pr in t ( z )
176 i = c t o l
177 cont inue
178 # in s t an c e s [ i tername ] = i t e r i n s t
179 # r e s u l t s e s [ i tername ] = i t e r r e s
180 s t a t e s d i c t [ i tername ] = [ [ va lue ( g e t a t t r ( i t e r i n s t , i ) [ j ] )
f o r j in i t e r i n s t . t ] f o r i in s e l f . s t a t e s ]
181 e r r = 2∗( l og ( va lue ( i t e r i n s t . obj ) ) − l og ( ob j CI ) )
182 v a r d i c t [ i tername ] = [ va lue ( g e t a t t r ( i t e r i n s t , parkey [ i ] ) )
f o r i in range ( l en ( parkey ) ) ]
183 o b j d i c t [ i tername ] = value ( i t e r i n s t . obj )
184
176
185 #adjus t s tep s i z e i f convergence slow
186 i f i >0:
187 prevname = ’ ’ . j o i n ( [ parkey [ j ] , ’ inst down ’ , s t r ( i −1) ] )
188 d = np . abs ( ( l og ( o b j d i c t [ prevname ] ) − l og ( o b j d i c t [
i tername ] ) ) ) / l og ( o b j d i c t [ prevname ] ) / s t e p f r a c [ j ]
189 e l s e :
190 d = e r r
191
192 i f d<=0.01:
193 pr in t ( ’ ’ . j o i n ( [ ’ S t ep s i z e i n c r ea s ed from ’ ,
194 s t r ( s t e p f r a c [ j ] ) , ’ to ’ ,
195 s t r (1 . 05∗ s t e p f r a c [ j ] ) ,
196 ’ with prev ious p value : ’ , s t r ( pardn [ j
] ) ] ) )
197 s t e p f r a c [ j ] = 1 .05∗ s t e p f r a c [ j ]
198 e l s e :
199 s t e p f r a c [ j ] = s t e p f r a c [ j ]+def SF [ j ]
200
201 pr in t ( ’ ’ . j o i n ( [ ’ f i n i s h e d LB i t e r a t i o n ’ , parkey [ j ] , s t r ( i ) ,
202 ’ with e r r o r : ’ , s t r ( e r r ) ,
203 ’ and parameter change : ’ , s t r ( pstep ) ] ) )
204 i f e rr>e t o l :
205 dnkey . append ( itername )
206 pr in t ( ’ Reached lower CI ! ’ )
207 e l i f i==cto l −1:
208 par lb [ j ] = −np . i n f
209
210 next down = s e l f . popt [ j ] + pstep − s t e p f r a c [ j ]∗ s e l f . popt [ j
]
211 i f next down < lower bound :
212 pr in t ( ’ Reached parameter lower bound ! ’ )
213 i+=1
214 i=0
215 e r r =0.0
216 pstep=0.0
217 pf ixCI [ j ] = p f i x ed [ j ]
218 parup = [ value ( g e t a t t r ( i t e r i n s t , parkey [ i ] ) ) f o r i in range ( l en
( parkey ) ) ]
219 pardn = [ value ( g e t a t t r ( i t e r i n s t , parkey [ i ] ) ) f o r i in range ( l en
( parkey ) ) ]
220 e l s e :
221 cont inue
222
223 s e l f . parub = parub
224 s e l f . par lb = par lb
225 s e l f . v a r d i c t = v a r d i c t
226 s e l f . o b j d i c t = o b j d i c t
227 s e l f . p f i x = p f ix ed
228 s e l f . data = data
229 s e l f . a lpha = alpha
230 s e l f . s t a t e t r a j = s t a t e s d i c t
231 s e l f . t imes = i t e r i n s t . t
232 # s e l f . mode l in s tance s = in s t an c e s
233 # s e l f . mode l r e s u l t s e s = r e s u l t s e s
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234 re turn { ’ Lower Bound ’ : parlb , ’Upper Bound ’ : parub}
235
236 # Plot a s imple bar p l o t with e r r oba r s at the CI va lue s
237 de f eba rp l o t s ( s e l f , ) :
238 import matp lo t l i b . pyplot as p l t
239 import seaborn as sns
240
241 nPars = len ( s e l f . popt )
242 sns . s e t ( s t y l e=’ wh i t eg r id ’ )
243 p l t . f i g u r e ( f i g s i z e =(21 ,12) )
244 nrow = np . f l o o r ( nPars /3)
245 nco l = np . c e i l ( nPars/nrow )
246 f o r i in range ( nPars ) :
247 ax = p l t . subp lot (nrow , ncol , i +1)
248 ax . bar (1 , s e l f . popt [ i ] , 1 , c o l o r=’ blue ’ )
249 pub = s e l f . parub [ i ]− s e l f . popt [ i ]
250 plb = s e l f . popt [ i ]− s e l f . par lb [ i ]
251 e r r s = [ [ plb ] , [ pub ] ]
252 ax . e r r o rba r (x=1.5 ,y=s e l f . popt [ i ] , y e r r=er r s , c o l o r=’ black ’ )
253 p l t . y l ab e l ( s e l f . pkey [ i ]+ ’ Value ’ )
254 p l t . x l ab e l ( s e l f . pkey [ i ] )
255
256 p l t . t i g h t l a y ou t ( )
257 p l t . show ( )
258
259 # Plot the p r o f i l e l i k e l i h o o d s
260 de f plot PL ( s e l f , ) :
261 import matp lo t l i b . pyplot as p l t
262 import seaborn as sns
263
264 nPars = len ( s e l f . p f i x ) − np . count nonzero ( s e l f . p f i x )
265 sns . s e t ( s t y l e=’ wh i t eg r id ’ )
266 PL f ig = p l t . f i g u r e ( f i g s i z e =(21 ,12) )
267 nrow = np . f l o o r ( nPars /3)
268 i f nrow<1:
269 nrow=1
270 nco l = np . c e i l ( nPars/nrow )
271 ndat , npat = np . shape ( s e l f . data )
272 j=1
273 f o r i , no t f i x ed in enumerate ( s e l f . p f i x ) :
274 i f n o t f i x ed==0:
275 dp=0.0
276 dob=0.0
277 k=0
278 PLub = [ ]
279 OBub = [ ]
280 PLlb = [ ]
281 OBlb = [ ]
282 whi le dp<s e l f . parub [ i ] and k<s e l f . c t o l :
283 kname = ’ ’ . j o i n ( [ s e l f . pkey [ i ] , ’ i n s t up ’ , s t r ( k ) ] )
284 dp = s e l f . v a r d i c t [ kname ] [ i ]
285 dob= log ( s e l f . o b j d i c t [ kname ] )
286 PLub . append (dp)
287 OBub. append (2∗dob )
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288 k=k+1
289 k=0
290 whi le dp>s e l f . par lb [ i ] and k<s e l f . c t o l :
291 kname = ’ ’ . j o i n ( [ s e l f . pkey [ i ] , ’ inst down ’ , s t r ( k ) ] )
292 dp = s e l f . v a r d i c t [ kname ] [ i ]
293 dob= log ( s e l f . o b j d i c t [ kname ] )
294 PLlb=np . append (dp , PLlb )
295 OBlb=np . append (2∗dob ,OBlb)
296 k=k+1
297 e l s e :
298 cont inue
299
300 PL = np . append (PLlb ,PLub)
301 OB = np . append (OBlb ,OBub)
302 ax = p l t . subp lot (nrow , ncol , j )
303 j=j+1
304 ax . p l o t (PL,OB)
305 chibd = OBub[0 ]+ ch i2 . i s f ( s e l f . alpha , 1 )
306 ax . p l o t (PLub [ 0 ] ,OBub [ 0 ] , marker=’ o ’ )
307 ax . p l o t ( [ PLlb [ 0 ] , PLub [ − 1 ] ] , [ chibd , chibd ] )
308 p l t . x l ab e l ( s e l f . pkey [ i ]+ ’ Value ’ )
309 p l t . y l ab e l ( ’ Object ive Value ’ )
310 p l t . show ( )
311 re turn PL f ig
312
313 # Plot s t a t e t r a j e c t o r i e s f o r the reques ted s t a t e s
314 de f p l o t t r a j e c t o r i e s ( s e l f , s t a t e s ) :
315 import matp lo t l i b . pyplot as p l t
316 import seaborn as sns
317
318 nrow = np . f l o o r ( l en ( s t a t e s ) /2)
319 i f nrow<1:
320 nrow=1
321 nco l = np . c e i l ( l en ( s t a t e s ) /nrow )
322 sns . s e t ( s t y l e=’ wh i t eg r id ’ )
323 t r a j F i g = p l t . f i g u r e ( f i g s i z e =(21 ,12) )
324 f o r k in s e l f . s t a t e t r a j :
325 j=1
326 f o r i in range ( l en ( s t a t e s ) ) :
327 ax = p l t . subp lot (nrow , ncol , j )
328 j=j+1
329 ax . p l o t ( s e l f . t imes , s e l f . s t a t e t r a j [ k ] [ i ] )
330 p l t . t i t l e ( s t a t e s [ i ] )
331 p l t . x l ab e l ( ’Time ’ )
332 p l t . y l ab e l ( s t a t e s [ i ]+ ’ Value ’ )
333 p l t . show ( )
334 re turn t r a j F i g
335
336 # Return the upper and lower CI f o r the reques ted parameter names
337 de f pop ( s e l f , pname , lb=True , ub=True ) :
338 CI d i c t = d i c t ( )
339 f o r i in range ( l en (pname) ) :
340 plb = s e l f . par lb [ i ]
341 pub = s e l f . parub [ i ]
179
342 CI d i c t [ pname [ i ] ] = ( plb , pub )
343 re turn CI d i c t
C.2 VAN DE VUSSE CASE STUDY CODE
The code to run the Van de Vusse Case Study of chapter 4 is below. In combination with
PyMPLE.py in its direction the run file and the model file will generate figures similar to
those in chapter 4.
First is the pyomo.dae model:
1
2 # −∗− coding : utf−8 −∗−
3 ”””
4 Created on Tue Sep 1 10 : 13 : 00 2015
5
6 @author : Matthew
7 ”””
8
9 #
10 #
11 # Pyomo : Python Optimizat ion Modeling Objects
12 # Copyright ( c ) 2014 Sandia Corporat ion .
13 # Under the terms o f Contract DE−AC04−94AL85000 with Sandia Corporation ,
14 # the U. S . Government r e t a i n s c e r t a i n r i g h t s in t h i s so f tware .
15 # This so f tware i s d i s t r i b u t e d under the BSD License .
16 #
17
18 # This import header should probably be used in every model
19
20 from pyomo . env iron import ∗
21 from pyomo . dae import ∗
22 from pyomo . opt import So lverFactory
23 #from pyomo . dae . p lug in s . f i n i t e d i f f e r e n c e import
F in i t e D i f f e r en c e Tran s f o rmat i on
24 #from pyomo . dae . p lug in s . c o l l o c import
Co l l o c a t i on D i s c r e t i z a t i on Tran s f o rma t i on
25
26 ’ ’ ’
27 You should s e t up your func t i on to look something l i k e t h i s . I t should have
28 a l l o f the arguments below , but you can add whatever e l s e you want .
29
30 data : i s your data . I t can be a l i s t or ndarray , but the va lue s have to be
31 f l o a t s i f you ’ re going to use a sum−squared e r r o r ob j e c t i v e .
32
33 s o l v e r : any AMPL so l v e r that i s compatible with pyomo
34
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35 n f i n e l s : the number o f f i n i t e e lements that you w i l l use f o r e i t h e r f i n i t e
36 d i f f e r e n c e or c o l l o c a t i o n on f i n i t e e lements methods .
37
38 p0 : the i n i t i a l parameter vec to r that pyomo i s going to operate on .
39
40 pkey : the l i s t o f name s t r i n g s f o r your parameters
41
42 bound : a tup l e or l i s t o f tup l e s ( p r e f e r ed ) conta in ing the bounds o f your
model
43 parameters . NOTE: t h i s i s not the p r o f i l e bounds ; i t i s the pyomo search−space
44 bounds . I f you j u s t want to search the p o s i t i v e r e a l s , you can use the d e f au l t
45 format g iven in the example func t i on d e c l a r a t i on below .
46
47 cp : i s the number o f c o l l o c a t i o n po in t s that you w i l l use i f you e l e c t to
48 employ c o l l o c a t i o n on f i n i t e e lements to i n t e g r a t e your system .
49
50 ’ ’ ’
51 de f VdV model ( data , s o lve r , n f i n e l s , p f ix , p0 , pkey , bound=(0.0 ,None ) , cp=3) :
52 import numpy as np
53 # You should inc lude t h i s i f and only i f you are too lazy to pass your own
54 # bounds l i s t .
55 i f type ( bound )==tup l e :
56 mbounds = [ bound f o r i in range ( l en ( p f i x ) ) ]
57 e l i f type ( bound )==l i s t :
58 mbounds = bound
59
60 # I n i t i l i a z e model as a pyomo ConcreteModel ( ) .
61 m = ConcreteModel ( )
62 t v a l s = l i s t ( data [ : , −1 ] )
63 # tva l s . extend ( [ i /10 .9 f o r i in range (110) ] )
64
65 m. t = ContinuousSet ( i n i t i a l i z e=np . l i n s p a c e (0 ,10 ,110) )
66 m. time = Set ( i n i t i a l i z e=tva l s , with in=m. t , ordered=True )
67
68 rA = data [ : , 0 ]
69 rB = data [ : , 1 ]
70 rC = data [ : , 2 ]
71 rD = data [ : , 3 ]
72
73 # Set your s t a t e s . This could be done automat i ca l l y in a s im i l a r way to
the
74 # parameters below . However , your s t a t e s are independent o f the p r o f i l i n g
75 # operat ion , so i t might be f a s t e r to j u s t hard code them .
76 m.A = Var (m. t )
77 m.B = Var (m. t )
78 m.C = Var (m. t )
79 m.D = Var (m. t )
80
81 f o r i in range ( l en ( p f i x ) ) :
82 # This f o r loop has to be pre sent in your model in order f o r the get CI ( )
83 # method to operate f o r a gene ra l s e t o f parameters s p e c i f i e d in the run
f i l e .
84 # I t accompl i shes the f o l l ow i n g ass ignments f o r the VdV example case when
85 # p r o f i l i n g only FV and kAB.
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86 # m.FV = Var ( i n i t i a l i z e =3/7)# True Value 4/7
87 # m. Caf = Param( i n i t i a l i z e =10)
88 # m.kAB = Var ( i n i t i a l i z e =3/6)# True Value 5/6
89 # m.kBC = Param( i n i t i a l i z e =5/3)
90 # m.kAD = Param( i n i t i a l i z e =1/6)
91
92 i f p f i x [ i ]==0:
93 dVar = Var ( i n i t i a l i z e=f l o a t ( p0 [ i ] ) , bounds=mbounds [ i ] )
94 s e t a t t r (m, pkey [ i ] , dVar )
95 de l ( dVar )
96 e l s e :
97 dPar = Param( i n i t i a l i z e=f l o a t ( p0 [ i ] ) )
98 s e t a t t r (m, pkey [ i ] , dPar )
99 de l ( dPar )
100
101 A0=m. Caf
102 B0=0
103 C0=0
104 D0=0
105
106 # Set your s t a t e d e r i v a t i v e s .
107 m. dAdt = Der ivat iveVar (m.A, wrt=m. t )
108 m. dBdt = Der ivat iveVar (m.B, wrt=m. t )
109 m. dCdt = Der ivat iveVar (m.C, wrt=m. t )
110 m. dDdt = Der ivat iveVar (m.D, wrt=m. t )
111
112 # Def ine your model equat ions as c on s t r a i n t s
113 de f A ode (m, i ) :
114 i f i ==0:
115 re turn Constra int . Skip
116 re turn m. dAdt [ i ] == m.FV∗(A0−m.A[ i ] ) − m.kAB∗m.A[ i ] − m.kAD∗m.A[ i ]∗∗2
117 m. A ode = Constra int (m. t , r u l e= A ode )
118
119 de f B ode (m, i ) :
120 i f i ==0:
121 re turn Constra int . Skip
122 re turn m. dBdt [ i ] == −m.FV∗(m.B[ i ] ) + m.kAB∗m.A[ i ] − m.kBC∗m.B[ i ]
123 m. B ode = Constra int (m. t , r u l e= B ode )
124
125 de f C ode (m, i ) :
126 i f i ==0:
127 re turn Constra int . Skip
128 re turn m. dCdt [ i ] == −m.FV∗(m.C[ i ] ) + m.kBC∗m.B[ i ]
129 m. C ode = Constra int (m. t , r u l e= C ode )
130
131 de f D ode (m, i ) :
132 i f i ==0:
133 re turn Constra int . Skip
134 re turn m. dDdt [ i ] == −m.FV∗(m.D[ i ] ) + 1/2∗m.kAD∗m.A[ i ]∗∗2
135 m. D ode = Constra int (m. t , r u l e= D ode )
136
137 # Def ine your i n i t i a l c ond i t i on s
138 de f i n i tCons (m) :
139 y i e l d m.A[ 0 ] == A0
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140 y i e l d m.B [ 0 ] == B0
141 y i e l d m.C[ 0 ] == C0
142 y i e l d m.D[ 0 ] == D0
143 m. in i tCons = Cons t ra in tL i s t ( r u l e= in i tCons )
144
145 # This i s your ob j e c t i v e . SSE i s probably pre f e red , but whatever .
146 de f ob j (m) :
147 Asum = sum( ( rA [ t v a l s . index ( i ) ]−m.A[ i ] ) ∗∗2 f o r i in m. time )
148 Bsum = sum( ( rB [ t v a l s . index ( i ) ]−m.B[ i ] ) ∗∗2 f o r i in m. time )
149 Csum = sum( ( rC [ t v a l s . index ( i ) ]−m.C[ i ] ) ∗∗2 f o r i in m. time )
150 Dsum = sum( ( rD [ t v a l s . index ( i ) ]−m.D[ i ] ) ∗∗2 f o r i in m. time )
151 re turn Asum+Bsum+Csum+Dsum
152 m. obj = Object ive ( s ense=minimize , r u l e= ob j )
153
154 # Di s c r e t i z e the problem
155 d i s c=TransformationFactory ( ”dae . f i n i t e d i f f e r e n c e ” )
156 d i s c . app ly to (m, n fe=len (m. t ) , wrt=m. t , scheme=”BACKWARD” )
157 # Solve the problem
158 opt = SolverFactory ( s o l v e r )
159 opt . opt ions [ ’ l i n e a r s o l v e r ’ ] = ”ma97”
160 opt . opt ions [ ’ t o l ’ ] = 1e−6
161 #model . p r ep roce s s ( )
162 r e s u l t s = opt . s o l v e (m, t ee=False )
163 #model . load ( r e s u l t s )
164 m. s o l u t i o n s . load from ( r e s u l t s )
165
166 re turn m, r e s u l t s
And here is the run file:
1
2 # −∗− coding : utf−8 −∗−
3 ”””
4 Created on Fr i Sep 9 10 : 57 : 45 2016
5
6 @author : Matthew
7 ”””
8
9 # This import b lock has b a s i c a l l y everyth ing you could need f o r c a l c u l a t i n g
10 # and graphing your r e s u l t s . Unused modules are l e f t in the code f o r r e f e r e n c e
.
11 from pyomo . env iron import ∗
12 from pyomo . dae import ∗
13 from pyomo . opt import So lverFactory
14 import numpy as np
15 import s c ipy as sp
16 from sc ipy . s t a t s . d i s t r i b u t i o n s import ch i2
17 import s c ipy . i o as s i o
18 import matp lo t l i b . pyplot as p l t
19 import seaborn as sns
20 import l a z y t o o l s as mrmtools
21
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22 # You must import a funct ion , here VdV model , that s o l v e s a pyomo
ConcreteModel
23 # and re tu rn s the so lved in s t ance and i t s r e s u l t s . See VdV model f o r an
example
24 # of that l ooks .
25 from VdV module import VdV model as model
26
27 # Import the PyMPLE c l a s s . This has everyth ing you need f o r p l o t t i n g and
28 # Analyzing your model re sponse to p r o f i l i n g .
29 from PyMPLE import PyMPLE
30
31 div=1
32
33 # This i s maybe the only example−s p e c i f i c l i n e o f code in here , but the data
34 # i s s p e c i f i c to the problem . Don ’ t use t h i s data on your problem . Or do . YOLO
.
35 da t a s t r u c t = s i o . loadmat ( ’VdVExData .mat ’ )
36 data = np . array ( [ l i s t ( da t a s t r u c t [ ’C ’ ] [ i , : ] ) f o r i in range (0 , l en ( da t a s t r u c t [
’C ’ ] [ : , 0 ] ) , d iv ) ] )
37
38 tdata = np . l i n s p a c e (0 ,10 ,110)
39 tdat = [ tdata [ i ] f o r i in range (0 , l en ( da t a s t r u c t [ ’C ’ ] [ : , 0 ] ) , d iv ) ]
40 data = np . i n s e r t ( data , l en ( data [ 0 , : ] ) , tdat , ax i s=1)
41
42 # Provide some i n i t i a l i z a t i o n va lue s f o r your pyomo model that the c l a s s can
43 # a l s o use a f t e r the i n i t i a l pyomo s o l u t i o n .
44 s o l v e r = ’ ipopt ’# your pyomo−approved s o l v e r
45
46 p0 = [4/7 , 10 . 0 , 3/6 , 5/2 , 2/6 ] # pyomo w i l l need an i n i t i a l cond i t i on vec to r
47 # might as we l l prov ide that here
48
49 pkey = [ ’FV ’ , ’ Caf ’ , ’kAB ’ , ’kBC ’ , ’kAD ’ ] # Your parameter names .
50
51 p f i x = [ 1 , 1 , 0 , 0 , 0 ] # This i s the vec to r o f parameters that you don ’ t want to
52 # p r o f i l e . Ask , ”Do I want to exc lude t h i s from p r o f i l i n g ?”
53 # I f yes , then ente r 1 at i t s index l o c a t i o n to exc lude i t .
54
55 n f i n e l s = 110 # Te l l pyomo ( and the c l a s s ) how many f i n i t e e lements you want .
56
57 mstates = [ ’A ’ , ’B ’ , ’C ’ , ’D ’ ] # This i s the names o f your s t a t e s f o r p l o t t i n g
t r a j e c t o r i e s
58
59 bds = [ ( 0 . 0 , None ) f o r i in range ( l en ( p f i x ) ) ] # Your model probably has bounds .
60 # You should add them here .
61 # Solve r your model to get an i n i t i a l po int f o r p r o f i l i n g
62 i n s t , mres = model ( data , s o lve r , n f i n e l s , p f ix , p0 , pkey , bound=bds )
63 # Load your model s o l u t i o n s .
64 i n s t . s o l u t i o n s . load from (mres )
65 # Get the r e f e r e n c e ob j e c t i v e value f o r p r o f i l i n g .
66 obj = value ( i n s t . obj )
67
68 # This l i s t comprehension auto−gene ra t e s your i n i t i a l parameter vec to r f o r
p r o f i l i n g
69 popt = [ va lue ( g e t a t t r ( in s t , pkey [ i ] ) ) f o r i in range ( l en ( pkey ) ) ]
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70
71 # Generate an in s t anc e o f the PyMPLE c l a s s
72 PyMPLE instance = PyMPLE( popt , model , obj , pkey , bds , s t a t e s=mstates )
73
74 # This an exomple o f how to generate a vec to r o f the r e l a t i v e step−s i z e s you
75 # want to take when p r o f i l i n g each parameter .
76 s f v e c = [ 0 . 0 0 5 f o r i in range ( l en ( popt ) ) ]
77 nsteps = 100 # the max number o f s t ep s to take when p r o f i l i n g .
78
79 # Perform the p r o f i l i n g with t h i s command . Returns the upper and lower bounds
80 f i n = PyMPLE instance . get CI ( p f ix , data , nsteps , s fvec , s o l ve r , n f i n e l s )
81
82 # Plot your p r o f i l e l i k e l i h o o d s that were obtained from the get CI method
83 PL Fig = PyMPLE instance . plot PL ( )
84 mrmtools . s e t f o n t s i z e ( PL Fig , 1 8 )
85 # You can a l s o use the eba rp l o t s method to p l o t your parameters as a bar with
CIs
86 PyMPLE instance . eba rp l o t s ( )
87
88 # And you can a l s o p l o t each o f the p r o f i l e d s t a t e t r a j e c t o r i e s
89 t r a j F i g = PyMPLE instance . p l o t t r a j e c t o r i e s ( mstates )
90 mrmtools . s e t f o n t s i z e ( t r a j F i g , 1 8 )
91 #Obviously , you can and should pop your PyMPLE in s tance to get upper and lower
CIs
92 PyMPLE instance . pop ( pkey )
93
94 A = [ ]
95 B = [ ]
96 C = [ ]
97 D = [ ]
98 rA= data [ : , 0 ]
99 rB= data [ : , 1 ]
100 rC = data [ : , 2 ]
101 rD = data [ : , 3 ]
102 t = [ ]
103
104 f o r i in so r t ed ( i n s t . t ) :
105 A. append ( value ( i n s t .A[ i ] ) )
106 B. append ( value ( i n s t .B[ i ] ) )
107 C. append ( value ( i n s t .C[ i ] ) )
108 D. append ( value ( i n s t .D[ i ] ) )
109 # rA . append ( value ( d i s c . rA [ i ] ) )
110 # rB . append ( value ( d i s c . rB [ i ] ) )
111 t . append ( i )
112
113 f i g = p l t . f i g u r e ( )
114 ax = f i g . add subplot ( 1 , 1 , 1 )
115 #ax . s e t x l a b e l ( ’ Distance x ’ )
116 #ax . s e t y l a b e l ( ’Time t ’ )
117 ax . s e t t i t l e ( ’Van de Vusse ! ’ )
118 ax . p l o t ( tdat , rA , ’ ob ’ )
119 ax . p l o t ( tdat , rB , ’ og ’ )
120 ax . p l o t ( tdat , rC , ’om ’ )
121 ax . p l o t ( tdat , rD , ’ oc ’ )
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122 ax . p l o t ( t ,A)
123 ax . p l o t ( t ,B)
124 ax . p l o t ( t ,C)
125 ax . p l o t ( t ,D)
126 ax . l egend ( [ ’A Data ’ , ’B Data ’ , ’C Data ’ , ’D Data ’ , ’A ’ , ’B ’ , ’C ’ , ’D ’ ] )
127 #ax . p l o t ( tva l s , data , ’ o ’ )
128 f i g . show ( )
129
130
131 # add the true parameter va lue s to the P r o f i l e P lo t s
132 numsps = len ( p f i x )−np . count nonzero ( p f i x )
133 trueOpt = [5/6 , 5/3 , 1/6 ]
134 f o r i in range ( numsps ) :
135 PL Fig . g e t axe s ( ) [ i ] . p l o t ( trueOpt [ i ] , 2∗ l og ( PyMPLE instance . obj )+ch i2 . i s f
( 0 . 0 5 , 1 ) , ’ o ’ , markers i ze=8)
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APPENDIX D
EXTERNAL STAKEHOLDER QUESTIONS, RESPONSES, AND
CATEGORIZATIONS
IN-HOME PATIENT
I have recently been diagnosed with end-stage kidney disease and my nephrologist said
that I only have twelve percent kidney function. After several weeks of training, I am legally
allowed to have in-home dialysis. I am glad to be able to do this in my own home because
I can do it more frequently and for less time each time, plus I’m more comfortable than in
a clinic. All of this is important because my nephrologist said I will be doing hemodialysis
for the rest of my life.
1. How much time do you set aside for your treatment on your dialysis days?
1. I spend two to three hours in each of my dialysis sessions, six times per week. FLUX
2. Other than your actual dialysis sessions, how many hours a week do you set aside for
your kidney disease?
1. I have routine check-ups once a month, which last about four hours each time in-
cluding meeting with my nephrologist, the nurse and the dietician. On average, I
would say that I spend about 13 hours per week for my kidney disease. N/A
3. What values did you have in mind when considering the flux of the membrane you use
for dialysis?
1. I’m not sure what you mean. I am not familiar with the flux of a membrane.
Therefore, I do not have any values in mind. N/A
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4. Are you willing to spend over $100 on a hemodialysis membrane?
1. It doesn’t matter to me how much it costs. Medicare and my secondary insurance
pay for all of it. COST
5. How often do you plan to specifically purchase membranes for your dialyzer?
1. My center just supplies them to me. But, membranes that don’t work properly
definitely cost me time and effort. RELIABILITY
6. Are you willing to sacrifice an efficient membrane for a membrane that reduces blood
cell reactivity?
1. I am not sure what blood cell reactivity is so I cannot answer this question. N/A
7. What is your pain threshold (how tolerant are you to pain)?
1. I feel as if I can tolerate a high amount of discomfort. BCR
8. Have you seen any commercials or magazine ads for dialyzer membranes?
1. Yes – on TV. I saw one that seemed to use really advanced technology and told my
nephrologist about it. I’m not sure if we’re using that one or not. MARKETABIL-
ITY
9. Would you be willing to pay more for a high-flux membrane?
1. Like I said, I don’t pay for it but if high-flux means less time for me, the answer is
yes! N/A
10. For your treatment, are you performing daily (3 sessions per week), short-daily (5-7
sessions per week) or nocturnal dialysis (3-6 night sessions per week)?
1. I am currently on a short-daily dialysis regimen about 6 times per week. N/A
NEPHROLOGIST
In my practice, I care for a lot of patients with end stage renal disease. Many of them use
hemodialysis. I want the most effective treatment for these patients in the shortest amount
of time. I have 15 hemodialysis machines available at my clinic that are in use 8 hours a
day, six days a week. These machines must be replaced after 25,000 to 40,000 hours of use
and with constant monitoring. I would like to purchase membranes that are as efficient as
possible and also reliable to avoid downtime.
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1. Would your practice be able to use a medium-high flux through the membrane if it saved
you money?
1. As long as the membrane is able to provide the patient with the best care possible
and save us money, then it would definitely be used. COST
2. Is your practice willing to purchase membranes in bulk (greater than 50 units at a time)?
1. My clinic typically would like to purchase materials in bulk to get a volume pricing
discount if possible since we have a very consistent, predictable and ongoing need.
COST
3. How many patients, on average, do you have monthly?
1. My practice has about 50 patients per month that come in for hemodialysis. N/A
4. Are you willing to use a membrane with lower flux if it means your patients will be in
dialysis longer?
1. No. We are not interested in doing so since our practice sees a lot of patients and if
the treatment takes longer we would have to reduce the number of patients that we
can treat. FLUX
5. Have you seen any magazine advertisements for our hemodialyzer membranes?
1. I have seen a few membrane ads in medical magazines, but I have not seen any of
yours specifically. MARKETABILITY
6. How many dialysis machines do you currently own and how many have you had to replace
since your practice originally opened?
1. My practice has 15 dialysis machines that are currently in use. I have had to replace
three of them since my practice opened. N/A
7. How closely do you monitor blood cell reactivity?
1. We try our best to minimize blood cell reactivity, as we do not want to impose any
more discomfort than necessary on our patients. While we maintain the minimum
legal requirement, we do not solely base our practice on the blood cell reactivity
rate. BCR
8. Are you willing to pay more for a high-flux dialyzer?
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1. The dialysis clinic is paid a set amount per treatment, and we have to provide care
within that budget. Therefore, the cost of the membranes is very important to us.
We would consider a higher cost membrane if it really improved patient care, but
I’d want to really know how it improves patient outcomes. COST
9. Have you heard about any of our membranes through any other clinics or during any
seminars?
1. To be honest, I have not heard about your membranes or anything related to your
company before. MARKETABILITY
10. How much is your clinic willing to pay for a membrane that has a suitable reliability?
1. Though the membrane may have good reliability, we are still on a budget and would
like to spend no more than $80 on the membranes that we use. COST
HOSPITAL ADMINISTRATOR
Nearly 175 acute and chronic kidney disease patients come into my hospital every month.
My job is to control costs while providing the best possible care. With that said, I would
like to purchase membranes that satisfy the minimal legal requirements (reliability, flux and
blood cell reactivity) in bulk from you. As with all of my bulk orders, I do expect the overall
price to be significantly lower than what a normal order would be due to volume discounts.
I also tend to be less concerned with the reliability of the membrane since I have a large
quantity in stock at the hospital.
1. Have you seen our ads for hemodialyzer membranes in any medical magazines or adver-
tisements?
1. What magazine did you advertise in? I have not seen any advertisements from your
company before. MARKETABILITY
2. Would you be willing to have smaller, more frequent orders rather than one large bulk
order?
1. I would much rather buy the membranes in a bulk order as we go through many of
them quickly. Frequent orders would mean I have to monitor membrane use much
more closely and spend time ordering this item more often. Also, if I order smaller
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quantities, any reliability problems could really affect the treatment of our patients.
RELIABILITY
3. Many patients tolerate different levels of pain. Are you willing to purchase membranes
with different blood cell reactivity rates associated with the membrane in order to ac-
commodate your patients?
1. I am not willing to order membranes based on different blood cell reactivity rates.
I am interested in ordering membranes that meet the minimum legal requirements
for blood cell reactivity. BCR
4. How many dialysis machines does your hospital currently have in use?
1. I currently have 15 dialysis machines in use in my hospital. N/A
5. Is your hospital willing to spend more money on a high-flux dialyzer for your patients?
1. As of right now, my hospital is not willing to spend more money in this area. We
tend to use the minimum legally required membranes within our hospital, which is
generally cheaper for us. COST
6. Would you ever consider making an exclusive sales contract with one company who
could supply all of your dialysis membrane needs?
1. I would need to know more details before I could make this type of decision. The
good part of having a large selection of vendors is that it is a competitive market
which enables our hospital to get the best product at a great price point. COST
7. How important is it for your hospital to provide your patients with a comfortable setting?
1. We want our hospital to be known for patient care and overall well-being. We want
our hospital to provide the maximum care for all patients and have them feel that
they are comfortable. BCR
8. How does your hospital deal with the blood cell reactivity involved with the hemodialysis
patients?
1. My hospital typically purchases membranes that have blood cell reactivity rates at
the minimum legal requirement. BCR
9. Are you familiar with the use of carbon nanotubes within membranes?
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1. I have heard of carbon nanotubes within dialysis membranes, and I do know that
it makes the membrane significantly stronger. However, I do not know much more
about them, or any details about the effects they have during dialysis. N/A
10. How long is a typical dialysis session at your hospital and would you be willing to accept
longer or shorter sessions?
1. A typical dialysis session in my hospital lasts for about four hours. Although shorter
sessions could be advantageous if the overall treatment efficacy were the same, we
wouldn’t want the sessions to last any longer because it would limit the number of
patients we could treat on a daily basis. FLUX
INDUSTRY THOUGHT LEADER
I have been working in the field of hemodialysis for the majority of my career (greater than
30 years). My current position is Chief Medical Officer (CMO) for one of the large medical
technology companies that work in the hemodialysis field. Recently, I was asked to compile
my thoughts and reflections on dialysis and all the transitions the field has gone through
over the course of my work in the field. Working together with other leading scientists, we
have published a book that documents the history of dialysis, the changes in this field and
the latest state of the art advances that we believe will lead this field into the next century.
1. Have you ever worked on the design of hemodialysis membranes?
1. I have not specifically designed membranes although I have worked closely with
biomedical engineers within my organization that have been involved in the design
of these membranes. N/A
2. What specifications do you feel are most important to consider when making a hemodial-
ysis membrane?
1. From a pure technical standpoint, I believe that the blood cell reactivity and the
flux you can achieve through the membrane are important to focus upon. FLUX
and BCR
3. At your company does cost play a significant issue in design?
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1. Cost always plays an issue but it is not the sole criterion. It is important that you
balance cost with the overall quality of the design to create a product that customers
will value. N/A
4. Have you ever seen any television or magazine ads for Nephrotex membranes?
1. I am aware of Nephrotex and their hemodialysis membranes. As an industry leader,
it is important to be aware of your competitors and what they are working on.
MARKETABILITY
5. In the book on dialysis that you were recently involved with can you share what design
parameters for membranes were discussed?
1. We discussed all the key design parameters: membrane flux, blood cell reactivity,
reliability and cost. N/A
6. In your expert position, do you feel that patients’ pain threshold is an important factor
in the design of hemodialysis membranes?
1. I believe that this is a factor that needs to be considered when designing a device.
However, this is not the sole criterion that needs to be accounted for. BCR
7. What are some of the state of the art advances that were discussed in the dialysis book?
1. We discussed developments in the field overall but didn’t examine specifically inno-
vations related to the design of hemodialysis membranes, so unfortunately I cannot
help you in this regard. N/A
8. As an industry leader, what compromises do you observe being made in the design of
hemodialysis membranes?
1. I believe that each company makes its own decisions; I wouldn’t necessarily call these
compromises, in order to provide the best possible product to their target customer.
N/A
9. When deciding on the target flux for a membrane, are there any specific questions you
seek answers for?
1. We seek to determine what is important for our target customer and then utilize
that information in the design of our membranes. N/A
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10. What are your thoughts on the use of carbon nanotubes in a hemodialysis membrane?
1. I have read that they have extremely smooth walls which will allow for increased
flow of fluids and gases through them. I believe that for this reason, they are an
interesting possibility to consider in hemodialysis membrane design. FLUX
MEDICARE GOVERNMENT ASSISTANT
As of 1972, the United States government extended Medicare coverage to all people of
any age with end-stage renal disease. We cover up to 80 percent of the costs for the treatment
of end-stage renal diseases, which includes both in-home and on-site patients. However, over
the past few years, we have seen an increase in the average cost of treatment per individual
with kidney disease. As of 2012, the average cost of treatment, dialysis, supplies and aide
per person was roughly $88,000. While we want every one of our customers to have the best
treatment possible, we recognize that we do need to cut down on some areas of coverage
for our customers due to the increasing costs. Our analysts have decided that one area
we can cut down on costs is through limiting the selection of membranes used during the
hemodialysis process for which we will cover costs. We would like to limit our coverage to a
lower cost membrane while still providing our customers the best possible care.
1. What is the maximum price range you will cover for customers’ membranes?
1. Medicare will cover up to $80.00 for customers’ membranes. COST
2. What percent of the total costs will you cover if your customers do in fact use a high
priced membrane?
1. After the $80.00 coverage, the customer will have to cover the cost. This is most
often through a secondary insurance company but could be as an individual co-pay.
COST
3. How important is it to you for your customers to be comfortable during the hemodialysis
process?
1. We want our customers to be as comfortable as possible throughout their hemodial-
ysis treatment. Additional pain and suffering would likely increase patient care costs
long-term. BCR
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4. How important is blood cell reactivity to the Medicare program?
1. I will have to double check with our analysts before I can answer this question.
Medicare wants to provide the most efficacious, efficient and comfortable treatment
for each patient that we can finically support in a responsible, sustainable way. BCR
5. Are you willing to cover a membrane that is shown to be successful in waste removal in
a smaller amount of time for the customer?
1. Medicare would like to cover as efficient a membrane as possible for our customers;
that is, one that reduces treatment times the most. As long as the membrane falls
within our coverage limit, Medicare will cover the cost of a more efficient membrane.
FLUX
6. Are you willing to cover a membrane that is associated with a small amount blood cell
reactivity during a hemodialysis session?
1. I will have to check my resources before I can answer any questions regarding blood
cell reactivity. N/A
7. Will you cover more expensive membranes if it is proven that lower priced membranes
did not sufficiently remove enough waste from the patients?
1. I have to check my resources before I answer any questions about the waste removal
rate. I do know that up until now, the membranes that Medicare has covered meet
the minimum legal requirements for all aspects of dialyzers. N/A
8. How often do you see our membrane advertisements in medical magazines?
1. As an agent for Medicare, I have not personally read or seen any magazines related
to hemodialysis membranes. Medicare analysts are always up to date, however, so I
would have to double check with them for this question. MARKETABILITY
9. Does your coverage fluctuate for the in-home or on-site patients?
1. Medicare’s coverage does not fluctuate between in-home and on-site patients. There
is an 80 percent coverage for approved fees for customers. A private insurance
company or a co-pay is required for the other 20 percent of the fees. N/A
10. How efficient of a membrane will Medicare cover?
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1. Medicare will cover up to $80.00 for any membrane that meets the minimal legal
requirements. The efficiency of the membrane is not a consideration. COST
That’s it. To God be the glory!
196
BIBLIOGRAPHY
[1] Markovetz MR, Corcoran TE, Locke LW, Myerburg MM, Pilewski JM, et al. (2014) A
Physiologically-Motivated Compartment-Based Model of the Effect of Inhaled Hyper-
tonic Saline on Mucociliary Clearance and Liquid Transport in Cystic Fibrosis. PLoS
ONE 9: e111972.
[2] Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn Ja, et al. (1995) CFTR as a
cAMP-dependent regulator of sodium channels. Science (New York, NY) 269: 847–
850.
[3] Bertrand Ca, Zhang R, Pilewski JM, Frizzell Ra (2009) SLC26A9 is a constitutively
active, CFTR-regulated anion conductance in human bronchial epithelia. The Journal
of general physiology 133: 421–438.
[4] Boucher RC (1994) Human Airway Ion Transport. American journal of respiratory
and critical care medicine 150: 581–593.
[5] Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, et al. (1998) Evidence for
periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of
cystic fibrosis airways disease. Cell 95: 1005–1015.
[6] Trimble AT, Donaldson SH (2015) Cftr modulator therapies for cystic fibrosis. Pediatric
Allergy, Immunology, and Pulmonology 28: 230–236.
[7] Bertrand C, Durand DM, Saidel GM, Laboisse C, Hopfer U (1998) System for dynamic
measurements of membrane capacitance in intact epithelial monolayers. Biophysical
journal 75: 2743–2756.
[8] Locke LW, Myerburg MM, Markovetz MR, Parker RS, Weber L, et al. (2014) Quanti-
tative imaging of airway liquid absorption in cystic fibrosis. The European respiratory
journal : 1–10.
[9] Matsui H, Davis CW, Tarran R, Boucher RC (2000) Osmotic water permeabilities
of cultured, well-differentiated normal and cystic fibrosis airway epithelia. Journal of
Clinical Investigation 105: 1419–1427.
197
[10] Sood N, Bennett WD, Zeman K, Brown J, Foy C, et al. (2003) Increasing concentration
of inhaled saline with or without amiloride: effect on mucociliary clearance in normal
subjects. American journal of respiratory and critical care medicine 167: 158–163.
[11] Boon M, Verleden SE, Bosch B, Lammertyn EJ, McDonough JE, et al. (2016) Mor-
phometric analysis of explant lungs in cystic fibrosis. American journal of respiratory
and critical care medicine 193: 516–526.
[12] Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC (2001) The relative roles
of passive surface forces and active ion transport in the modulation of airway surface
liquid volume and composition. The Journal of general physiology 118: 223–36.
[13] Myerburg MM, Harvey PR, Heidrich EM, Pilewski JM, Butterworth MB (2010) Acute
regulation of the epithelial sodium channel in airway epithelia by proteases and traf-
ficking. American journal of respiratory cell and molecular biology 43: 712–9.
[14] Castellani S, Favia M, Guerra L, Carbone A, Abbattiscianni A, et al. (2016) Emerging
relationship between cftr, actin and tight junction organization in cystic fibrosis airway
epithelium. Histology and histopathology : 11842.
[15] Palmer LG (1982) Ion selectivity of the apical membrane Na channel in the toad urinary
bladder. The Journal of Membrane Biology 67: 91–98.
[16] Garcia GJM, Boucher RC, Elston TC (2013) Biophysical model of ion transport across
human respiratory epithelia allows quantification of ion permeabilities. Biophysical
journal 104: 716–26.
[17] O’Donoghue DL, Dua V, Moss GWJ, Vergani P (2013) Increased apical Na+ perme-
ability in cystic fibrosis is supported by a quantitative model of epithelial ion transport.
The Journal of physiology 591: 3681–92.
[18] Button B, Cai L, Ehre C, Kesimer M (2012) A periciliary brush promotes the lung
health by separating the mucus layer from airway epithelia. Science 937.
[19] Regnis Ja, Robinson M, Bailey DL, Cook P, Hooper P, et al. (1994) Mucociliary clear-
ance in patients with cystic fibrosis and in normal subjects. American journal of
respiratory and critical care medicine 150: 66–71.
[20] Mauroy B, Fausser C, Pelca D, Merckx J, Flaud P (2011) Toward the modeling of
mucus draining from the human lung: role of the geometry of the airway tree. Physical
biology 8: 056006.
[21] Corcoran TE, Thomas KM, Myerburg MM, Muthukrishnan a, Weber L, et al. (2010)
Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis
airway. The European respiratory journal 35: 781–6.
198
[22] Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, et al. (2006) Mucus
clearance and lung function in cystic fibrosis with hypertonic saline. The New England
journal of medicine 354: 241–50.
[23] Goralski JL, Boucher RC, Button B (2010) Osmolytes and ion transport modulators
: new strategies for airway surface rehydration. Current Opinion in Pharmacology 10:
294–299.
[24] Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, et al. (2005) Normal and
cystic fibrosis airway surface liquid homeostasis the effects of phasic shear stress and
viral infections. Journal of Biological Chemistry 280: 35751–35759.
[25] Chen JH, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, et al. (2010) Loss of anion
transport without increased sodium absorption characterizes newborn porcine cystic
fibrosis airway epithelia. Cell 143: 911–23.
[26] La¨uger P (1984) Thermodynamic and kinetic properties of electrogenic ion pumps.
Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes 779: 307–341.
[27] Goldman DE (1943) Potential, impedance, and rectification in membranes. The Jour-
nal of General Physiology 27: 37–60.
[28] Fromter E, Diamond J (1972) Route of passive ion permeation in epithelia. Nat New
Biol 235: 9–13.
[29] House CR (1974) Water transport in cells and tissues. E. Arnold.
[30] Ussing HH, Zerahn K (1951) Active transport of sodium as the source of electric current
in the short-circuited isolated frog skin. Acta physiologica Scandinavica 23: 110–127.
[31] Levi H, Ussing HH (1949) Resting potential and ion movements in the frog skin. Nature
164: 928–928.
[32] Li H, Sheppard DN, Hug MJ (2004) Transepithelial electrical measurements with the
Ussing chamber. Journal of Cystic Fibrosis 3: 123–126.
[33] Frizzell RA, Hanrahan JW (2012) Physiology of epithelial chloride and fluid secretion.
Cold Spring Harbor perspectives in medicine 2: a009563.
[34] Anderson J, Van Itallie C (1995) Tight junctions and the molecular basis for regula-
tion of paracellular permeability. American Journal of Physiology-Gastrointestinal and
Liver Physiology 269: G467–G475.
[35] Fronius M, Rehn M, Eckstein-Ludwig U, Clauss W (2001) Inhibitory non-genomic
effects of progesterone on na+ absorption in epithelial cells from xenopus kidney (a6).
Journal of Comparative Physiology B 171: 377–386.
199
[36] Bosch B, De Boeck K (2016) Searching for a cure for cystic fibrosis. a 25-year quest in
a nutshell. European journal of pediatrics 175: 1–8.
[37] Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, et al. (2009) Rescue of CF
airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of
the National Academy of Sciences of the United States of America 106: 18825–18830.
[38] Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, et al. (2014)
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-
blind, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine 2: 539–547.
[39] Brodlie M, Haq IJ, Roberts K, Elborn JS (2015) Targeted therapies to improve cftr
function in cystic fibrosis. Genome medicine 7: 1.
[40] Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, et al. (2015)
Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for phe508del cftr.
New England Journal of Medicine 373: 220–231.
[41] Accurso F, Rowe S (2010) Effect of VX-770 in persons with cystic fibrosis and the
G551D-CFTR mutation. . . . England Journal of . . . : 1991–2003.
[42] Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Stack JH, et al. (2011) Correction
of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-
809. Proceedings of the National Academy of Sciences of the United States of America
108: 18843–8.
[43] Pilewski J, Cooke J, Lekstrom-Himes J, Donaldson S, et al. (2015) Ws01. 4 vx-661 in
combination with ivacaftor in patients with cystic fibrosis and the f508del-cftr muta-
tion. Journal of Cystic Fibrosis 14: S1.
[44] Jones AM, Barry PJ (2015) Lumacaftor/ivacaftor for patients homozygous for
phe508del-cftr: should we curb our enthusiasm? Thorax 70: 615–616.
[45] for Sick Children H (2011). Cftr mutations database. URL http://www.genet.
sickkids.on.ca/StatisticsPage.html.
[46] Joyner MJ, Paneth N (2015) Seven questions for personalized medicine. Jama 314:
999–1000.
[47] Stutts MJ, Rossier BC, Boucher RC (1997) Cystic fibrosis transmembrane conductance
regulator inverts protein kinase a-mediated regulation of epithelial sodium channel
single channel kinetics. Journal of Biological Chemistry 272: 14037–14040.
[48] Dorwart MR, Shcheynikov N, Yang D, Muallem S (2008) The solute carrier 26 family
of proteins in epithelial ion transport. Physiology 23: 104–114.
[49] Tarran R, Button B, Boucher RC (2006) Regulation of normal and cystic fibrosis airway
surface liquid volume by phasic shear stress. Annual review of physiology 68: 543–561.
200
[50] Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, et al. (2008) Tmem16a, a
membrane protein associated with calcium-dependent chloride channel activity. Science
322: 590–594.
[51] Manzanares D, Gonzalez C, Ivonnet P, Chen RS, Valencia-Gattas M, et al. (2011)
Functional apical large conductance, ca2+-activated, and voltage-dependent k+ chan-
nels are required for maintenance of airway surface liquid volume. Journal of Biological
Chemistry 286: 19830–19839.
[52] Schreiber R, Nitschke R, Greger R, Kunzelmann K (1999) The cystic fibrosis trans-
membrane conductance regulator activates aquaporin 3 in airway epithelial cells. The
Journal of biological chemistry 274: 11811–11816.
[53] Miyamoto H, Ikehara T, Yamaguchi H, Hosokawa K, Yonezu T, et al. (1986) Kinetic
mechanism of na+, k+, cl–cotransport as studied by rb+ influx into hela cells: effects
of extracellular monovalent ions. The Journal of membrane biology 92: 135–150.
[54] Lindenmayer GE, Schwartz A, Thompson HK (1974) A kinetic description for sodium
and potassium effects on (na++ k+)-adenosine triphosphatase: a model for a two-
nonequivalent site potassium activation and an analysis of multiequivalent site models
for sodium activation. The Journal of physiology 236: 1–28.
[55] Falkenberg CV, Jakobsson E (2010) A biophysical model for integration of electrical,
osmotic, and pH regulation in the human bronchial epithelium. Biophysical journal
98: 1476–85.
[56] Willumsen NJ, Boucher RC (1991) Sodium transport and intracellular sodium activity
in cultured human nasal epithelium. American Journal of Physiology-Cell Physiology
261: C319–C331.
[57] Shachar-Hill B, Hill A (1993) Convective fluid flow through the paracellular system
of necturus gall-bladder epithelium as revealed by dextran probes. The Journal of
physiology 468: 463.
[58] Hill AE, Shachar-Hill Y (2013) Response to “what do aquaporin knockout studies tell
us about fluid transport in epithelia?” maclaren oj, sneyd j, crampin ej (2013) j membr
biol 246:297–305. The Journal of Membrane Biology 246: 665–667.
[59] Fischbarg J, Diecke FPJ, Iserovich P, Rubashkin a (2006) The role of the tight junction
in paracellular fluid transport across corneal endothelium. Electro-osmosis as a driving
force. Journal of Membrane Biology 210: 117–130.
[60] Fischbarg J (2010) Fluid transport across leaky epithelia: central role of the tight
junction and supporting role of aquaporins. Physiological reviews 90: 1271–1290.
[61] Reuss L (2009) Water transport by epithelia. eLS .
201
[62] Maclaren OJ, Sneyd J, Crampin EJ (2013) What do aquaporin knockout studies tell us
about fluid transport in epithelia? The Journal of Membrane Biology 246: 297–305.
[63] Kovbasnjuk O, Leader JP, Weinstein AM, Spring KR (1998) Water does not flow across
the tight junctions of mdck cell epithelium. Proceedings of the National Academy of
Sciences 95: 6526–6530.
[64] Spring KR (1998) Routes and mechanism of fluid transport by epithelia 1. Annual
Review of Physiology 60: 105–119.
[65] Corcoran TE, Thomas KM, Brown S, Myerburg MM, Locke LW, et al. (2013) Liquid
hyper-absorption as a cause of increased DTPA clearance in the cystic fibrosis airway.
EJNMMI research 3: 14.
[66] Kitano H (2002) Systems biology: a brief overview. Science 295: 1662–1664.
[67] Bard J (2013) Systems biology — the broader perspective. Cells 2: 414.
[68] Smith N, Crampin E (2004) Development of models of active ion transport for whole-
cell modelling: cardiac sodium–potassium pump as a case study. Progress in biophysics
and molecular biology 85: 387–405.
[69] Benjamin B, Johnson E (1997) A quantitative description of the na-k-2cl cotransporter
and its conformity to experimental data. American Journal of Physiology-Renal Phys-
iology 273: F473–F482.
[70] Warren NJ, Tawhai MH, Crampin EJ (2009) A mathematical model of calcium-induced
fluid secretion in airway epithelium. Journal of Theoretical Biology 259: 837–849.
[71] Federoff HJ, Gostin LO (2009) Evolving from reductionism to holism: is there a future
for systems medicine? JAMA 302: 994–996.
[72] Ledzewicz U, Scha¨ttler H (2002) Optimal Bang-Bang Controls for a Two-Compartment
Model in Cancer Chemotherapy. J Optimization Theory Appl 114: 609–637.
[73] Friberg LE, Henningson A, Maas H, \it et al (2002) Model of Chemotherapy-induced
Myelosuppression with Parameter Consistency Across Drugs. Cancer Res 20: 523–527.
[74] Harrold JM, Eiseman JL, Joseph E, Strychor S, Zamboni WC, et al. (2005) Control-
relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing
HT29 human colon xenografts. Journal of pharmacokinetics and pharmacodynamics
32: 65–83.
[75] Florian Ja, Eiseman JL, Parker RS (2008) Nonlinear model predictive control for dosing
daily anticancer agents using a novel saturating-rate cell-cycle model. Computers in
biology and medicine 38: 339–47.
202
[76] Ho T, Clermont G, Parker RS (2013) A model of neutrophil dynamics in response to in-
flammatory and cancer chemotherapy challenges. Computers & Chemical Engineering
51: 187–196.
[77] Parker RS, Doyle FJ, Peppas NA (1999) A model-based algorithm for blood glucose
control in type i diabetic patients. IEEE Transactions on biomedical engineering 46:
148–157.
[78] Kitano H, Oda K, Kimura T, Matsuoka Y, Csete M, et al. (2004) Metabolic syndrome
and robustness tradeoffs. Diabetes 53 Suppl 3: S6–S15.
[79] Roy A, Parker RS (2006) Dynamic modeling of free fatty acid, glucose, and insulin:
An extended” minimal model”. Diabetes technology & therapeutics 8: 617–626.
[80] Lin J, Razak NN, Pretty CG, Le Compte A, Docherty P, et al. (2011) A physiolog-
ical intensive control insulin-nutrition-glucose (icing) model validated in critically ill
patients. Computer methods and programs in biomedicine 102: 192–205.
[81] Vilkhovoy M, Pritchard-Bell A, Clermont G, Parker RS (2014) A control-relevant
model of subcutaneous insulin absorption. IFAC Proceedings Volumes 47: 10988–
10993.
[82] Knab TD, Clermont G, Parker RS (2015) Zone model predictive control and moving
horizon estimation for the regulation of blood glucose in critical care patients. IFAC-
PapersOnLine 48: 1002–1007.
[83] Dick TE, Molkov YI, Nieman G, Hsieh YH, Jacono FJ, et al. (2012) Linking inflam-
mation, cardiorespiratory variability, and neural control in acute inflammation via
computational modeling. Frontiers in Physiology 3 JUL.
[84] Zhang LA, Parker RS, Swigon D, Banerjee I, Bahrami S, et al. (2016) A one-nearest-
neighbor approach to identify the original time of infection using censored baboon
sepsis data. Critical care medicine 44: e432–e442.
[85] Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) Hiv-1 dynamics
in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science
271: 1582.
[86] Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of
epidermal growth factor receptor signaling. Molecular systems biology 1.
[87] Hartmann T, Verkman aS (1990) Model of ion transport regulation in chloride-secreting
airway epithelial cells. Integrated description of electrical, chemical, and fluorescence
measurements. Biophysical journal 58: 391–401.
[88] Novotny JA, Jakobsson E (1996) Computational studies of ion-water flux coupling in
the airway epithelium. i. construction of model. American Journal of Physiology-Cell
Physiology 270: C1751–C1763.
203
[89] Novotny JA, Jakobsson E (1996) Computational studies of ion-water flux coupling in
the airway epithelium. ii. role of specific transport mechanisms. American Journal of
Physiology-Cell Physiology 270: C1764–C1772.
[90] Fischbarg J, Diecke FPJ (2005) A mathematical model of electrolyte and fluid transport
across corneal endothelium. The Journal of membrane biology 203: 41–56.
[91] Zhu H, Chauhan A (2007) Tear dynamics model. Current eye research 32: 177–97.
[92] Terashima K, Takeuchi a, Sarai N, Matsuoka S, Shim EB, et al. (2006) Modelling Cl-
homeostasis and volume regulation of the cardiac cell. Philosophical transactions Series
A, Mathematical, physical, and engineering sciences 364: 1245–1265.
[93] Willumsen NJ, Boucher RC (1991) Transcellular sodium transport in cultured cystic
fibrosis human nasal epithelium. American Journal of Physiology-Cell Physiology 261:
C332–C341.
[94] Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, et al. (1997) Ion compo-
sition of airway surface liquid of patients with cystic fibrosis as compared with normal
and disease-control subjects. Journal of Clinical Investigation 100: 2588.
[95] Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, Boucher RC (2006) Physiological
regulation of atp release at the apical surface of human airway epithelia. Journal of
Biological Chemistry 281: 22992–23002.
[96] Herschlag G, Garcia GJM, Button B, Tarran R, Lindley B, et al. (2013) A
mechanochemical model for auto-regulation of lung airway surface layer volume. Jour-
nal of theoretical biology 325: 42–51.
[97] Harvey PR, Tarran R, Garoff S, Myerburg MM (2011) Measurement of the airway
surface liquid volume with simple light refraction microscopy. American journal of
respiratory cell and molecular biology 45: 592–9.
[98] Liu L, Shastry S, Byan-Parker S, Houser G, K Chu K, et al. (2014) An Autoregulatory
Mechanism Governing Mucociliary Transport Is Sensitive to Mucus Load. American
Journal of Respiratory Cell and Molecular Biology 51: 485–493.
[99] Bennett WD, Laube BL, Corcoran T, Zeman K, Sharpless G, et al. (2013) Multisite
comparison of mucociliary and cough clearance measures using standardized methods.
Journal of aerosol medicine and pulmonary drug delivery 26: 157–64.
[100] Rocci ML, Jusko WJ (1983) Lagran program for area and moments in pharmacokinetic
analysis. Computer programs in biomedicine 16: 203–216.
[101] Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW (2002) Pharmacoki-
netics and bioavailability of aerosolized tobramycin in cystic fibrosis. CHEST Journal
122: 219–226.
204
[102] Burness CB, Keating GM (2012) Mannitol Dry Powder for Inhalation. Drugs 72:
1411–1421.
[103] Wilkinson PK, Sedman AJ, Sakmar E, Kay DR, Wagner JG (1977) Pharmacokinetics
of ethanol after oral administration in the fasting state. Journal of pharmacokinetics
and biopharmaceutics 5: 207–224.
[104] Li J, Coulthard K, Milne R, Nation RL, Conway S, et al. (2003) Steady-state pharma-
cokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
Journal of Antimicrobial Chemotherapy 52: 987–992.
[105] Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C (2007) Novel tobramycin
inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatric
pulmonology 42: 307–313.
[106] Vic P, Ategbo S, Turck D, Husson M, Launay V, et al. (1998) Efficacy, tolerance, and
pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic
fibrosis. Archives of disease in childhood 78: 536–539.
[107] Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, et al. (1977) Pharma-
cokinetics of methicillin in patients with cystic fibrosis. Journal of Infectious Diseases
135: 828–831.
[108] Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, et al. (2006) Pharmacokinetics
of inhaled colistin in patients with cystic fibrosis. Journal of Antimicrobial Chemother-
apy 57: 306–311.
[109] Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, et al. (2016) Population
pharmacokinetics and safety of ceftolozane/tazobactam in adult cystic fibrosis patients
admitted with acute pulmonary exacerbation. Antimicrobial Agents and Chemother-
apy : AAC–01566.
[110] Xu H, Zhou W, Zhou D, Li J, Al-Huniti N (2016) Evaluation of aztreonam dosing
regimens in patients with normal and impaired renal function: A population phar-
macokinetic modeling and monte carlo simulation analysis. The Journal of Clinical
Pharmacology .
[111] Costabile G, d’Angelo I, di Villa Bianca Rd, Mitidieri E, Pompili B, et al. (2016)
Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine
repositioning in local therapy of lung infections. Journal of Controlled Release 238:
80–91.
[112] Devereux G, Steele S, Griffiths K, Devlin E, Fraser-Pitt D, et al. (2016) An open-label
investigation of the pharmacokinetics and tolerability of oral cysteamine in adults with
cystic fibrosis. Clinical drug investigation : 1–8.
205
[113] Le Brun P, De Boer A, Mannes G, De Fraıˆture D, Brimicombe R, et al. (2002) Dry
powder inhalation of antibiotics in cystic fibrosis therapy: part 2: inhalation of a novel
colistin dry powder formulation: a feasibility study in healthy volunteers and patients.
European Journal of Pharmaceutics and Biopharmaceutics 54: 25–32.
[114] Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, et al. (2006) Micro-
biology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients
with cystic fibrosis. Pediatric pulmonology 41: 656–665.
[115] Geller DE, Flume PA, Griffith DC, Morgan E, White D, et al. (2011) Pharmacokinet-
ics and safety of mp-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.
Antimicrobial agents and chemotherapy 55: 2636–2640.
[116] Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption
and disposition of inhaled therapeutics for systemic delivery. Advanced drug delivery
reviews 58: 1030–60.
[117] Sakagami M, Byron PR, Venitz J, Rypacek F (2002) Solute disposition in the rat
lung in vivo and in vitro: determining regional absorption kinetics in the presence of
mucociliary escalator. Journal of pharmaceutical sciences 91: 594–604.
[118] Weber B, Hochhaus G (2013) A pharmacokinetic simulation tool for inhaled corticos-
teroids. The AAPS journal 15: 159–71.
[119] O’Reilly R, Elphick HE (2013) Development, clinical utility, and place of ivacaftor in
the treatment of cystic fibrosis. Drug design, development and therapy 7: 929–37.
[120] Boucher RC (2007) Cystic fibrosis: a disease of vulnerability to airway surface dehy-
dration. Trends in molecular medicine 13: 231–40.
[121] Elkins MR, Sc MH, Robinson M, Ph D, Rose BR, et al. (2006) new england journal.
New England Journal of . . . 354: 229–240.
[122] Bennett WD, Ilowite JS (1989) Dual pathway clearance of 99mtc-dtpa from the
bronchial mucosa1˜ 3. The American review of respiratory disease 139: 1132.
[123] Ilowite JS, Bennett WD, Sheetz MS, Groth ML, Nierman DM (1989) Permeability
of the bronchial mucosa to 99mtc-dtpa in asthma. American Review of Respiratory
Disease 139: 1139–1143.
[124] Eckford PDW, Li C, Ramjeesingh M, Bear CE (2012) Cystic fibrosis transmembrane
conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective
channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent
manner. The Journal of biological chemistry 287: 36639–49.
[125] Corcoran T, Niven R, Verret W, Dilly S, Johnson B (2014) Lung deposition and phar-
macokinetics of nebulized cyclosporine in lung transplant patients. Journal of aerosol
medicine and pulmonary drug delivery 27: 178–184.
206
[126] BYRON P, PATTON J (1994) Drug delivery via the respiratory tract. Journal of
Aerosol medicine 7: 49–75.
[127] Sturm R (2012) An advanced stochastic model for mucociliary particle clearance in
cystic fibrosis lungs. Journal of Thoracic Disease 4: 48–57.
[128] Akaike H (1974) A new look at the statistical model identification. Automatic Control,
IEEE Transactions on .
[129] Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike’s information criterion
(AIC) in the evaluation of linear pharmacokinetic equations. Journal of pharmacoki-
netics and biopharmaceutics 6: 165–75.
[130] Biddiscombe MF, Meah SN, Underwood SR, Usmani OS (2011) Comparing lung re-
gions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol depo-
sition. Journal of aerosol medicine and pulmonary drug delivery 24: 165–173.
[131] Donaldson SH, Corcoran TE, Laube BL, Bennett WD (2007) Mucociliary clearance as
an outcome measure for cystic fibrosis clinical research. Proceedings of the American
Thoracic Society 4: 399–405.
[132] Locke LW, Myerburg MM, Weiner DJ, Markovetz MR, Parker RS, et al. (2016) Pseu-
domonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.
European Respiratory Journal : ERJ–01880.
[133] Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, et al. (2012)
Standardization of techniques for using planar (2D) imaging for aerosol deposition
assessment of orally inhaled products. J Aerosol Med Pulm Drug Deliv 25 Suppl 1:
S10–28.
[134] Raue a, Kreutz C, Maiwald T, Bachmann J, Schilling M, et al. (2009) Structural and
practical identifiability analysis of partially observed dynamical models by exploiting
the profile likelihood. Bioinformatics (Oxford, England) 25: 1923–9.
[135] Hoegger MJ, Awadalla M, Namati E, Itani Oa, Fischer AJ, et al. (2014) Assessing
mucociliary transport of single particles in vivo shows variable speed and preference
for the ventral trachea in newborn pigs. Proceedings of the National Academy of
Sciences of the United States of America 111: 2355–60.
[136] Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, et al. (1999) The effect of
inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: A pilot
study. European Respiratory Journal 14: 678–685.
[137] Birket DSE, Chu DKK, Liu DL, Houser DGH, Diephuis MBJ, et al. (2014) A Functional
Anatomic Defect of the Cystic Fibrosis Airway 190: 421–432.
207
[138] Va´zquez E, Nobles M, Valverde Ma (2001) Defective regulatory volume decrease in
human cystic fibrosis tracheal cells because of altered regulation of intermediate con-
ductance Ca2+-dependent potassium channels. Proceedings of the National Academy
of Sciences of the United States of America 98: 5329–5334.
[139] Chanson M, Scerri I, Suter S (1999) Defective regulation of gap junctional coupling in
cystic fibrosis pancreatic duct cells. The Journal of clinical investigation 103: 1677–84.
[140] Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, et al. (2002) Reg-
ulation of airway tight junctions by proinflammatory cytokines. Molecular biology of
the cell 13: 3218–3234.
[141] Molina SA, Stauffer B, Moriarty HK, Kim AH, McCarty NA, et al. (2015) Junctional
abnormalities in human airway epithelial cells expressing delF508 CFTR. American
journal of physiology Lung cellular and molecular physiology : ajplung.00060.2015.
[142] Hogg JS (2013) Advances in rule-based modeling: compartments, energy, and hybrid
simulation, with application to sepsis and cell signaling. Ph.D. thesis, University of
Pittsburgh.
[143] Boucher RC (1994) Human Airway Ion Transport. American journal of respiratory
and critical care medicine1 150: 271–281.
[144] Fischbarg J, Kuang KY, Vera JC, Arant S, Silverstein SC, et al. (1990) Glucose trans-
porters serve as water channels. Proceedings of the National Academy of Sciences of
the United States of America 87: 3244–7.
[145] Farinas J, Simanek V, Verkman aS (1995) Cell volume measured by total internal re-
flection microfluorimetry: application to water and solute transport in cells transfected
with water channel homologs. Biophysical journal 68: 1613–1620.
[146] Farinas J, Verkman aS (1996) Cell volume and plasma membrane osmotic water per-
meability in epithelial cell layers measured by interferometry. Biophysical journal 71:
3511–3522.
[147] Ballard DH (1981) Generalizing the hough transform to detect arbitrary shapes. Pat-
tern recognition 13: 111–122.
[148] Lennerna¨s H (1995) Does fluid flow across the intestinal mucosa affect quantitative
oral drug absorption? Is it time for a reevaluation? Pharmaceutical research .
[149] Schnermann J, Chou CL, Ma T, Traynor T, Knepper Ma, et al. (1998) Defective
proximal tubular fluid reabsorption in transgenic aquaporin-1 null mice. Proceedings
of the National Academy of Sciences of the United States of America 95: 9660–9664.
[150] Goralski J, Button B (2013) Faster is not always better: relationship between hyper-
tonic saline aerosolization rate, airway hydration, and cell volume. In: PEDIATRIC
208
PULMONOLOGY. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774,
NJ USA, volume 48, pp. 243–243.
[151] Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, et al. (2010) The particle
has landed—characterizing the fate of inhaled pharmaceuticals. Journal of Aerosol
Medicine and Pulmonary Drug Delivery 23: S–71.
[152] ParionSciences (2013) INVESTIGATOR BROCHURE - tPAD trans-Nasal Pulmonary
Aerosol Delivery of Hypertonic Saline : 1–61.
[153] Weibel E (1965) Morphometry of the human lung. Anesthesiology .
[154] Martonen T (1993) Mathematical model for the selective deposition of inhaled phar-
maceuticals. Journal of pharmaceutical sciences 82: 1191–1199.
[155] Gerrity TR, Lee PS, Hass FJ, Marinelli A, Werner P, et al. (1979) Calculated deposition
of inhaled particles in the airway generations of normal subjects. Journal of Applied
Physiology 47: 867–873.
[156] Bennett WD, Wu J, Fuller F, Balcazar JR, Zeman KL, et al. (2015) Duration of action
of hypertonic saline on mucociliary clearance in the normal lung. Journal of Applied
Physiology : jap–00404.
[157] Itani Oa, Chen Jh, Karp PH, Ernst S, Keshavjee S, et al. (2011) Human cystic fibrosis
airway epithelia have reduced Cl- conductance but not increased Na+ conductance.
Proceedings of the National Academy of Sciences of the United States of America 108:
10260–5.
[158] Cobelli C, Distefano JJ, Distefano JJ, Parameter III (2013) Parameter and structural
identifiability concepts and ambiguities : a critical review and analysis Parameter and
structural identifiability concepts and ambiguities : a critical review and analysis .
[159] Rooney WC, Biegler LT (2001) Design for Model Parameter Uncertainty Using Non-
linear Confidence Regions. AIChE Journal 47.
[160] Raue A, Becker V, Klingmu¨ller U, Timmer J (2010) Identifiability and observability
analysis for experimental design in nonlinear dynamical models. Chaos: An Interdis-
ciplinary Journal of Nonlinear Science 20: 045105.
[161] Cobelli C, Lepschy A, Jacur GR (1979) Identifiability of compartmental systems and
related structural properties. Mathematical Biosciences 44: 1–18.
[162] Kalman RE (1963) Mathematical description of linear dynamical systems. Journal of
the Society for Industrial and Applied Mathematics, Series A: Control 1: 152–192.
[163] Hermann R, Krener A (1977) Nonlinear controllability and observability. IEEE Trans-
actions on automatic control 22: 728–740.
209
[164] Whalen AJ, Brennan SN, Sauer TD, Schiff SJ (2015) Observability and controllability
of nonlinear networks: The role of symmetry. Physical Review X 5: 011005.
[165] Wa¨chter A, Biegler LT (2006) On the implementation of an interior-point filter line-
search algorithm for large-scale nonlinear programming. Mathematical Programming
106: 25–57.
[166] Moles CG, Mendes P, Banga JR (2003) Parameter estimation in biochemical pathways:
a comparison of global optimization methods. Genome research 13: 2467–2474.
[167] Hirmajer T, Balsa-Canto E, Banga JR (2009) Dotcvpsb, a software toolbox for dynamic
optimization in systems biology. BMC bioinformatics 10: 1.
[168] Raue A, Schilling M, Bachmann J, Matteson A, Schelker M, et al. (2013) Lessons
learned from quantitative dynamical modeling in systems biology. PloS one 8: e74335.
[169] Sahinidis NV (1996) Baron: A general purpose global optimization software package.
Journal of global optimization 8: 201–205.
[170] Byrd RH, Nocedal J, Waltz RA (2006) Knitro: An integrated package for nonlinear
optimization. In: Large-scale nonlinear optimization, Springer. pp. 35–59.
[171] Runarsson TP, Yao X (2000) Stochastic ranking for constrained evolutionary optimiza-
tion. IEEE Transactions on evolutionary computation 4: 284–294.
[172] Szu H, Hartley R (1987) Fast simulated annealing. Physics letters A 122: 157–162.
[173] Zhang LA, Parker RS, Clermont G Apt-mcmc. In Preparation .
[174] Landaw E, DiStefano JJ (1984) Multiexponential, multicompartmental, and noncom-
partmental modeling. ii. data analysis and statistical considerations. American Journal
of Physiology-Regulatory, Integrative and Comparative Physiology 246: R665–R677.
[175] Word DP, Young JK, Cummings DA, Iamsirithaworn S, Laird CD (2013) Interior-point
methods for estimating seasonal parameters in discrete-time infectious disease models.
PloS one 8: e74208.
[176] Gallant AR (1987) Nonlinear statistical models, volume 310. John Wiley & Sons.
[177] Hart WE, Laird C, Watson JP, Woodruff DL (2012) Pyomo–optimization modeling in
python, volume 67. Springer Science & Business Media.
[178] Fourer R, Gay D, Kernighan B (1993) Ampl, volume 117. Boyd & Fraser Danvers,
MA.
[179] Nicholson B, Siirola JD, Watson JP, Zavala VM, Biegler LT pyomo. dae: A modeling
and automatic discretization framework for optimization with differential and algebraic
equations .
210
[180] Esposito WR, Floudas CA (2000) Global optimization for the parameter estimation
of differential-algebraic systems. Industrial & Engineering Chemistry Research 39:
1291–1310.
[181] Van de Vusse J (1964) Plug-flow type reactor versus tank reactor. Chemical Engineering
Science 19: 994–996.
[182] Doyle III FJ, Ogunnaike BA, Pearson RK (1995) Nonlinear Model-based Control Using
Second-order {V}olterra Models. {A}utomatica 31: 697–714.
[183] Feinberg M, Hildebrandt D (1997) Optimal reactor design from a geometric view-
point—i. universal properties of the attainable region. Chemical Engineering Science
52: 1637–1665.
[184] Sistu PB, Bequette BW (1995) Model predictive control of processes with input mul-
tiplicities. Chemical engineering science 50: 921–936.
[185] Gadkar KG, Gunawan R, Doyle FJ (2005) Iterative approach to model identification
of biological networks. BMC bioinformatics 6: 1.
[186] Daun S, Rubin J, Vodovotz Y, Roy A, Parker R, et al. (2008) An ensemble of models of
the acute inflammatory response to bacterial lipopolysaccharide in rats: results from
parameter space reduction. Journal of theoretical biology 253: 843–53.
[187] Kremling A, Fischer S, Gadkar K, Doyle FJ, Sauter T, et al. (2004) A benchmark for
methods in reverse engineering and model discrimination: problem formulation and
solutions. Genome Research 14: 1773–1785.
[188] Faller D, Klingmu¨ller U, Timmer J (2003) Simulation methods for optimal experimental
design in systems biology. Simulation 79: 717–725.
[189] Rymut SM, Ivy T, Corey DA, Cotton CU, Burgess JD, et al. (2015) Role of exchange
protein activated by camp 1 in regulating rates of microtubule formation in cystic
fibrosis epithelial cells. American journal of respiratory cell and molecular biology 53:
853–862.
[190] Manzanares D, Krick S, Baumlin N, Dennis JS, Tyrrell J, et al. (2015) Airway sur-
face dehydration by transforming growth factor β (tgf-β) in cystic fibrosis is due to
decreased function of a voltage-dependent potassium channel and can be rescued by
the drug pirfenidone. Journal of Biological Chemistry 290: 25710–25716.
[191] Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, et al. (2011) Denu-
fosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung
function. American journal of respiratory and critical care medicine 183: 627–634.
[192] Muske KR, Rawlings JB (1993) Model Predictive Control with Linear Models.
{AIChE} {J} 39: 262–287.
211
[193] Byers T, Seelig T, Sheppard S, Weilerstein P (2013) The Bridge - Summer 2013 -
v43n2. The Bridge 43.
[194] Bodnar CA, Clark RM, Besterfield-Sacre M (2015) Lessons Learned through Sequential
Offerings of an Innovation and Entrepreneurship Boot Camp for Sophomore Engineer-
ing Students. Journal of Engineering Entrepeneurship 6: 52–67.
[195] Purzer S, Fila N, Nataraja K (2016) Evaluation of current assessment methods in
engineering entrepreneurship education. Advances in Engineering Education 5: n1.
[196] Ta¨ks M, Tynja¨la¨ P, Toding M, Kukemelk H, Venesaar U (2014) Engineering students’
experiences in studying entrepreneurship. Journal of Engineering Education 103: 573–
598.
[197] Rogy KM (2010) Examining the Entrepreneurial Mindset of Senior Chemical Engi-
neering Stu- dents as a Result of Exposure to the Epistemic Game ” Nephrotex ”
Examining the Entrepreneurial Mindset of Senior Chemical Engineering Students as a
Result of Exposure to the Episte .
[198] Schar M, Sheppard S, Brunhaver S, Cuson M, Grau MM (2014) Bending moments to
business models: Integrating an entrepreneurship case study as part of core mechanical
engineering curriculum. The Journal of Engineering Entrepreneurship 5: 1–18.
[199] Litzinger T, Lattuca LR, Hadgraft R, Newstetter W (2011) Engineering Education
and the Development of Expertise. Journal of Engineering Education 100: 123–150.
[200] Gibb A (2002) In pursuit of a new ‘enterprise’ and ‘entrepreneurship’ paradigm for
learning: creative destruction, new values, new ways of doing things and new combi-
nations of knowledge. International Journal of Management Reviews 4: 233.
[201] Ramsey E, Smith K, Martin L, Gibb A (2011) Concepts into practice: meeting the
challenge of development of entrepreneurship educators around an innovative paradigm:
The case of the international entrepreneurship educators’ programme (ieep). Interna-
tional Journal of Entrepreneurial Behavior & Research 17: 146–165.
[202] Kriewall, Timothy J, Mekemson K (2010) Instilling the Entrepreneurial Mindset Into
Engineering. The Journal Of engineering entrepreneurship 1: 5–19.
[203] Ortiz-Medina, Leovigilda, Ferna´ndez-Ahumada E, Lara-Ve´lez P, Garrido-Varo A,
Pe´rez-Mar´ın D, Guerrero-Ginel JE (2014) Assessing an Entrepreneurship Education
Project in Engineering Studies by Means of Participatory Techniques. Advances in
Engineering Education : 1–30.
[204] Damon W, Lerner R (2008) Entrepreneurship across the life span: A developmental
analysis and review of key findings. Kansas City: Kauffman Foundation .
[205] Antoncic B, Hisrich RD (2003) Clarifying the intrapreneurship concept. Journal of
Small Business and Enterprise Development 10: 7–24.
212
[206] Akao Y (2004) Quality function deployment .
[207] Woodruff RB (1997) Customer value: The next source for competitive advantage.
Journal of the Academy of Marketing Science 25: 139–153.
[208] Pahl G, Beitz W, Feldhusen J, Grote KH, Approach aS (2007) Engineering design: a
systematic approach. doi:10.1007/978-1-84628-319-2.
[209] Lin MC, Wang CC, Chen MS, Chang CA (2008) Using AHP and TOPSIS approaches
in customer-driven product design process. Computers in Industry 59: 17–31.
[210] Norman DA (2013) The Design of Everyday Things, Revised and Expanded Edition.
Currency-Doubleday.
[211] Rae D (2003) Opportunity centred learning: an innovation in enterprise education?
Education + Training 45: 542–549.
[212] Newstetter, Wendy, McCracken M (2001) Novice conceptions of design: Implications
for the design of learning environments. In: Design Knowing and Learning: Cognition
in Design Education. pp. 63–77.
[213] Chi, MT, Glaser, R FM (1998) The nature of expertise. Hillsdale, NJ: Lawrence
Erlbaum Assoc., Inc.
[214] Freeman S, Eddy SL, McDonough M, Smith MK, Okoroafor N, et al. (2014) Active
learning increases student performance in science, engineering, and mathematics. Pro-
ceedings of the National Academy of Sciences 111: 8410–8415.
[215] Mina M, Gerdes RM (2006) The pedantic 21st century freshman engineering student.
European journal of engineering education 31: 509–516.
[216] Hatfield D, Shaffer DW (2006) Press play: Designing an epistemic game engine for
journalism. In: Proceedings of the 7th international conference on Learning sciences.
International Society of the Learning Sciences, pp. 236–242.
[217] Svarovsky GN, Shaffer DW (2007) Sodaconstructing knowledge through exploratoids.
Journal of Research in Science Teaching 44: 133–153.
[218] Shaffer DW (2004) Epistemic frames and islands of expertise: Learning from infusion
experiences. In: Proceedings of the 6th international conference on Learning sciences.
International Society of the Learning Sciences, pp. 473–480.
[219] Chesler NC, Arastoopour G, D’Angelo CM, Bagley EA, Shaffer DW (2013) Design of
a professional practice simulator for educating and motivating first-year engineering
students. Advances in Engineering Education 3: 1–29.
[220] Rohde M, Shaffer DW (2003) Us, ourselves, and we: Thoughts about social (self-)
categorization. ACM SIGGROUP Bulletin 24: 19–24.
213
[221] Shaffer DW (2006) Epistemic frames for epistemic games. Computers & education 46:
223–234.
[222] Arastoopour G, Chesler NC, Shaffer DW (2014) Epistemic persistence: A simulation-
based approach to increasing participation of women in engineering. Journal of Women
and Minorities in Science and Engineering 20.
[223] Langford J, McDonagh D (2003) Focus groups: supporting effective product develop-
ment. CRC press.
[224] Arastoopour G, Collier W, Chesler NC, Linderoth J, Shaffer DW (2015) Measuring the
complexity of simulated engineering design problems. American Society for Engineering
Education .
[225] Neuendorf KA (2002) The content analysis guidebook. Sage.
[226] Sullivan GM, Feinn R (2012) Using Effect Size - or Why the P Value Is Not Enough.
Journal of graduate medical education 4: 279–82.
214
